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THESIS ABSTRACT 
Background and Objectives  
The prevalence of obesity has escalated in many world populations, 
representing a major public health issue. Despite recommendations that 
adiposity should be routinely assessed within clinical practice, controversy 
exists as to how excess adiposity should be defined using anthropometry. In 
particular, there is uncertainty and ongoing controversy as to whether 
surrogate measures of central adiposity such as waist circumference (WC), 
waist-hip ratio or waist-height ratio (WHtR) are better indicators of obesity-
related risk when compared to general adiposity as measured by body mass 
index (BMI). 
 
This thesis contributes to the current evidence base regarding methods to 
detect patients with type 2 diabetes, and those at increased obesity-related 
cardiometabolic risk. In particular, it aimed to determine how useful surrogate 
measures of adiposity might be to identify high-risk patients within a clinical 
setting. The main objectives of this thesis were:  
 
1. to examine the rationale for adiposity assessment within clinical 
practice, and whether methods used for disease classification and 
anthropometric measurement procedure are important for diagnosing 
cardiometabolic risk and type 2 diabetes; 
 
2. to compare adiposity variable relationships with a range of 
cardiometabolic disease features, biomarkers of chronic low-grade 
inflammation and type 2 diabetes; 
 
3. to explore whether central adiposity indices provide additional 
information regarding disease and risk status, compared to BMI; 
 
4. to investigate the clinical utility of a composite index using both 
general and central adiposity measures. 
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Literature Review 
The literature review focused on meta-analytic studies which explored 
adiposity variable relationships with cardiometabolic features, obesity-related 
diseases and mortality. A majority of studies showed that central adiposity 
measures were more strongly related to examined outcomes as indicated by 
statistical measures of association. However, with regard to the clinical utility 
of central adiposity assessment, the findings from the review were 
inconclusive. 
 
 
Methods and Papers  
The papers included in this thesis were derived from analysis of baseline 
data from the Cork and Kerry Diabetes and Heart Disease Study (Phase II), 
a cross-sectional study involving a random sample of 2,047 men and women 
aged 46-73 years, recruited from a single primary care centre. Standard 
diagnostic criteria were used to define cardiometabolic disease features and 
chronic conditions which included high blood pressure, atherogenic 
dyslipidaemia, insulin resistance, pre-diabetes and type 2 diabetes. Adverse 
inflammatory biomarker levels were classified according to percentile 
thresholds. Waist circumference (measured at two sites), hip circumference, 
pelvic width and BMI were assessed. Correlation and logistic regression 
analyses were used to explore metabolic, anthropometric and other health-
related variable relationships. Discrimination was determined using the 
receiver operating characteristic curve and integrated discrimination 
improvement analysis.  
 
The findings are presented in a series of five interlinked papers which relate 
directly to the thesis objectives. Paper 1 addressed the prevalence of type 2 
diabetes within the sample, with particular reference to undiagnosed 
diabetes. Paper 2 examined cardiometabolic profiles in patients diagnosed 
with diabetes and pre-diabetes using two different diagnostic methods 
[glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG)]. Paper 
3 compared general and central adiposity variable relationships with 
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cardiometabolic disease features and type 2 diabetes. In Paper 4, BMI and 
WC associations with biomarkers of chronic low-grade inflammation and type 
2 diabetes were explored. Paper 5 investigated the utility of a composite 
index, using both BMI and WHtR, to assess cardiometabolic risk. 
 
 
Results 
Paper 1: The prevalence of type 2 diabetes within this sample was 8.5% 
(95% CI: 7.4%-9.8%), a rate comparable to estimates determined from 
recent nationally representative research within Ireland. A high percentage of 
diabetes cases were undiagnosed (41%), suggesting that better detection 
methods are needed.  
 
Paper 2: The cardiometabolic profiles of patients diagnosed with type 2 
diabetes by HbA1c or FPG were broadly similar, indicating that either test is 
acceptable for defining this outcome. In contrast, the risk profiles of subjects 
classified as having pre-diabetes varied considerably according to diagnosis 
by either assay, with patients diagnosed by both tests displaying the least 
optimal profile. Adiposity, high blood pressure, atherogenic dyslipidaemia, 
insulin resistance and adverse cardiometabolic feature clustering were 
significantly related to both type 2 diabetes and pre-diabetes. Subjects with 
these outcomes also displayed a chronic low-grade pro-inflammatory profile 
as indicated by the examined biomarkers. 
 
Paper 3: Central adiposity variables demonstrated stronger associations with 
adverse cardiometabolic features, metabolic feature clustering and type 2 
diabetes than BMI. Central adiposity measures were also better 
discriminators of patients with type 2 diabetes, and they improved 
discrimination of diabetes by 3%-7% (men) and 5%-7% (women) compared 
to BMI. However, it was also noted that the utility of central adiposity 
measurement was significantly influenced by the procedure used for 
estimating WC. 
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Paper 4: Central adiposity defined by WC was more strongly related to a 
majority of the examined biomarkers of inflammation and adverse biomarker 
clustering. The association between chronic low-grade inflammation and type 
2 diabetes was reduced in analyses which included either BMI or WC. 
Logistic regression models incorporating WC displayed the greatest 
attenuation, thus supporting the theory that measures of central adiposity are 
better indicators of visceral fat. 
 
Paper 5: A combination of BMI and WHtR tertiles identified consistent and 
significant metabolic variable differences relative to those characterised as 
overweight or obese discordantly by BMI and WHtR. Significant 
discriminatory improvement, using joint-measurement, was also observed for 
detecting individual cardiometabolic disease features and adverse 
inflammatory biomarker levels when indices were examined as both 
continuous and categorical variables. In a fully adjusted regression model, 
only individuals within the highest tertile for both measures displayed a 
significant and positive association with pre-diabetes (odds ratio: 3.4, 95% 
CI: 1.9-6.0, P<0.001). 
 
 
Conclusions 
The results from this thesis suggest that surrogate measures of central 
adiposity provide information regarding disease status and cardiometabolic 
risk, independent of that provided by BMI, and that a composite index using 
BMI and WHtR together may help refine body fat classification.  
 
Future research should concentrate on determining an optimal procedure for 
measuring WC, and whether a composite index might be useful for predicting 
type 2 diabetes and cardiovascular and mortality outcomes. Other novel 
adiposity measurement procedures should also be explored. Earlier 
identification of patients at increased cardiometabolic risk, and those with 
type 2 diabetes, could allow earlier targeted interventions to be implemented, 
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thus reducing the incidence of related complications, premature mortality and 
financial costs associated with the obesity epidemic.  
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_____________________________CHAPTER 1  
BACKGROUND,  
LITERATURE REVIEW, 
RESEARCH AIMS 
AND METHODS 
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1.0 Overview 
Obesity is a chronic disorder described by the World Health Organisation 
(WHO) as a condition of abnormal or excessive fat accumulation to the 
extent that health may be impaired [1]. Over the last four decades, the 
percentage of people who are overweight or obese has risen dramatically 
across many world populations, representing a major public health issue [2-
5]. The positive relationship between excess adiposity and cardiometabolic 
disease features such as hypertension, dyslipidaemia and insulin resistance 
has been repeatedly observed in both cross-sectional and prospective 
research [6]. Abundant evidence also supports an association between 
obesity and a wide range of chronic disorders including type 2 diabetes and 
cardiovascular disease (CVD) [7-11]. Epidemiological studies have 
demonstrated a clear dose-response relationship between higher levels of 
adiposity and cardiometabolic risk, and the consistency of this correlation 
across world populations reflects the strength of this relationship [12]. 
 
Research has shown that in the Republic of Ireland, 36% of adults aged 50+ 
are obese, with a further 43% being overweight [13]. Recent unpublished 
estimates from the WHO Modelling Obesity Project, presented at the 
European Congress on Obesity in 2015, suggest that if current trends 
continue, 89% of Irish men and 85% of women are likely to be either 
overweight or obese by 2030. If these projections are correct, Ireland will 
soon be the most obese nation in Europe [14]. In addition to the major health 
consequences associated with obesity, there are also economic implications 
[15]. Overweight and obesity are estimated to cost at least €1.13 billion per 
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annum to the Irish economy through increased health services utilisation and 
premature mortality [16]. The percentage of the Irish population over the age 
of 65 is projected to double from 11% in 2006 to 22% by 2041 [17]. Thus, the 
combination of an ageing population with the increasing prevalence of 
obesity and related chronic disorders will likely lead to considerably greater 
healthcare needs and financial costs [13]. 
 
  
1.1 Cardiometabolic Disease 
Cardiometabolic disease is defined according to a number of interrelated 
features, associated with increased adiposity, which may contribute to the 
development of type 2 diabetes and atherosclerotic vascular disease [18]. 
These features include elevated blood pressure (BP) or hypertension and 
atherogenic dyslipidaemia, the presence of high triglyceride levels and 
reduced high-density lipoprotein cholesterol (HDL-C) concentrations. 
Cardiometabolic disease is also characterised by insulin resistance. This 
occurs when liver, skeletal and adipose tissue become less sensitive and 
eventually resistant to insulin, the hormone produced by β-cells in the 
pancreas to facilitate glucose absorption. Insulin resistance may in turn lead 
to dysglycaemia, as glucose is no longer being efficiently absorbed by cells 
and remains in the bloodstream [19]. 
 
Notably, excess adiposity is associated with a clustering of these features, a 
state described as the metabolic syndrome (MetS) [19]. The exact origins of 
MetS are not fully understood and the clinical implications of the condition 
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have been subject to debate [20,21]. Nevertheless, several working 
definitions of the MetS using combinations of these metabolic markers, in 
conjunction with measures of adiposity, have been devised by national and 
international organisations in order to facilitate the identification of individuals 
at increased cardiometabolic risk [21]. 
 
 
1.2 Type 2 Diabetes 
1.2.1 Definition and diagnostic criteria 
Type 2 diabetes mellitus is a chronic metabolic disease characterised by 
persistent hyperglycaemia. Current WHO, International Diabetes Federation 
(IDF) [22] or American Diabetes Association [23] definitions for diagnosing 
diabetes include the following: (1) a fasting plasma glucose (FPG) level >7.0 
mmol/l; (2) a random blood glucose level >11.1 mmol/l and associated 
features; (3) a 2-hour plasma glucose level >11.1 mmol/l indicated by the 
oral glucose tolerance test (OGTT); (4) a glycated haemoglobin A1c (HbA1c) 
level >6.5% (>48 mmol/mol). Although controversy exists as to which test 
more accurately defines the condition, and prevalence estimates may vary 
according to procedures used [24], current diagnostic thresholds have been 
derived from epidemiological studies examining the prevalence and 
incidence of diabetes-related complications [22]. These complications may 
lead to a lower quality of life and reduced life expectancy. 
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1.2.2 Diabetes complications 
Type 2 diabetes is a major cause of morbidity and mortality as chronic 
hyperglycaemia may lead to impairment and malfunction of the renal, 
ophthalmic, vascular and nervous systems [25]. If undiagnosed or untreated 
diabetes can lead to long-term microvascular damage. Microvascular 
diabetic complications include retinopathy, the leading cause of blindness in 
adults [26], diabetic nephropathy, the leading cause of end-stage renal 
disease [27] and diabetic neuropathy, the leading cause of non-traumatic 
lower extremity amputations [28]. In addition to microvascular damage, 
macrovascular complications are frequently observed. Importantly, 
individuals with type 2 diabetes are at increased risk of developing CVD. 
Research has shown that up to 80% of diabetes patients will die from 
cardiovascular-related events [29] and that they have a two to four-fold 
increased risk of coronary artery disease (CAD) and stroke when compared 
to diabetes-free subjects [30,31]. 
  
 
1.2.3 Diabetes prevalence 
Diabetes has become an epidemic in developed and developing countries 
representing a major public health concern. Current estimates predict an 
excess of 400 million individuals with type 2 diabetes worldwide by 2030 [32]. 
In 2013, the number of people with diabetes in Europe was determined to 56 
million, with an overall prevalence rate of 8.5% [33]. Until recently the 
prevalence of type 2 diabetes within the Republic of Ireland was largely 
unknown, as estimates were derived from incomplete primary care data. 
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However, a number of recent studies have suggested a prevalence of 
between 7%-10% in middle-aged adults [34]. Alarmingly, research has also 
indicated that a considerable proportion of diabetes cases within Ireland are 
undiagnosed [35] and that a high percentage of adults are at risk of 
developing the condition [36,37]. 
 
 
1.2.4 Diabetes risk factors 
The diabetes epidemic has been driven by complex gene-environment 
interactions [38]. Approximately half of the risk of developing type 2 diabetes 
has been attributed to non-modifiable genetic factors [39], with the other half 
to environmental exposures which may contribute to excess adiposity [40], 
due to an increasingly sedentary lifestyle and “westernised” calorie-dense 
diet [41]. Other factors associated with diabetes include age, gender, 
ethnicity, smoking and alcohol use [42-46].  
 
All obesity-related cardiometabolic disease markers are thought to be 
correlated with diabetes development. It has been observed that even before 
blood glucose levels are high enough for an individual to be diagnosed with 
the disorder, hypertension, adverse changes in lipid and lipoprotein levels, 
insulin resistance and dysglycaemia may occur [19]. Whether a combination 
of these features, as defined by MetS definitions, indicates a greater risk of 
developing type 2 diabetes is disputed [20,47]. However, it has been 
suggested that a clustering of these metabolic abnormalities may confer a 
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substantial additional risk, over and above the sum of the risk of each 
individual MetS component [19,48].  
 
Recently the term “pre-diabetes” has also emerged as another potentially 
greater risk factor [47]. This umbrella term for impaired FPG, impaired 
glucose tolerance (IGT) [49] or HbA1c levels that are higher than normal [23], 
represents intermediate stages of elevated glucose levels between normal 
glucose regulation and diabetes. A meta-analysis of prospective studies 
conducted in different populations estimated a relative risk of 4.7-12.0 for 
progression from impaired FPG and/or IGT to type 2 diabetes, with absolute 
annual risks between 5% and 10% [50].  
 
 
1.2.5 Screening for diabetes 
As type 2 diabetes has become a major public health priority, there is 
increasing interest in methods to identify individuals who have diabetes, and 
patients who are at high-risk of developing the condition. The pathway from 
obesity through insulin resistance, pre-diabetes to overt type 2 diabetes 
represents a progressive phenotype [51]. That diabetes is preventable 
through lifestyle changes in diet and physical activity is well accepted [52,53]. 
Given the long asymptomatic period preceding the disorder, earlier 
identification of individuals at increased risk could allow earlier targeted 
interventions. These might include implementation of healthy lifestyle 
changes or pharmacological treatments, thus attenuating development of 
type 2 diabetes and related micro- and macrovascular complications. 
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However, population screening using blood sampling to detect patients with 
type 2 diabetes, dysglycaemia or dyslipidaemia is time-consuming and cost 
prohibitive [51]. In addition, longitudinal studies have also shown that only 
about half of subjects with impaired FPG or IGT will progress to diabetes 
[54]. Increasingly, the idea of risk stratification has been seen as an 
important further tool for risk assessment. This may be thought of as a two-
step process, whereby step one identifies a subset of individuals at 
increased risk, using cheap and non-invasive procedures, with step two 
involving blood testing [55]. Various diabetes risk assessment scores, using 
self-administered questionnaires, have been developed in numerous 
populations, either for self-assessment or for use within clinical practice 
[51,56].  
 
 
1.2.6 Adiposity as a diabetes risk factor 
Obesity is considered to be the primary modifiable risk factor related to 
cardiometabolic disease and diabetes development [19,57]. Accordingly, 
non-invasive diabetes risk scores typically include a measurement of 
adiposity, most commonly body mass index (BMI), an anthropometric 
measure of general adiposity. However, despite strong observed 
associations between BMI and morbidity [6], it is now well established that 
body fat distribution is a further indicator of health status, beyond the total 
body mass assessed by BMI [58,59]. Recent research has high-lighted the 
inherent problems of measuring body fat using BMI, as subjects with 
increased adiposity may exhibit favourable outcomes in some studies 
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[60,61]. Conversely, other studies have demonstrated increased 
cardiometabolic risk among non-obese and normal weight individuals [62-
64].  
 
Important behind the idea of any risk assessment tool is that it is able to 
detect high-risk subjects [65]. However, it is equally important not to 
overextend the risk criteria to low-intermediate risk patients [66]. This 
concept is aptly demonstrated in the relationship between adiposity and 
diabetes. Although prevalence rates for overweight/obesity and type 2 
diabetes have increased considerably in world populations, a high 
percentage of individuals with increased adiposity will not have diabetes [67-
70] or ever develop the condition [71,72]. It is also relevant in the context of 
the middle-aged population within Ireland, where a majority of subjects 
classified by BMI are overweight or obese [13].  
 
 
1.3 Visceral Adiposity 
Increasing evidence suggests that central adiposity (sometimes termed 
central obesity or abdominal obesity) is a greater metabolic risk factor when 
compared to the general adiposity (or general obesity) assessed by BMI 
[19,73]. Visceral adipose tissue (VAT) is defined as the adipose tissue found 
deep within the body cavity surrounding the internal organs in the 
intrathoracic, intraabdominal and intrapelvic areas [74]. Visceral adiposity is 
thought to play an important function in the development of cardiometabolic 
disease, with subcutaneous adipose tissue (SAT) playing a lesser role. 
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Accumulation of excess VAT is related to the development of MetS, insulin 
resistance and type 2 diabetes [75-77]. Although the exact mechanism of 
association between VAT and cardiometabolic disease is still poorly 
understood, various theories have been proposed to explain this connection.  
 
According to the portal-visceral hypothesis, VAT releases nonesterified fatty 
acids that overload the liver and skeletal muscle with lipids, causing 
metabolic dysfunction within these organs [78]. Alternatively, cytokines and 
select proteins released by VAT may promote a low-grade inflammatory 
response in adipose and vascular tissue [79], leading to insulin resistance 
and β-cell and microvascular dysfunction. Thus the pathophysiology of 
cardiometabolic disease, type 2 diabetes and atherosclerotic CVD events 
may have a common inflammatory origin [80]. A third premise suggests that 
genes which predispose preferential deposition of fat in VAT depots 
independently cause cadiometabolic disease [81]. In this scenario, VAT may 
simply be a marker of a dysmetabolic profile rather than a causal factor. 
Intraabdominal fat accumulation may be an indicator of the inability of SAT 
(adipose tissue deposited beneath the skin’s surface) to act as “energy sink”, 
which might result in the accumulation of fat in undesirable locations in the 
liver, skeletal muscle, heart and pancreatic β-cells [73]. Nonetheless, surgical 
removal of VAT in animal models has documented significant improvements 
in both hepatic and peripheral insulin sensitivity and glucose tolerance [82]. 
 
As noted by Klein et al., these hypotheses are not mutually exclusive. It is 
also possible that other unknown mechanisms may contribute [83]. Some 
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studies have suggested SAT to be equally important as a determinant of 
insulin resistance [84-86]. However, surgical removal of SAT in animal 
models failed to demonstrate an effect on glucose tolerance [82]. 
Additionally, liposuction of SAT in human subjects showed no improvement 
in insulin sensitivity [87]. It also had no noticeable effect on other 
cardiometabolic disease markers. Collectively, these findings support the 
theory that SAT plays a less important role in the aetiology of 
cardiometabolic disease than VAT [88].  
 
 
1.4 Direct Measurement of Adiposity 
A variety of measurement procedures have been proposed to assess VAT 
levels in order to enumerate individual susceptibility to cardiometabolic 
disease. Direct imaging techniques such as computed tomography, magnetic 
resonance imaging, and dual energy X-ray absorptiometry (DEXA) are used 
and allow direct quantification of body composition. Other non-imaging 
methods include hydrodensitometry, bioelectrical impedance, air 
displacement plethysmography and photonic scanning. However, many of 
these procedures require expensive apparatus and specialised personnel, 
while certain methods may carry an added risk of radiation exposure. As a 
result, anthropometry is more frequently utilised as a surrogate measure of 
body composition in research and clinical settings.  
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1.5 Surrogate Measures of Adiposity 
1.5.1 Body mass index 
Body mass index is the traditional diagnostic tool used in overweight and 
obesity classification most commonly employed within epidemiological 
research and healthcare practice. Calculated by dividing a subject’s weight 
by the square of their height, BMI correlates with cardiometabolic disease 
features, morbidity and mortality [6,89-93]. As a commonly used measure of 
general adiposity, BMI is understood by clinicians and public health workers, 
is simple to assess, and allows non-gender or ethnic-specific risk thresholds 
to be used. The WHO classifies a BMI of 25-29.9 as overweight, 30-34.9 as 
obese class I, 35-39.9 as obese class II, and one equal to or above 40 as 
obese class III [94]. While research has suggested that risk of type 2 
diabetes and CVD development may be higher in certain populations at a 
cut-off lower than 25, a WHO expert consultation committee recently 
concluded that current classifications should remain [95].  
 
Although straightforward to calculate, measurement of BMI does require the 
use of a calibrated electronic weighing scale and a stadiometer, which may 
not always be available in a clinical or field setting. Studies examining self-
reported BMI have reported discrepancies [96,97]. More importantly, as BMI 
is a weight-for-height measure, it is unable to distinguish between fat and 
lean mass. Findings have suggested that approximately half of obese 
subjects are metabolically healthy when classified using DEXA-derived body 
fat percentage, compared to approximately one-third by BMI [98]. 
Furthermore, a recent meta-analysis [61] found that class I obesity was not 
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associated with higher all-cause mortality and that overweight was related to 
significantly lower all-cause mortality, a relationship noted in other studies 
and described as the “obesity paradox” [99]. In light of this research, it has 
been suggested that BMI may misclassify adiposity in certain individuals.  
 
 
1.5.2 Central adiposity 
1.5.2.1 Waist circumference 
Waist circumference (WC) measurement has been recommended as a more 
direct method for central adiposity and VAT assessment. Determined by 
measuring the circumference of the waist using a flexible tape, studies 
suggest it to be more strongly related to cardiometabolic disease and 
mortality than BMI [58,100,101]. Waist circumference appraisal has also 
been adopted by the IDF as a mandatory component for diagnosing the 
MetS [19], and is also the only adiposity variable used in four alternative 
MetS definitions [21]. However, partly due to a lack of agreement on a 
universal measurement protocol, its clinical usefulness and superiority over 
BMI for evaluating cardiometabolic health has been questioned [12,102]. The 
WHO and IDF recommend WC assessment exactly midway between the 
lowest rib and iliac crest [12,19], while the United States National Institutes of 
Health suggest measurement at the superior border of the iliac crest [103]. 
Various other sites have been proposed and used, such as umbilical level, 
lowest rib and the narrowest point between the last rib and iliac crest 
[102,104-106]. Although a recent report [107] concluded that the procedure 
used for estimating WC had minimal effect on morbidity or mortality 
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outcomes, this is still uncertain [102]. Waist circumference cut-points for 
determining metabolic risk are used [12] but are region and gender-specific, 
due to ethnic and sex differences in body composition. This necessitates the 
use of separate risk cut-offs in different populations [108-112]. 
 
 
1.5.2.2 Waist-hip ratio 
Waist-hip ratio (WHR) is calculated by dividing WC by hip circumference and 
is thought to represent an aspect of body composition, related to 
cardiometabolic risk, not reflected in BMI or WC measurement. This index is 
also associated with cardiometabolic disease and mortality [113-116], and is 
the only central adiposity measure included in the WHO working definition of 
MetS [21]. Critics of WHR claim that as a ratio, it is complicated to interpret 
within a clinical setting [117]. Nevertheless, it should be noted that BMI is 
also a ratio and is easily used. A ratio allows universal population risk 
thresholds to be utilised, although this has not been fully explored [112,118], 
and current WHO recommendations do specify different WHR cut-offs for 
men and women [12]. The WHR also requires an additional anthropometric 
measurement, which may affect the reliability of this index, although hip 
circumference is more easily assessed than WC. Of greater concern is that 
WHR may remain unchanged in an individual even when body fat levels rise, 
as WC and hip circumference may increase or decrease proportionally [117]. 
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1.5.2.3 Waist-height ratio 
A more recently proposed central adiposity measure, the waist-height ratio 
(WHtR) is calculated by dividing WC by height. Similar to WHR, this variable 
is thought to more accurately reflect body fat distribution, and several studies 
suggest that it is a better discriminator of obesity-related conditions when 
compared to BMI, WC and WHR [119-122]. Unlike WHR, the WHtR only 
varies with an increase in body composition, as adult height remains 
relatively constant over time. Proponents of WHtR have also advised that the 
inclusion of height in an adiposity variable is desirable [123], as height is 
inversely associated with cardiometabolic disease and mortality [124]. 
 
As a ratio, WHtR may also allow the use of non-gender or ethnic-specific risk 
cut-points, which might make it additionally attractive from a clinical and 
public health perspective [125,126]. However, as calculation of this index 
also requires accurate height measurement, this may affect its practical 
usefulness. Moreover, some studies have suggested WHtR to be minimally 
superior, or even inferior, to WC as an indicator of cardiometabolic risk, and 
have questioned the measurement of height in addition to WC [127,128]. 
 
 
1.5.3 Novel indices 
Periodically, novel indices are constructed using transformations of general 
or central adiposity measures. Among these are Rohrer’s Index [129], the 
Conicity Index [130], the Abdominal Volume Index [131], A Body Shape 
Index [132] and several equations for determining body fat percentage 
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(BF%) using sagittal diameter [133] or skin-fold thickness measurements 
[134,135]. Recently, two novel adiposity indices for estimating BF% were 
proposed; Bergman et al. [136] determined a DEXA-validated measure using 
hip circumference and height, while Gómez-Ambrosi et al. [137] designed an 
equation utilising BMI, age and gender, and conducted a comparison study 
with other anthropometric measures and BF% estimated using air 
displacement plethysmography. However, as many of these novel indices 
use calculations which are complex, and perhaps difficult to interpret, their 
clinical utility and general usability must be questioned. Furthermore, there is 
a lack of research validating their usefulness. It is for these reasons that this 
PhD thesis exclusively examined the four most commonly assessed 
surrogate measures of general and central adiposity: BMI, WC, WHR and 
WHtR. 
 
 
1.6 Literature Review 
Over the last 20 years a considerable number of cross-sectional and 
prospective studies have attempted to quantify relationships between 
surrogate measures of adiposity and cardiometabolic disease, morbidity and 
mortality. However, results have been conflicting and inconclusive, and 
controversy still exists as to which index better indicates obesity-related 
metabolic risk. Increasingly, meta-analysis has gained recognition as a 
useful way of pooling results from numerous cohorts in order to average 
effect sizes across different studies. The benefits include increasing effective 
sample sizes and neutralising the influence of confounding factors, thus 
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allowing for a more precise evaluation of a risk, intervention, treatment or 
test.  
 
 
1.6.1 Methods 
1.6.1.1 Selection of studies 
This meta-review investigated BMI, WC, WHR and WHtR relationships with 
cardiometabolic features, obesity-related chronic diseases and mortality. 
Published meta-analyses relating to these topics from the year 2007 
onwards were searched using PubMed, Science Direct, Web of Knowledge, 
Academic Search Complete, JSTOR and Google Scholar databases. Search 
terms included a combination of keywords: body mass index or BMI, waist 
circumference or WC, waist-hip ratio, WHR or waist-to-hip ratio, waist-height 
ratio, WHtR, waist-to-height ratio, waist-to-stature ratio or WSR, meta-
analysis and systematic review and meta-analysis. There were no language 
restrictions as long as abstracts were published in English.  
 
The following were included: (1) meta-analyses which compared any two of 
the four indices of general or central adiposity (either BMI, WC, WHR or 
WHtR) using male, female or mixed adults of any ethnic group or age; (2) 
research using prospective or cross-sectional data; (3) studies examining 
cardiometabolic features or morbidity and mortality outcomes, including 
systolic or diastolic BP (SBP, DBP), triglycerides, HDL-C, low-density 
lipoprotein cholesterol (LDL-C), total cholesterol (Total-C) or FPG 
concentrations, elevated BP and hypertension, dyslipidaemia, MetS, type 2 
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diabetes, CVD (including CAD) or mortality. Children or adolescents were not 
included in any of the examined studies. 
 
 
1.6.1.2 Details of included studies 
Thirteen meta-analytic studies met inclusion criteria. Details and results are 
presented in Table 1. Five [127,138-141] studies included research which 
examined BMI, WC, WHR and WHtR, five [142-146] investigated three of the 
four indices, one [147] included studies examining WC and WHR, one [148] 
compared BMI with WHtR and one [149] contrasted BMI with central 
adiposity as defined by either WC measurement or the WHR. Seven 
[127,138,139,142,143,146,148] studies examined incident or prevalent type 
2 diabetes as an outcome, six [138,139,141-143,148] explored elevated BP 
or hypertension, three [138,143,148] dyslipidaemia, two [143,148] 
investigated MetS, three [143,147,148] either incident or prevalent CVD 
events, four [144,145,148,149] examined either all-cause or CVD mortality 
and one [140] compared adiposity variable correlations with metabolic 
features. Ten [127,138,140-144,146,148,149] studies included samples from 
multiple ethnic groups, one [145] included Europeans only and one [139] 
examined Asian subjects. Sampled populations for one meta-analysis [147] 
were not stated, although reviewed studies were listed. All meta-studies 
included subjects of both genders.  
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1.6.2 Results 
The main findings from these studies are stratified by the measures of 
association or discrimination reported [relative risk (RR), hazard ratio (HR), 
odds ratio (OR), area under the curve (AUC) or other] and are discussed in 
the context of cardiometabolic disease, morbidity and mortality outcomes.  
 
 
1.6.2.1 Studies reporting relative risks or hazard ratios 
Seven studies presented results as RRs or HRs. Both effect measures 
assess the risk of an event occurring by comparing the proportion of subjects 
(with or without an exposure) that develop an outcome [150].  
 
Three studies exclusively used prospective data and examined index 
relationships using defined thresholds. In a meta-regression analysis, using a 
random effects model restricted to nine cohorts which provided categorical 
boundaries for BMI, WC and WHR, Carmienke et al. [144] found the risk of 
all-cause mortality for BMI to be 27% comparing obese class II to normal 
weight. This contrasted with a 32% increased probability for WC and a 13% 
increased risk for WHR using gender-specific categorical cut-points 
compared to a normal reference value. Conversely, using overall pooled 
results from 15 studies comparing sex-specific extreme quantiles, de Koning 
et al. [147] suggested WHR to be more strongly related to CVD events (1.95, 
95% CI: 1.55-2.44) than WC (1.63, 95% CI: 1.31-2.04) in both men and 
women, although this difference was not statistically significant. Interestingly, 
in an individual participant meta-analysis using gender-specific tertiles, 
 
 
20 | P a g e  
 
Coutinho et al. [149] determined the risk of CAD mortality in subjects with 
central adiposity (defined by either WC or WHR) to be 70%, whereas BMI 
was inversely associated with mortality: 0.64, 95% CI: 0.59-0.69.  
 
In research employing both prospective and cross-sectional data, Savva et 
al. [148] also found central adiposity defined by WHtR to be a greater risk 
factor for CVD and all-cause mortality, type 2 diabetes and MetS, compared 
to BMI, in pooled estimates from 34 studies which defined both measures 
using optimal thresholds. Nevertheless, substantial heterogeneity between 
included studies was observed. It should be equally noted that the use of 
categorical cut-offs based on arbitrary cut-points, as used by Savva and 
Carmienke, poses problems regarding the validity of comparisons between 
adiposity measures. Also, as alluded to by Huxley et al. [151], a limitation of 
the de Koning study was that BMI was not included as a comparison index 
and that the analysis was not restricted to studies which examined both WC 
and WHR.   
 
Three studies employing longitudinal data used standardised Z-scores in 
analysis. Standardising values allows a uniform comparison of index 
relationships, and RRs or HRs represent the risk associated with a standard 
deviation (SD) increase in each measure. In a meta-analysis comparing data 
from 82,864 European subjects, Czernichow et al. [145] reported measures 
of central adiposity to be consistently and positively related to all-cause and 
CVD mortality. The risk of all-cause mortality was higher for WHR (12%) 
compared to WC (5%) while CVD mortality risk was the same for both 
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measures (15%). In a multivariable-adjusted model, a one SD increase in 
BMI appeared to confer protection against all-cause mortality (0.95, 95% CI: 
0.91-0.99), and showed no association with cardiovascular-related death 
(1.05, 95% CI: 0.98-1.14). In another study which used pooled RRs to 
examine index relationships with type 2 diabetes, Kodama et al. [127] found 
WC (63%) and WHtR (62%) to have a modest, but significantly stronger 
association compared to BMI (55%) and WHR (52%) in both men and 
women. Conversely, Vazquez et al. [146] observed similar risk of developing 
type 2 diabetes for BMI, WC, and WHR (87%-88%) using overall pooled 
effects from 32 cohorts. 
 
 
1.6.2.2 Studies reporting odds ratios or other statistic 
Three studies reported effect measures as ORs which represent the ratio of 
the odds of an event occurring in one group to the odds of it occurring in 
another. Although similar in interpretation to RRs, ORs generally 
overestimate associations between variables but are an approximation of the 
RR when the rare disease assumption holds [150].  
 
In an individual participant meta-analysis which stratified effect measures by 
ethnicity, Huxley et al. [142] found a 0.5 SD increment increase in BMI to be 
associated with a 20%-30% increased odds of having type 2 diabetes in 
Asian subjects. The corresponding odds using WC or WHR were 40%. 
However, ORs for hypertension were comparable between BMI, WC and 
WHR. Mohan [141] likewise noted similar strengths of association for BMI, 
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WC and WHtR regarding hypertension. A 0.5 SD increase was associated 
with a 40% versus 30% increased odds in Asian and non-Asians 
respectively. Nyamdorj et al. [139] also observed both general and central 
adiposity measures to be equally related with hypertension, while WHtR was 
more strongly associated with diabetes in men and women. Finally, research 
conducted by van Dijk et al. [140], which calculated the Pearson product-
moment correlation (an appraisal of the linear dependence of two variables), 
indicated WC to be more strongly correlated with each of the examined 
metabolic features in both genders, with the exception of HDL-C and LDL-C 
in men. 
 
 
1.6.2.3 Studies reporting measures of discrimination 
Five studies included results from receiver operating characteristic curve 
(ROC) analysis. The ROC curve is a graphical representation of the 
relationship between sensitivity and specificity. The AUC provides a scale 
from 0.5 to 1.0 (with 0.5 representing random chance and 1.0 indicating 
perfect discrimination) which allows the discriminatory abilities of different 
adiposity variables to be compared [150].  
 
In a meta-analysis of 31 prospective or cross-sectional studies which 
examined WHtR and either BMI or WC, Ashwell et al. [143] demonstrated 
WHtR to be a better discriminator than both BMI and WC for detecting type 2 
diabetes, hypertension, dyslipidaemia, MetS and CVD. Pooled results 
showed that WC improved discrimination of all outcomes by 3% (P<0.05), 
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compared to BMI, with WHtR showing an average AUC that was 4%-5% 
(P<0.01) larger than BMI. Results stratified by gender and cardiometabolic 
outcomes indicated similar relationships. Comparable findings were reported 
by Mohan [141], using cross-sectional data from the Obesity in Asia 
Collaboration. Central adiposity variables were found to be better 
discriminators of hypertension. Although the authors concluded that 
differences in AUC values were minimal, the WHtR displayed the highest 
discriminatory capacity compared to BMI in both male (AUC for WHtR=0.67 
versus AUC for BMI=0.63) and female (AUC for WHtR=0.71 versus AUC for 
BMI=0.66) subjects.  
 
In contrast, Nyamdorj et al. [139] found BMI to be a better discriminator of 
hypertension but not type 2 diabetes. In this study, which included over 
20,000 subjects, AUC values for WHtR in relation to prevalent diabetes were 
greater than BMI in both genders, although not statistically different. Similar 
results were again confirmed in a pooled analysis of 10 studies comparing 
BMI, WC, WHR and WHtR discrimination of incident and prevalent type 2 
diabetes, hypertension and dyslipidaemia. Lee et al. [138] reported that 
central adiposity measures were better discriminators than BMI, with WHtR 
showing a greater AUC for each outcome in both genders. However, 
statistical differences between WHtR and BMI were noticed only in men for 
type 2 diabetes (AUC for WHtR=0.726 versus AUC for BMI=0.672, P<0.01) 
and hypertension (AUC for WHtR=0.684 versus AUC for BMI=0.641, 
P=0.04). The authors also observed that a combination of BMI with any of 
the three abdominal measures did not improve discrimination of 
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cardiovascular risk factors. Of note is that within each of these meta-studies, 
index discrimination, using either BMI or central adiposity, was greater in 
women.  
 
Conversely, Czernichow et al. [145] found no clinically relevant difference 
between BMI, WC and WHR when comparing discrimination of all-cause or 
CVD mortality. Integrated discrimination improvement analysis, which 
measures the percentage of increased discrimination when a variable is 
added to a prediction model, identified a modest (<1%) but significant 
change when WHR was substituted for BMI. Discriminatory improvement for 
a model with WC, and models including any two of the examined adiposity 
measures, was also marginal. 
 
 
1.6.2.4 Recent research 
Although this review concentrated on meta-analytic studies, recent research 
employing large cohorts should also be considered in the context of 
surrogate measures of adiposity and cardiometabolic disease. In a cross-
sectional study, utilising data from 7,447 Spanish men and women aged 55-
80, Guasch-Ferré et al. [152] concluded that measures of central adiposity 
displayed greater discrimination of type 2 diabetes, impaired FPG, 
dyslipidaemia and MetS. The AUC values for WC and WHtR were 
significantly higher than AUCs for BMI with respect to each outcome except 
hypertension. Results were not stratified by gender, as no interactions 
between sex and examined outcomes were observed.  
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In another Spanish study, using prospective data from 37,733 subjects, 
Huerta et al. [153] found both general and central adiposity to be 
independently associated with diabetes. The WHtR index displayed the 
highest AUC values in both men (AUC=0.687) and women (AUC=0.776) 
compared to BMI (AUC=0.676 for men and AUC=0.759 for women) although 
discriminatory differences were small. The HRs of having type 2 diabetes 
were greater for central adiposity indices in women only, with BMI indicating 
the strongest association with diabetes in men. Similar results were 
demonstrated by the InterAct Consortium, a pan-European cohort with 
340,234 participants which examined incident diabetes. In this study, 
Langenberg et al. [154] also reported BMI and WC to be independently 
associated with diabetes. The association between WC and type 2 diabetes 
was especially strong in women, leading the authors to recommend central 
adiposity assessment as an effective strategy for risk stratification.  
 
Gender heterogeneity was additionally noted by Wannamethee et al. [155] in 
a seven year prospective study which compared BMI, WC and WHR abilities 
to predict diabetes development in 6,923 older men and women. The ROC 
analysis revealed similar AUCs for BMI and WC in males (AUC=0.726 and 
AUC=0.713 respectively), with WHR showing the least predictive ability 
(AUC=0.656). In females, WC was a significantly better discriminator 
(AUC=0.780) compared to both BMI (AUC=0.733) and WHR (AUC=0.728, 
P<0.01 for both). Conversely, in an analysis using pooled data from four 
German population-based longitudinal cohorts (N=10,258), Hartwig et al. 
[156] found WHtR to be equally predictive of type 2 diabetes in both genders 
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(AUC=0.75) compared to BMI (AUC=0.72 for men and AUC=0.71 for 
women). However, in a cross-sectional study of 12,294 adults, Mooney et al. 
[157] reported similar discriminatory capabilities for all indices regarding 
cardiometabolic risk factors in both men and women. Although central 
adiposity variables were superior discriminators of impaired FPG, BMI was a 
better discriminator of hypertension. 
 
 
1.6.3 Discussion 
Of the nine meta-analyses included in this review that reported effect 
measures as either RRs, HRs or ORs (and which included indices of both 
general and central adiposity), six [127,139,142,145,148,149] showed that 
central adiposity, defined by either WC, WHR or WHtR, was more strongly 
associated with a majority of the examined obesity-related conditions or 
mortality. Three [141,144,146] concluded that general and central adiposity 
indices displayed similar risk patterns. Subsequently, these results might 
suggest that central adiposity is a better indicator of cardiometabolic risk and 
chronic disease than BMI. However, these findings are ambiguous. Although 
on average, central adiposity measures displayed stronger relationships 
when compared to BMI, similar strengths of association were observed in 
many of the included studies. 
 
Equally important to consider is that measures of association do not 
necessarily indicate an ability to discriminate an outcome of interest. Of the 
five meta-studies which reported results from ROC analysis, only one [143] 
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demonstrated that central adiposity variables were significantly better 
discriminators than BMI, while one [138] reported that they were statistically 
superior in men only. Two [139,141] determined that AUCs were larger for 
central indices, but not significantly so, or that differences were minimal, and 
one concluded that there was no clinically relevant difference in 
discriminatory capabilities between either BMI, WC or WHR [145].  
 
As discussed by Pepe et al. [158], although a strong association is a 
necessary condition when comparing measures in terms of ability to 
discriminate, it is not sufficient, as even variables with strong associations 
may not adequately discriminate between subjects with or without an 
outcome. Moreover, while two of the examined meta-studies suggested that 
AUC values were significantly greater for central indices regarding specific 
outcomes, and the WHtR index was a noticeably better discriminator in 
several, the AUC is a summary statistic regarding the overall discriminatory 
performance of a marker and lacks clinical relevance. In addition, observed 
discriminatory differences between BMI and central adiposity indices were 
modest.  
  
Other factors should also be considered when drawing conclusions from this 
review. Meta-analysis, while an effective tool within epidemiological 
research, is not without its limitations. Several studies included numerous 
comparisons between one or more adiposity measures and outcomes, and 
less for others, thus giving some variables an inordinate weight in analysis 
[151]. Furthermore, as WC measurement has not been standardised 
 
 
28 | P a g e  
 
internationally, optimal measurement protocols for assessing metabolic risk 
may be different between included studies, thus influencing observed 
associations. The results from this meta-review also suggest heterogeneous 
relationships between adiposity measures and cardiometabolic disease 
relating to gender [143], and studies which do not stratify or use appropriate 
statistical methods may over or underestimate effect sizes and discriminatory 
differences. Also importantly, cardiometabolic outcomes may be classified 
differently within studies, with several using optimal procedures and different 
tests to define conditions (e.g. the OGTT for type 2 diabetes compared with 
FPG or the HbA1c assay) and some using only self-reported diagnosis 
[23,159,160]. Other aspects such as age or ethnicity may also influence 
results [58,161].  
 
 
1.6.4 Conclusions and rationale for further research 
Studies comparing BMI with central adiposity suggest the latter provides 
additional information (beyond that which is measured by BMI), as 
relationships between BMI and cardiometabolic disease are attenuated in 
regression models after the inclusion of WC [58,100], thus indicating that 
central adiposity explains a greater variance of obesity-related risk, or that 
both adiposity variables provide independent information 
[59,92,144,153,154]. In addition, research has suggested that centrally 
obese subjects classified as normal weight by BMI represent a particularly 
high-risk group [149,162-164]. However, just as critics of central adiposity 
assessment – who claim it as unnecessary, inaccurate and time-consuming 
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– neglect to state how much of an increase in discriminatory accuracy would 
be clinically relevant, so it is also true that proponents of WC, WHR or WHtR 
measurement often fail to clarify how much added information these indices 
might provide over BMI or other variables currently utilised in cardiometabolic 
risk algorithms.  
 
These concerns were examined by Klein et al. [83], who determined that 
measurement of WC in clinical practice would not be trivial, as providing 
such an assessment competes for the limited time available during patient 
appraisal and requires specific training to ensure reliable data are obtained. 
Nevertheless, WC measurement was recommended as a method to identify 
a potentially non-trivial number of patients at increased risk who might not be 
detected using conventional methods. Central adiposity indices might be 
effective tools for identifying metabolically unhealthy, normal weight or non-
obese subjects who could benefit from an intervention or lifestyle therapy, 
but who would not otherwise be considered for treatment if adiposity were 
measured using BMI. This idea was further explored in a WHO report [12] 
which suggested that central adiposity variables, used in conjunction with 
BMI, might contribute to the development of a composite index to 
discriminate high-risk patients.  
 
However, despite potential uses for central adiposity measures, a majority of 
research continues to demonstrate a significant and strong relationship 
between BMI and obesity-related conditions. This suggests its continued 
relevance for defining and assessing metabolic risk within epidemiology and 
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clinical practice. While results from this review might imply that central 
adiposity is a greater risk factor for cardiometabolic disease, type 2 diabetes 
and mortality, with regard to the clinical utility of central adiposity 
assessment, these findings are inconclusive. 
 
By exploring issues raised by this review, this thesis adds to the current 
knowledge base regarding the clinical relevance and potential usefulness of 
surrogate measures of adiposity as tools to identify high-risk patients. 
Specifically, it examines the rationale for routine assessment of adiposity 
within healthcare practice, and whether methods used for disease 
classification and anthropometric measurement procedure are important for 
diagnosing cardiometabolic risk and type 2 diabetes. It also compares 
adiposity variable relationships with a range of cardiometabolic disease 
features, biomarkers of chronic low-grade inflammation and type 2 diabetes. 
Finally, it explores whether central adiposity indices provide additional 
information regarding disease and risk status, beyond that which is normally 
assessed by BMI, and whether a composite index using both general and 
central adiposity measures might be clinically useful. 
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Table 1––Details and results from meta-analytic studies. 
Reference No. of 
Studies 
Population 
and No. of Subjects 
Indices 
Examined 
Main Outcome 
Measure 
Analysis Type Results Comments 
Ashwell 
et al. (2012) 
[143] 
31 4 Europe 
2 South America 
2 Australasia 
6 Asia 
2 Middle-East 
1 Caribbean 
14 other 
 
123,231 men 
182,620 women 
BMI 
WC 
WHtR 
Incident and 
prevalent type 
2 diabetes, 
hypertension, 
dyslipidaemia, 
MetS and CVD 
Pooled ROC 
analysis 
Pooled AUCs for all outcomes were: 0.667, 
0.650-0.684 (BMI), 0.694, 0.678-0.709 (WC) and 
0.704, 0.689-0.718 (WHtR) in men and 0.681, 
0.658-0.704 (BMI), 0.714, 0.698-0.731 (WC) and 
0.725, 0.709-0.741 (WHtR) in women 
 
 
WHtR was a better discriminator than 
BMI for all five specific health outcomes 
 
Statistical comparisons of central 
adiposity with BMI indicated that both 
WC and WHtR were significantly better 
at discriminating type 2 diabetes  
 
Compared with BMI, WC improved 
discrimination of adverse outcomes by 
3% (P<0.05) and WHtR improved 
discrimination by 4%-5% (P<0.01) 
 
Discriminatory ability was greater in 
women 
Carmienke 
et al. (2013) 
[144] 
18 6 Europe 
10 North America 
2 Australasia 
 
693,739 
men and women 
BMI 
WC 
WHR 
All-cause 
mortality 
Pooled RR using 
categorical 
variables 
RRs for all-cause mortality were: 1.27 (1.21-
1.33), 1.32 (1.22-1.43) and 1.13 (1.11-1.59) for 
1BMI, 2WC and 2WHR respectively 
 
1Obese class II compared to normal weight 
 
2Gender-specific categorical cut-point compared 
to normal reference 
Meta-regression analysis was restricted 
to nine cohorts that provided RRs and 
95% CIs and which defined category 
boundaries for adiposity measures 
 
All measures showed similar risk 
patterns for upper quartiles in 
comparison to reference quartiles 
 
Patterns of general and central adiposity 
remained significantly associated with 
mortality when adjusted for both 
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Table 1 continued 
Reference No. of 
Studies 
Population 
and No. of Subjects 
Indices 
Examined 
Main Outcome 
Measure 
Analysis Type Results Comments 
Coutinho 
et al. (2011) 
[149] 
5 2 Europe 
2 North America 
1 Asia 
 
15,923 
(59% men) 
BMI and 
central 
adiposity 
defined by 
either WC 
or WHR 
CAD mortality Individual 
participant meta-
analysis 
 
HR by index 
tertiles 
Overall gender-specific pooled RRs comparing 
upper to lower index tertiles were: 0.64 (0.59-
0.69) for BMI and 1.70 (1.58-1.83) for central 
adiposity defined by either WC or WHR 
Central adiposity was associated with 
mortality whereas BMI was inversely 
associated with mortality 
 
Central adiposity was also associated 
with higher mortality in a subset of 
subjects with normal BMI 
Czernichow 
et al. (2011) 
[145] 
9 Europe 
 
82,864 
men and women 
BMI 
WC 
WHR 
All-cause and 
CVD mortality 
Individual 
participant meta-
analysis 
 
HR comparing 
upper quintiles to 
lower quintiles 
and for a 1 SD 
increase in each 
index 
 
ROC and 
integrated 
discrimination 
improvement 
analysis  
For all-cause mortality, multivariable adjusted 
HRs for a 1 SD increase were: 0.95 (0.91-0.99), 
1.05 (1.00-1.09) and 1.12 (1.06-1.18) for BMI, 
WC and WHR respectively 
 
For CVD mortality, multivariable adjusted HRs 
for a 1 SD increase were: 1.05 (0.98-1.14), 1.15 
(1.05-1.25) and 1.15 (1.04-1.27) for BMI WC and 
WHR respectively 
 
 
 
 
Measures of central adiposity were more 
strongly associated with CVD mortality 
 
BMI was related to CVD mortality in age 
and gender adjusted models only 
 
There was a modest (<1%) enhancement 
in discriminative capability using WHR 
compared to BMI 
 
The advantage of using WC was also 
marginal 
 
Models combining two adiposity indices 
did not provide improvement in the 
prediction of mortality 
de Koning 
et al. (2007) 
[147] 
15 Not stated 
 
258,114  
(35.7% men) 
WC 
WHR 
Incident CVD 
events 
Pooled RR 
comparing highest 
to lowest quantiles 
of WC and WHR 
Overall risk estimate comparing extreme 
gender-specific quantiles for each measure 
were: 1.63 (1.31-2.04) for WC and 1.95 (1.55-
2.44) for WHR 
The results suggested that WHR was 
more strongly associated with CVD than 
WC although differences were not 
statistically significant 
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Table 1 continued 
Reference No. of 
Studies 
Population 
and No. of Subjects 
Indices 
Examined 
Main Outcome 
Measure 
Analysis Type Results Comments 
Huxley 
et al. (2008) 
[142] 
21 Asian (73%) 
Caucasian (27%) 
 
>263,000 
men and women 
BMI 
WC 
WHR 
Prevalent type 
2 diabetes and 
hypertension 
Individual 
participant meta-
analysis 
 
OR for a 0.5 SD 
increase in each 
index 
A 0.5 SD increment increase in BMI was 
associated with a 20%-30% increased odds of 
type 2 diabetes in Asian subjects 
 
A 0.5 SD increment increase in WC or WHR was 
associated with a 40% increased odds of type 2 
diabetes in Asian subjects 
ORs of having hypertension were similar 
for all measures of general and central 
adiposity 
 
Ethnic heterogeneity was observed in 
obesity/morbidity associations  
Kodama  
et al. (2012) 
[127] 
15 8 Western 
7 Non-Western 
 
120,012 
men and women 
BMI 
WC 
WHR 
WHtR 
Incident type 2 
diabetes 
Pooled RR for a 1 
SD increase in each 
index 
Pooled RRs for a 1 SD increase (men and women 
combined) were: 1.55 (1.43-1.69), 1.63 (1.49-
1.79), 1.52 (1.40-1.66) and 1.62 (1.48-1.78) for 
BMI, WC, WHR and WHtR respectively 
WC and WHtR showed a modest but 
significantly stronger association with 
type 2 diabetes compared to BMI or 
WHR, but measuring height in addition 
to WC appeared to have little additional 
benefit 
Lee 
et al. (2008) 
[138] 
10 1 Europe 
7 Asian 
1 Caribbean 
1 Iran 
 
88,514 
(54% women) 
BMI 
WC 
WHR 
WHtR 
Incident and 
prevalent type 
2 diabetes, 
hypertension 
and 
dyslipidaemia 
Pooled ROC 
analysis 
Pooled AUCs for type 2 diabetes were: 0.672, 
0.646-0.697 (BMI), 0.701, 0.670-0.732 (WC), 
0.721, 0.664-0.778 (WHR) and 0.726, 0.698-
0.754 (WHtR) in men and 0.693, 0.629-0.757 
(BMI), 0.744, 0.695-0.794 (WC), 0.748, 0.687-
0.810 (WHR) and 0.756, 0.700-0.811 (WHtR) in 
women 
WHtR was the best discriminator of type 
2 diabetes, hypertension and 
dyslipidaemia in both genders 
 
Statistical differences between BMI and 
WHtR were noticed only in men for type 
2 diabetes and hypertension 
 
Higher pooled AUCs were observed in 
females compared to males suggesting 
that discrimination is more precise in 
women 
 
The authors concluded that evidence 
supports the superiority of measures of 
central adiposity over BMI for detecting 
CVD risk factors 
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Table 1 continued 
Reference No. of 
Studies 
Population 
and No. of Subjects 
Indices 
Examined 
Main Outcome 
Measure 
Analysis Type Results Comments 
Mohan 
(2008) 
[141] 
19 Asian 
(62.8%) 
Caucasian (36.7%) 
Pacific Islanders 
(0.5%) 
 
>173,709 
(53% women) 
 
 
BMI 
WC 
WHR 
WHtR 
Prevalent 
hypertension 
Individual 
participant meta-
analysis 
 
Adjusted linear 
regression 
between indices 
and SBP/DBP 
stratified by 
ethnicity 
 
OR for a 0.5 SD 
increase in each 
index 
 
ROC analysis 
stratified by 
ethnicity and 
overall pooled 
results 
Similar strengths of association with 
hypertension were noted for BMI, WC and 
WHtR: 40% versus 30% in Asian and non-Asians 
respectively 
 
Pooled AUCs for hypertension were: 0.63, 0.62-
0.66 (BMI), 0.66, 0.64-0.67 (WC), 0.65, 0.63-0.67 
(WHR) and 0.67, 0.66-0.69 (WHtR) in men and 
0.66, 0.64-0.68 (BMI), 0.69, 0.63-0.72 (WC), 0.68, 
0.65-0.70 (WHR) and 0.71, 0.68-0.73 (WHtR) in 
women 
Measures of central adiposity tended to 
be better discriminators of hypertension 
in both genders 
 
Overall, WHtR had the highest 
discriminatory capability, although the 
authors concluded that no 
anthropometric variable was 
systematically better than the others for 
discriminating hypertension 
 
Heterogeneity in associations and 
discriminatory capacity were observed 
between different ethnic populations 
 
 
Nyamdorj 
et al. (2008) 
[139] 
16 Asia 
 
9,095 men 
11,732 women 
 
 
BMI 
WC 
WHR 
WHtR 
Prevalent type 
2 diabetes and 
hypertension 
Individual 
participant meta-
analysis 
 
OR for a 1 SD 
increase in each 
index 
 
ROC analysis 
Pooled AUCs for type 2 diabetes were: 0.725, 
0.706-0.743 (BMI), 0.729, 0.711-0.747 (WC), 
0.729, 0.711-0.747 (WHR), and 0.735, 0.717-
0.753 (WHtR) in men and 0.742, 0.726-0.756 
(BMI), 0.749, 0.734-0.765 (WC), 0.742, 0.727-
0.758 (WHR) and 0.748, 0.733-0.764 (WHtR) in 
women 
WHtR displayed a stronger association 
with diabetes compared to BMI but all 
indices were equally strongly associated 
with hypertension 
 
AUCs were slightly higher for diabetes 
using WHtR (both genders) and for WC 
(in women), and greater for BMI 
regarding hypertension, in both genders 
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Table 1 continued 
Reference No. of 
Studies 
Population 
and No. of Subjects 
Indices 
Examined 
Main Outcome 
Measure 
Analysis Type Results Comments 
Savva 
et al. (2013) 
[148] 
34 Asian and non-
Asians 
 
512,809 men and 
women 
BMI 
WHtR 
Incident and 
prevalent type 
2 diabetes, 
elevated BP, 
dyslipidaemia, 
MetS, CVD, all-
cause and CVD 
mortality  
Pooled estimate of 
the ratio of RRs 
(rRR [=RRBMI/ 
RRWHtR]) using 
optimal BMI and 
WHtR cut-offs 
 
WHtR was found to have a stronger association 
than BMI with type 2 diabetes (RR: 0.71, 0.59–
0.84) and MetS (RR: 0.92, 0.89–0.96) in cross-
sectional studies 
 
In prospective studies, WHtR appeared to be 
more strongly associated with several outcomes 
including incident CVD, all-cause and CVD 
mortality 
The usefulness of WHtR appears to be 
better in Asian than in non-Asian 
populations 
 
There was substantial heterogeneity 
between included studies 
van Dijk 
et al. (2012) 
[140] 
20 11 Europe 
7 North America 
1 Turkey 
1 Australasia 
 
21,139 men 
24,139 women 
BMI 
WC 
WHR 
WHtR 
Metabolic 
features: FPG, 
SBP, DBP,  
HDL-C, LDL-C, 
Total-C and 
triglycerides 
Pooled mean 
Pearson 
correlation 
coefficients 
between each 
index and 
metabolic features 
Mean Pearson correlation coefficients for FPG 
were: 0.188 ± 0.019 (BMI), 0.227 ± 0.030 (WC), 
0.213 ± 0.029 (WHR) and 0.136 ± 0.013 (WHtR) 
in men and 0.243 ± 0.024 (BMI), 0.289 ± 0.038 
(WC), 0.261 ± 0.035 (WHR) and 0.171 ± 0.014 
(WHtR) in women 
WC displayed the strongest correlation 
with metabolic features in both men and 
women, except for HDL-C and LDL-C in 
men 
 
When comparing BMI to WC, the latter 
showed significantly better correlation 
with metabolic features, except for DBP 
in women and HDL-C and Total-C in men 
Vazquez 
et al. (2007) 
[146] 
32 9 Europe 
12 North America 
4 Asia 
7 Other 
 
31,702 
men and women 
BMI 
WC 
WHR 
Incident type 2 
diabetes 
Pooled RR for a 1 
SD increase in each 
index 
Pooled RRs for a 1 SD increase were: 1.87 (1.67-
2.10), 1.87 (1.58-2.20) and 1.88 (1.61-2.19) for 
BMI WC and WHR respectively 
Similar associations with type 2 diabetes 
were noted for all adiposity measures  
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1.7 Thesis Outline 
1.7.1 Aims and objectives 
The overall aim of this PhD research was to determine how useful surrogate 
measures of adiposity might be to identify high-risk patients within a clinical 
setting. Specific aims and objectives of the research and corresponding 
chapters are presented in Figure 1. 
 
Four specific research aims were identified. These were: 
1. to examine the rationale for adiposity measurement within clinical 
practice; 
2. to compare cardiometabolic feature relationships with type 2 diabetes 
and pre-diabetes diagnosed by different tests; 
3. to investigate mechanisms of association between measures of 
adiposity and type 2 diabetes; 
4. to assess adiposity variable discriminatory capability. 
 
The specific objectives were: 
1. to examine why adiposity measurement might be clinically useful 
within Ireland to identify high-risk patients, such as those with 
undiagnosed diabetes; 
2. to determine how type 2 diabetes and cardiometabolic risk should be 
diagnosed within clinical practice and epidemiological research;  
3. to determine which metabolic variables are related to type 2 diabetes 
and diabetes development with reference to both established 
components of the MetS and novel inflammatory biomarkers; 
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4. to explore adiposity variable relationships (including individual 
variables and derived composite indices) with features of 
cardiometabolic disease and type 2 diabetes; 
5. to examine adiposity index discrimination of cardiometabolic risk and 
type 2 diabetes using different anthropometric measurements; 
6. to investigate whether a composite index using measures of both 
general and central adiposity might be clinically useful. 
 
 
1.7.2 Research outputs  
Chapter 2 (Paper 1) examines the prevalence of undiagnosed and 
diagnosed type 2 diabetes within our sample. This study compares features 
between these two groups in order to determine why certain individuals 
remain undetected. It also evaluates variables which might be useful in 
screening programmes within Ireland to identify undiagnosed cases, and 
suggests a rationale for adiposity measurement within clinical practice. The 
findings from this research were published in the journal PLOS ONE in 
November 2013 [165]. 
 
Chapter 3 (Paper 2) compares cardiometabolic feature relationships with 
type 2 diabetes and pre-diabetes diagnosed by different procedures (HbA1c 
and FPG). Although these conditions represent the two major 
cardiometabolic outcomes within our sample, they are “soft” outcomes 
defined on the basis of a positive test. Glycated haemoglobin A1c 
measurement has been recommended for diagnosis of type 2 diabetes, and 
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as a procedure to detect subjects at a high-risk state of developing diabetes. 
However, controversy exists regarding its use within clinical practice and as 
a method for defining outcomes within epidemiology. In particular, research 
has suggested discordance between HbA1c and the FPG test, which was 
more commonly employed as a diagnostic tool in Ireland before 2010. The 
objectives of this paper were to validate HbA1c measurement within our 
sample against FPG as a method for classifying diabetes and 
cardiometabolic disease risk, and also to observe metabolic variable 
relationships with type 2 diabetes and pre-diabetes. The results from this 
study were published in the journal PLOS ONE in August 2015 [166]. 
 
Chapter 4 (Paper 3) examines adiposity variable relationships with diabetes-
related metabolic features and type 2 diabetes. It investigates whether WC 
measurement protocol influences discriminatory accuracy. It also compares 
BMI with central obesity measures to determine whether general or central 
adiposity is a better indicator of cardiometabolic risk and type 2 diabetes. 
The findings from this research were published in the journal PLOS ONE in 
June 2015 [167]. 
 
Chapter 5 (Paper 4) explores general and central adiposity relationships with 
biomarkers of inflammation. Chronic low-grade inflammation has been 
suggested as a possible mechanism linking adiposity with type 2 diabetes. 
This paper compares BMI and WC associations with markers of low-grade 
inflammation and type 2 diabetes in order to ascertain whether general or 
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central adiposity is a greater risk factor for diabetes-related systemic 
inflammation.  
 
Chapter 6 (Paper 5) assesses the utility of a composite index for adiposity 
measurement. It examines if joint use of BMI and WHtR might refine body fat 
classification, and whether a combination of both adiposity measures could 
help stratify high and low-risk patients. The results from this study were 
published in the BMC journal Diabetology & Metabolic Syndrome in 
September 2015 [168]. 
 
 
1.7.3 Author’s contribution 
I was the lead author of the research papers presented in Chapters 3, 4, 5 
and 6. This involved the formulation of the research question for each 
chapter, conducting literature searching, data analysis and the drafting of 
each manuscript.  
 
The research question for Chapter 2 was originally examined as part of 
Master’s thesis project on which I was a tutor. I was involved in the 
formulation of the research question. In addition, the data analysis, writing 
and revisions of the submitted manuscript were performed by me. These 
contributions are acknowledged in the author contributions section of the 
published paper.  
 
 
 
Figure 1––Overview of aims, objectives and research outputs. 
 
 
 
 
Research Question 
Objectives 
Outputs 
Could surrogate measures of adiposity be clinically useful as tools to 
identify high-risk patients? 
 
To examine the 
rationale for adiposity 
measurement within 
clinical practice 
 
To compare 
cardiometabolic feature 
relationships with type 2 
diabetes and pre-diabetes 
diagnosed by different tests 
 
To investigate 
mechanisms of 
association between 
measures of adiposity 
and type 2 diabetes 
 
To assess adiposity 
variable discriminatory 
capability  
 
To examine why adiposity 
measurement might be 
clinically useful within 
Ireland to identify high-risk 
patients 
 
To determine which 
metabolic variables 
are related to type 2 
diabetes and diabetes 
development 
 
To determine how 
type 2 diabetes and 
cardiometabolic risk 
should be diagnosed 
within clinical practice 
and epidemiological 
research 
To explore adiposity 
variable relationships 
with features of 
cardiometabolic 
disease and type 2 
diabetes 
 
To examine adiposity 
index discrimination of 
cardiometabolic risk and 
type 2 diabetes using 
different anthropometric 
measurements 
 
To investigate whether 
a composite index 
using measures of both 
general and central 
adiposity might be 
clinically useful 
 
Aims
Chapter 2: 
The Prevalence and 
Determinants of 
Undiagnosed and 
Diagnosed Type 2 
Diabetes in Middle-Aged 
Irish Adults 
 
Chapter 3: 
HbA1c Alone is a Poor 
Indicator of Cardiometabolic 
Risk in Middle-Aged 
Subjects with Pre-Diabetes 
but is Suitable for Type 2 
Diabetes Diagnosis:  
A Cross-Sectional Study 
 
Chapter 4: 
Optimal Central 
Obesity Measurement 
Site for Assessing 
Cardiometabolic and 
Type 2 Diabetes Risk 
in Middle-Aged Adults 
 
Chapter 5: 
General and Central 
Obesity Measurement 
Associations with 
Markers of Chronic Low-
Grade Inflammation and 
Type 2 Diabetes 
 
Chapter 6: 
Assessing Cardiometabolic 
Risk in Middle-Aged Adults 
Using Body Mass Index and 
Waist-Height Ratio – Are 
Concordant Results by Two 
Indices Better than 
Discordant Results?  
A Cross-Sectional Study 
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1.8 Methods 
1.8.1 The Cork and Kerry Diabetes and Heart Disease Study 
This thesis makes use of data from the Cork and Kerry Diabetes and Heart 
Disease Study – Phase II (The Mitchelstown Cohort). In 2010, as part of the 
Health Research Board Centre for Health and Diet Research, we received 
funding to recruit a cohort of subjects in order to provide an updated profile of 
glucose tolerance status, cardiometabolic health and related factors in a 
middle-aged Irish population. This study utilised field survey procedures and 
equipment similar to those used in the original 1998 Cork and Kerry Diabetes 
and Heart Disease Study [169].  
 
 
1.8.2 Ethical approval and sampling procedure 
A cross-sectional random sample of 2,047 middle-aged men and women 
was recruited from patients attending a single large primary care centre in 
Mitchelstown, County Cork, Ireland. The Livinghealth Clinic includes nine 
general practitioners and the practice serves a catchment area of 
approximately 20,000, with a mix of urban and rural residents. Ethics 
committee approval conforming to the Declaration of Helsinki was obtained 
from the Clinical Research Ethics Committee of University College Cork.  
 
The name, address, gender and date of birth were provided for all registered 
attending patients in the clinic, and stratified sampling was employed to 
recruit equal numbers of men and women in the 46-73 year age group. In 
total, 3,807 potential participants were selected from the practice list. 
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Following the exclusion of duplicates, deaths, and subjects incapable of 
consenting or attending appointment, 3,051 were invited to participate in the 
study and of these, 2,047 (49.2% male) completed the questionnaire and 
physical examination components of the baseline assessment (response 
rate: 67.1%).  
 
The status of non-responders included individuals refusing to participate 
(59.4%) and those who did not reply (40.6%). Male subjects accounted for 
53.7% of non-responders while 43.5% (versus 42.8% of responders) were 
>60 years of age. All non-responders were followed up with a phone call 
where possible and otherwise with a single postal reminder. Signed informed 
consent was obtained from each participant before commencing the 
assessment.  
 
 
1.8.3 Study delivery and quality control 
Fasting blood samples were taken to determine lipid and lipoprotein 
concentrations, glycaemic status, full blood counts and a biochemical profile. 
Clinical measurements taken by trained researchers included BP readings 
and anthropometric measurements. Anthropometric variables assessed 
included weight, height, WC measured at two sites (midway and lowest rib), 
hip circumference and pelvic width. Details regarding anthropometric 
measurement protocols are included in Appendix 5. Survey instruments and 
variable definitions are addressed in each of the relevant chapters to follow.  
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Participants were required to complete a General Health Questionnaire 
(GHQ) [170]. Physical activity levels were assessed using the International 
Physical Activity Questionnaire (IPAQ) [171]. Both the GHQ and IPAQ have 
been proven to be valid and reliable and were used in the 1998 study [169] 
and the SLÁN 2007: Survey of Lifestyle, Attitudes and Nutrition [172].   
 
All procedures were carried out with reference to guidelines outlined in a 
standard operating procedures manual and all results were recorded on a 
clinical report form. Data from the report form, GHQ and IPAQ were scanned 
using TeleformTM and information was verified against the hard copy. Data 
were subsequently exported to MS-Excel and were again checked against 
the hard copy. When data entry was complete for each variable, 10% of the 
sample was randomly checked for errors.  
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2.0 Abstract 
Background and Objectives  
The prevalence of type 2 diabetes within the Republic of Ireland is poorly 
defined, although a recent report suggested 135,000 cases in adults aged 
45+, with approximately one-third of these undiagnosed. This study aims to 
assess the prevalence of undiagnosed and diagnosed diabetes in middle-
aged Irish adults and compare features between these two groups in order to 
investigate why certain individuals remain undetected. 
 
 
Materials and Methods  
This was a cross-sectional study involving a random sample of 2,047 men 
and women aged 46-73 years. Univariate logistic regression was used to 
explore socio-economic, metabolic and other health-related variable 
associations with undiagnosed and diagnosed diabetes. A final multivariable 
analysis was used to determine odds ratios of having undiagnosed 
compared to diagnosed diabetes, adjusting for age, gender and significant 
covariates determined from univariate models. 
 
 
Results 
The total prevalence of diabetes was 8.5% (95% CI: 7.4%-9.8%); 72 subjects 
(3.5%) had undiagnosed diabetes (95% CI: 2.8%-4.4%) and 102 subjects 
(5.0%) had diagnosed diabetes (95% CI: 4.1%-6.0%). Adiposity, 
dyslipidaemia and having a family history of diabetes were positively 
 
 
46 | P a g e  
 
associated with both undiagnosed and diagnosed type 2 diabetes. When 
compared to diagnosed subjects, study participants with undiagnosed 
diabetes were significantly more likely to have higher levels of adiposity and 
low levels of physical activity, and they were less likely to be on treatment for 
diabetes-related conditions or to have private medical insurance.  
 
 
Conclusions 
The prevalence of type 2 diabetes within the Cork and Kerry Diabetes and 
Heart Disease Study is comparable to a recent estimate from the SLÁN 
2007: Survey of Lifestyle, Attitudes and Nutrition, a study which was 
nationally representative of the general population. A high percentage of 
diabetes cases were undiagnosed (41%), emphasising the need for more 
effective detection strategies and equitable access to primary healthcare. 
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2.1 Introduction  
Type 2 diabetes mellitus, a chronic disease which causes significant 
morbidity and mortality, was the ninth leading cause of death worldwide in 
2008 [173]. Diabetes is associated with obesity, dyslipidaemia and 
hypertension, and is characterised by chronic hyperglycaemia due to 
insufficient insulin release, impaired insulin action, or a combination of both 
[23]. Importantly, the persistent hyperglycaemia that is associated with 
diabetes may cause serious health complications such as cardiovascular 
disease (CVD) and impairment and malfunction of the renal, ophthalmic, 
vascular and nervous systems [25]. These complications pose significant 
financial burdens on healthcare services; research conducted in 2006, which 
examined economic consequences related to type 2 diabetes, estimated that 
almost 10% of total healthcare expenditure was spent on diabetes care in the 
Republic of Ireland alone [174]. 
 
The prevalence of type 2 diabetes is increasing globally, representing a key 
public health issue [175]. There is a lack of research relating to diabetes in 
Ireland, although recent studies have indicated that the condition may be 
reaching epidemic proportions [176,177]. In 1998, the prevalence of diabetes 
amongst subjects in a primary care based sample was estimated to be 3.9% 
[169]. A recent report from the Irish Institute of Public Health (IPH) [178] 
based on findings from the SLÁN 2007: Survey of Lifestyle, Attitudes and 
Nutrition [172], suggested a prevalence of 8.9% in adults aged 45+. This 
estimate consisted of 94,000 subjects with clinically diagnosed type 2 
diabetes and 41,000 with undiagnosed diabetes. While the efficacy and cost-
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effectiveness of routine screening for diabetes in primary care has not been 
established [179-181], there is an ongoing need for contemporary data on 
the prevalence of type 2 diabetes, in population and primary care settings, in 
order to guide policy in this area. This could help formulate strategies that 
further develop effective diabetes prevention, detection and management, as 
individuals with undiagnosed diabetes are at a high-risk of diabetic 
complications [182]. 
 
The aim of this study was to estimate the prevalence of undiagnosed and 
diagnosed type 2 diabetes in a random sample of men and women aged 46-
73 years, drawn from a primary care setting similar to that studied in 1998 
[169], using the same field survey procedures and methods. In particular, we 
compared features between these two groups in order to determine why 
certain individuals remain undetected. 
 
 
2.2 Materials and Methods 
2.2.1 Study design 
The study design is described in detail in Chapter 1. In summary, the Cork 
and Kerry Diabetes and Heart Disease Study (Phase II) was a single centre, 
cross-sectional study conducted between 2010 and 2011. A random sample 
was recruited from a large primary care centre in Mitchelstown, County Cork, 
Ireland. The Livinghealth Clinic serves a population of approximately 20,000, 
with a mix of urban and rural residents. Stratified sampling was employed to 
recruit equal numbers of men and women from all registered attending 
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patients in the 46-73 year age group. In total, 3,807 potential participants 
were selected from the practice list. Following the exclusion of duplicates, 
deaths, and subjects incapable of consenting or attending appointment, 
3,051 were invited to participate in the study and of these, 2,047 (49.2% 
male) completed the questionnaire and physical examination components of 
the baseline assessment (response rate: 67.1%). Details regarding the study 
design, sampling procedures and methods of data collection have been 
reported previously [183].  
 
Ethics committee approval conforming to the Declaration of Helsinki was 
obtained from the Clinical Research Ethics Committee of University College 
Cork. A letter signed by the contact GP in the clinic was sent out to all 
selected participants with a reply slip indicating acceptance or refusal. All 
subjects gave signed informed consent, including permission to use their 
data for research purposes.  
 
 
2.2.2 Clinical and laboratory procedures  
The weight and height of each subject were measured to the nearest 0.1 kg 
and 0.1 cm respectively by trained researchers. Study participants were 
asked to remove heavy outer clothing and footwear. Portable electronic 
Tanita WB-100MA weighing scales (Tanita Corporation, IL, USA) were 
placed on a firm, flat surface and were calibrated weekly to ensure accuracy. 
Height was measured using a portable Seca Leicester height/length 
stadiometer (Seca, Birmingham, UK). Three measurements of systolic and 
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diastolic blood pressure (SBP and DBP respectively) were obtained with the 
subject in a seated position using an Omron M7 digital sphygmomanometer 
(Omron Healthcare Co. Ltd., Japan). The mean of the second and third 
readings was considered to be a subject’s blood pressure.  
 
After an overnight fast, participants were invited to attend the clinic for the 
sampling of blood between 8 and 10 A.M. Triglyceride and high-density 
lipoprotein cholesterol (HDL-C) levels were measured by Cork University 
Hospital Biochemistry Laboratory on Olympus 5400 biochemistry analysers 
with Olympus reagents using standardised procedures and fresh samples 
(Olympus Diagnostica Gmbh, Hamburg, Germany). Fasting plasma glucose 
(FPG) concentrations were determined using a glucose hexokinase assay 
(Olympus Life and Material Science Europa Ltd., Lismeehan, Co. Clare, 
Ireland). Glycated haemoglobin A1c (HbA1c) levels were measured in the 
haematology laboratory on an automated high-pressure liquid 
chromatography instrument Tosoh G7 (Tosoh HLD-723 (G7), Tosoh Europe 
N.V, Tessenderlo, Belgium).  
 
A self-administered General Health Questionnaire (GHQ) [170] was used to 
collect supplementary information which included prescription (Rx) 
medication use, demographic characteristics, medical cover, family diabetes 
history, past medical history of CVD and smoking/alcohol behaviours. 
Physical activity levels were assessed using the International Physical 
Activity Questionnaire (IPAQ) [171]. 
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2.2.3 Metabolic and anthropometric variables 
Lipid, lipoprotein and FPG levels were classified according to National 
Cholesterol Education Program: Adult Treatment Panel III guidelines [184]. 
Abnormal metabolic risks were defined as high triglycerides >1.7 mmol/l, low 
HDL-C (<1.03 mmol/l in males or <1.29 mmol/l in females) and impaired 
FPG >5.6 mmol/l. Dyslipidaemia was determined according to both elevated 
triglyceride and low HDL-C levels. Hypertension was defined according to 
World Health Organisation guidelines as SBP >140 mmHg and/or DBP >90 
mmHg [185]. Body mass index (BMI) was calculated by dividing a subject’s 
weight by the square of their height and was categorised as <25 = normal 
weight, 25-29.9 = overweight and >30 = obese [94]. 
 
 
2.2.4 Morbidity  
Type 2 diabetes [23] was defined as HbA1c >6.5% (>48 mmol/mol), (N=146). 
Undiagnosed diabetes was determined if subjects had positive HbA1c tests 
but did not report a medical diagnosis of diabetes or oral medication use for 
the condition (N=72). Diagnosed diabetes was classified according to 
positive test results and a self-reported physician diagnosis or diabetes 
medication use (N=74), or by diagnosis or medication use alone (N=28, total 
diagnosed=102). The presence of CVD was obtained from the GHQ by 
asking study participants if they had been diagnosed with one of the 
following seven conditions: heart attack (including coronary thrombosis or 
myocardial infarction), heart failure, angina, aortic aneurysm, hardening of 
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the arteries, stroke or any other heart trouble. Subjects indicating a diagnosis 
of any of these disorders were classified as having CVD. 
 
 
2.2.5 Covariates 
Other covariates utilised from the GHQ included age, gender, use of Rx anti-
hypertensive and cholesterol-lowering medications, family diabetes history, 
education, social class, medical cover, smoking status and alcohol use. Age 
was included either as a dichotomous (<60/>60 years of age) or continuous 
variable in univariate or multivariable regression models. Education was 
divided into four categories: primary, secondary, diploma and bachelor or 
higher. Social class was defined according to the European Socio-economic 
Classification method (ESeC) [186], and collapsed into three groups: high 
income, middle income and low income. The health service variables – 
private insurance, no insurance and means-tested, state-assisted general 
practice visit card (GPC) and full medical card (FMC) – were transformed 
into a dummy variable: private insurance, state insurance, no insurance. 
Subjects reporting more than one insurance type were assigned to the higher 
insurance category. Self-reported physical activity within the previous six 
months, measured using the IPAQ questionnaire, was divided into three 
categories: high, moderate and no physical exercise. Alcohol use was 
assessed by asking study participants how often they consumed alcohol on a 
monthly or weekly basis, and was classified as follows: “never or less than 
once a month” = non-drinker, “2-4 times monthly” = occasional drinker and 
“twice or more weekly” = regular drinker. Subjects were considered to have 
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ever smoked if they smoked cigarettes during the recruitment phase, had 
smoked within the last 10 years or had smoked more than 100 cigarettes in 
their lifetime, and non-smokers if they had smoked less than this or had 
never smoked. 
 
 
2.2.6 Statistical analysis 
The descriptive characteristics of the study population were examined 
according to diabetes status. Gender differences in type 2 diabetes 
prevalence were compared using chi-square tests. Health condition, health 
behaviour, health insurance, socio-economic and metabolic variable 
associations with undiagnosed or diagnosed diabetes were explored through 
multiple univariate binary logistic regressions. Diagnosed subjects were 
excluded from models examining undiagnosed type 2 diabetes, while models 
investigating relationships between features and diagnosed diabetes 
excluded undiagnosed cases. Distinctions between undiagnosed and 
diagnosed diabetes were explored in univariate analyses excluding non-
diabetic patients.  
 
To further compare feature/morbidity relationships and strengths of 
association with either undiagnosed or diagnosed diabetes, multivariable 
logistic regressions were performed. To select independent predictor 
variables (IPV) to be included in analysis, IPVs that had a P value of less 
than 0.2 in univariate models were included in stepwise forward and 
backwards entry elimination multivariable analysis, with model stability 
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assessed using the likelihood ratio (LR). Variables indicating a significant 
relationship (P<0.05) with either condition were then entered sequentially, by 
order of magnitude of the chi-square association, into two independent 
logistic regressions, adjusting for gender and age as a dichotomous 
(<60/>60) variable. Using the same procedures, a final multivariable model 
comparing undiagnosed to diagnosed diabetes was determined, adjusting for 
gender and age as a continuous measure.  
 
The discriminatory properties of clinically relevant IPVs indentified in analysis 
were evaluated. Models including these variables were assessed for their 
ability to detect undiagnosed or diagnosed diabetes using the c statistic. The 
c statistic is identical to the area under the receiver operating characteristic 
curve (ROC), with values ranging from 0.5 (no better than chance) to 1.0 
(indicating perfect discrimination) [150].  
 
Primary data analysis was conducted using IBM SPSS Statistics Version 20 
(IBM Corp., Armonk, NY, USA) for Windows. Confidence intervals for 
prevalence proportions were calculated using the VasserStats statistical 
website [187]. For all analyses, a P value (two-tailed) of less than 0.05 was 
considered to indicate statistical significance. Glycated haemoglobin A1c test 
results and diagnostic status information were available for 1,995 (97.5%) 
and 1,999 (97.7%) subjects respectively. Analysis indicated a similar 
percentage of missing data according to either undiagnosed or diagnosed 
diabetes classifications. Missing data were thus assumed to be ignorable 
and missing at random.  
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2.3 Results 
2.3.1 Descriptive characteristics 
The baseline characteristics of the study population for participants with 
undiagnosed, diagnosed and no diabetes are shown in Table 2. The total 
prevalence of type 2 diabetes was 8.5% (95% CI: 7.4%-9.8%); 102 (5.0%) 
subjects had diagnosed diabetes (95% CI: 4.1%-6.0%) and 72 (3.5%) had 
undiagnosed diabetes (95% CI: 2.8%-4.4%), representing 41% of all 
diabetes cases. The prevalence of diabetes was higher in male subjects 11% 
(N=112) compared to females 6% (N=62, P<0.001), and a greater proportion 
of males had both undiagnosed and diagnosed diabetes. When compared to 
non-diabetic subjects, a high percentage of patients with type 2 diabetes 
were overweight or obese, used Rx anti-hypertensive and cholesterol-
lowering medications, had CVD and a family history of diabetes, finished 
education at primary level and reported having low levels of physical activity 
within the previous six months. Variations in health insurance were also 
noted, with a higher percentage of diabetes cases having state-assisted 
healthcare. 
 
 
2.3.2 Risk feature associations with type 2 diabetes  
In univariate analysis (Appendix 1, Supporting Table 1), overweight and 
obesity, CVD, family diabetes history, elevated triglycerides, low HDL-C and 
dyslipidaemia were significantly associated with both undiagnosed and 
diagnosed diabetes. Relationships between reduced physical activity levels 
and type 2 diabetes were noticeably strong, with seven-fold and approximate 
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two-fold increased odds for undiagnosed and diagnosed diabetes 
respectively. With regard to health services related factors, there was a two-
fold increased likelihood of undiagnosed diabetes in patients on treatment for 
hypertension versus a five-fold increased odds for diagnosed diabetes. 
Similarly, the odds of having undiagnosed diabetes were approximately two-
fold higher in patients on treatment with cholesterol-lowering therapy versus 
an approximate four-fold increased odds for diagnosed diabetes. The 
probability of both undiagnosed and diagnosed type 2 diabetes was 
significantly reduced in patients with private medical insurance, whilst the 
odds of having undiagnosed diabetes were significantly increased in subjects 
with no medical insurance (OR: 3.0, 95% CI: 1.6-5.6). 
 
Multivariable analysis (Table 3) revealed overweight and obesity, use of 
cholesterol-lowering medication, family diabetes history and dyslipidaemia to 
be associated with both undiagnosed and diagnosed type 2 diabetes. Low-
level physical activity (OR: 5.8, 95% CI: 2.7-12.5) and health service 
variables remained significant determinants of undiagnosed diabetes, with 
odds that were approximately two-fold higher in subjects with state-assisted 
healthcare and for participants without medical insurance. Characteristics 
associated with diagnosed diabetes included CVD, Rx anti-hypertensive 
therapy and alcohol use. In addition, male subjects were statistically more 
likely to have diagnosed diabetes compared to females (OR: 2.5, 95% CI: 
1.5-4.1).  
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Table 4 shows univariate odds ratios of having undiagnosed compared to 
diagnosed type 2 diabetes. Within this subsample of diabetes cases, 
significant effects were observed for Rx medication use, family diabetes 
history, triglyceride levels and dyslipidaemia. Both health insurance and 
physical activity IPVs demonstrated strong associations with undiagnosed 
diabetes, with approximate four-fold increased odds in subjects without 
healthcare insurance and in those reporting low levels of physical activity. 
Individuals with undiagnosed diabetes were also more likely to have higher 
levels of adiposity. Overall, metabolic characteristics were less optimal in 
undiagnosed cases, and a greater proportion had uncontrolled hypertension.  
 
Results from a multivariable analysis comparing undiagnosed to diagnosed 
type 2 diabetes are presented in Table 5. Significant associations were noted 
for BMI (continuous) and physical inactivity. Undiagnosed patients were also 
significantly less likely to be on treatment for hypertension or to have a family 
history of diabetes relative to subjects with diagnosed diabetes. 
 
 
2.3.3 ROC analysis 
Figures 2 and 3 show ROC curves for models to discriminate undiagnosed or 
diagnosed type 2 diabetes (compared to no diabetes). Models which 
included both health insurance and physical activity IPVs displayed a higher 
discriminatory capacity to detect undiagnosed subjects (c=0.74, 95% CI: 
0.67-0.80) compared to diagnosed diabetes (c=0.61, 95% CI: 0.54-0.67). A 
model including health insurance, physical activity and BMI (continuous) 
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demonstrated further improved discrimination (c=0.81, 95% CI: 0.76-0.87 for 
undiagnosed diabetes versus c=0.70, 95% CI: 0.65-0.75 for diagnosed 
patients). 
 
 
2.4 Discussion 
The results from previous research investigating the prevalence of type 2 
diabetes in middle-aged adults within Ireland are conflicting. In 1998, a study 
conducted by Perry et al. [169] suggested an overall prevalence of 3.9%, 
30% of whom were undiagnosed, whereas research in 2003, examining 
diabetes in primary care [188], estimated a population prevalence of 9.2%, 
with undiagnosed patients representing 23.5% of all cases. Prevalence 
disparities between these studies are possibly explained by differences in 
age groups assessed or by methods used for diabetes detection.  
 
The higher percentage of undiagnosed cases identified within our sample 
may be due to use of the HbA1c assay as compared to the FPG test that was 
more commonly employed in the Republic of Ireland before 2010. Research 
conducted in the United States and Germany, which compared FPG and oral 
glucose tolerance test procedures, reported that overall prevalence would 
have been lower if FPG had been used alone [189,190]. We also observed 
that 14 (19%) undiagnosed patients (who were positively identified according 
to HbA1c concentrations) had FPG levels that were less than 5.6 mmol/l, and 
would have been classified as non-diabetic if this test had been used to 
diagnose diabetes in the present study. This finding is consistent with 
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previous research high-lighting discrepancies between HbA1c and FPG 
[191,192].  
 
A recent study from the United States suggested that regular use of HbA1c as 
a diagnostic procedure would not significantly alter type 2 diabetes 
prevalence, and that diabetes categorisation would remain unchanged in 
97.7% of subjects [193]. However, evidence to support this claim is still 
equivocal. Numerous studies have shown poor concordance between HbA1c 
and FPG [191], in particular regarding pre-diabetes classification [194-196]. 
In addition, factors such as age or ethnicity are thought to influence results 
[191,192,197]. Nevertheless, as discussed by Bonora et al., comparisons 
between diagnostic methods for type 2 diabetes are ambiguous, as a true 
gold standard test is unavailable [24]. It should be noted that although we 
classified type 2 diabetes using HbA1c in this study, the discrepancies we 
observed between HbA1c and FPG led us to further evaluate the 
appropriateness of this diagnostic test. The implications of using HbA1c alone 
for diagnosing diabetes and cardiometabolic risk are examined in Chapter 3. 
 
The Irish IPH report [178], based on the nationally representative SLÁN 
2007: Survey of Lifestyle, Attitudes and Nutrition [172] (which also used the 
HbA1c test), estimated the prevalence of type 2 diabetes in adults 45+ to be 
8.9%, which is similar to the result suggested by our study. In the IPH report, 
undiagnosed diabetes prevalence was determined to be 2.7% (30% of all 
diabetes cases). Of note, however, is that the IPH research determined the 
prevalence of undiagnosed and diagnosed diabetes in adults aged 55-64 to 
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be 4.6% and 6.3% respectively, which are comparable to outcomes attained 
from this study population (3.6% and 5.6%) for the same age group.  
 
Also of interest, is that results from the SLÁN data are consistent with our 
finding that the prevalence of type 2 diabetes in Ireland’s middle-aged 
population is higher in men. Although this gender difference may be a 
consequence of selection bias due to non-response, similarity in outcomes 
between the 2007 SLÁN survey and the Cork and Kerry Diabetes and Heart 
Disease Study imply that observed prevalence estimates are valid. It is 
possible that the lower prevalence of diabetes in women may be as a result 
of random opportunistic screening due to higher GP consultation rates 
observed in females [198]. An alternative explanation may be the higher 
percentage of overweight and obese individuals within this male population 
(males: 85.8% versus females: 70.6%, P for difference <0.001), a 
relationship noted in previous research examining obesity within Ireland 
[198,199]. 
 
As numerous studies have indicated, adverse cardiometabolic disease 
features such as high triglycerides and low HDL-C were significantly and 
positively associated with both undiagnosed and diagnosed diabetes 
[19,57,190,200]. It was observed that a greater proportion of undiagnosed 
patients had uncontrolled hypertension, increased triglyceride concentrations 
and dyslipidaemia, perhaps reflecting access to treatment, as a higher 
percentage of diagnosed subjects used Rx anti-hypertensive and 
cholesterol-lowering medications. Undiagnosed individuals were also less 
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likely to have a family history of diabetes and CVD, or to engage in regular 
physical activity compared to diagnosed subjects. Nevertheless, 
unfavourable lipid/lipoprotein profiles, family diabetes history, low-level 
physical activity and CVD were all positively associated with both 
undiagnosed and diagnosed diabetes. The inverse relationship between 
diabetes and regular alcohol use was also of interest as correlations between 
alcohol use and MetS have been reported previously [201]. Markedly, 96.6% 
(N=168) of study participants with both undiagnosed and diagnosed type 2 
diabetes were either overweight or obese, confirming results from previous 
research which suggest that obesity is a primary and significant risk factor 
related to diabetes development [202]. Screening for type 2 diabetes may be 
more efficient within these subgroups, particularly individuals with a 
combination of these features. 
 
Within Ireland, residents accessing public healthcare are divided into two 
categories: (1) those who hold a medical card (either a FMC or GPC) and 
thus qualify for means-tested, state-assisted healthcare insurance. A FMC 
entitles individuals to free GP services, Rx medications, public hospital 
services, dental, optical and aural services, community care and personal 
social services. A GPC entitles individuals to free GP care; (2) non-card 
holders, who are entitled to free public hospital services but who must pay for 
GP care and may also have to pay in-patient and out-patient hospital 
charges. In addition to the public health system there is also a large private 
healthcare market [203].  
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Results from the present study suggest that within this population, subjects 
with private medical insurance are less likely to have type 2 diabetes. This 
may indicate that these individuals have greater financial resources and 
access to healthcare, or an increased awareness of diabetes risk factors. 
This awareness could be due to higher educational levels, as it was also 
noted that study participants who had only completed education to a primary 
level were more likely to have the condition. Although social class (defined 
by the ESeC) [186] was not a diabetes risk factor, it is possible that the lower 
prevalence of diabetes amongst subjects with private medical insurance was 
due to socio-economic inequalities, as study participants in receipt of state-
assisted medical insurance were notably at a higher risk. These findings 
suggest that diabetes cases occur disproportionately amongst individuals 
who are economically deprived and who have lower educational levels, and 
this concurs with previous research which found significant correlations 
between social deprivation and type 2 diabetes [204].  
 
Importantly, our findings also imply that health service inequalities are 
significant determinants of diagnostic status, as a greater proportion of 
undiagnosed cases indicated having no state-assisted or private healthcare 
insurance. This is consistent with outcomes observed in previous studies 
which have examined relationships between healthcare inequities and 
diabetes [182,205]. Univariate analysis suggested three-fold and four-fold 
increased odds of having undiagnosed type 2 diabetes in subjects without 
medical insurance when compared to individuals with no diabetes (Appendix 
1, Supporting Table 1) or diagnosed diabetes (Table 4) respectively. This 
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association was also noted in a multivariable logistic regression comparing 
undiagnosed to non-diabetic individuals (Table 3) but was not observed in 
multivariable analysis restricted to patients with type 2 diabetes (Table 5).  
 
To investigate this discrepancy, we forced the health insurance IPV into a 
model and entered covariates independently to assess confounder-adjusted 
relationships. In a logistic regression which controlled for family diabetes 
history, Rx anti-hypertensives, BMI, age and gender, having no healthcare 
insurance remained strongly associated with undiagnosed diabetes (OR: 3.5, 
95% CI: 1.2-10.4, P=0.025) although this was attenuated when the physical 
activity IPV was included (OR: 2.4, 95% CI: 0.7-8.9, P=0.184). This may 
indicate a relationship between physical activity and both health insurance 
and undiagnosed diabetes or that physical activity levels explain most of the 
variance. Equally possible is that missing data from the IPAQ questionnaire 
resulted in a loss of statistical power.  
 
We further explored health insurance/physical activity relationships with 
undiagnosed/diagnosed type 2 diabetes using the LR. Tests for model 
assessment included significant covariates, age, gender and either health 
insurance or physical activity IPVs. Both models implied similar goodness-of-
fit (LR chi-square: 33.29, P<0.001 for a model with health insurance versus 
LR chi-square: 32.68, P<0.001 for a model with physical activity) in full 
models against a constant, indicating that both variables may be clinically 
relevant. In addition, it was noted that models including health insurance, 
physical activity and adiposity IPVs displayed differences in discriminative 
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ability to detect undiagnosed and diagnosed patients (Figures 2 and 3). This 
suggests that use of these variables in type 2 diabetes screening algorithms 
may be useful for identifying a subset of diabetes cases.  
 
Although assessment of physical activity levels in clinical practice (as 
measured using self-completed patient questionnaires) is subject to reporting 
bias, socio-economic status (determined using a proxy measure such as 
health insurance status) and adiposity levels are variables that may be 
objectively assessed by a clinician. In particular, as non-invasive diabetes 
risk scores typically include a measurement of adiposity, determining an 
appropriate method for assessing overweight and obesity was the primary 
aim of this research. Optimal methods for measuring adiposity are explored 
in the following chapters. 
 
 
2.4.1 Strengths and limitations of the research 
As one of the largest cross-sectional studies performed to date within the 
Republic of Ireland, the Cork and Kerry Diabetes and Heart Disease Study 
sample size is comparable to other related Irish studies. Selection bias was 
minimised as a comparable number of male and female subjects, aged 46-
73 years of age, were randomly selected from a register of patients within a 
single primary care centre. Furthermore, non-responders had similar 
numbers for both males and females and likewise for age groups. Few 
studies have assessed the prevalence of undiagnosed or diagnosed type 2 
diabetes within one broadly representative population sample or compared 
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features between undiagnosed and diagnosed subjects. Finally, use of HbA1c 
measurement demonstrated prevalence rates comparable to those from a 
recent nationally representative study, the SLÁN 2007: Survey of Lifestyle, 
Attitudes and Nutrition [172].  
 
Notwithstanding these strengths, several limitations can be identified. The 
use of self-reported questionnaires is subject to potential inaccuracies, recall 
and reporting bias [159,160]. In particular, misclassification of diabetes from 
self-reporting is a recognised limitation present in all surveys, and is 
particularly relevant in Ireland due to the absence of a unique health identifier 
within the Irish healthcare system [206]. This makes linkage with other 
records, such as disease registries or death records problematic [183]. 
Nonetheless, several studies have indicated a reasonable or high degree of 
concordance between type 2 diabetes prevalence and self-reporting 
[160,207-209]. Additionally, within this sample there was a high level of 
agreement between self-reported physician diagnosis of diabetes and Rx 
diabetes medication use (Kappa: 0.854).  
 
Equally of concern is that prevalence estimates were derived from a single 
primary care based sample which may not be representative of the source 
population. However, previous research suggests that approximately 98% of 
Irish adults are registered with a GP and that, even in the absence of a 
universal patient registration system, it is possible to perform population-
based epidemiological studies that are representative using our methods 
[210]. Further studies are needed to definitively confirm this conclusion. If 
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correct, it may indicate that findings from the Cork and Kerry Diabetes and 
Heart Disease Study are generalisable to the Irish middle-aged adult 
population. Also, as this research makes use of cross-sectional data, 
interpretations of these findings are compromised by the inability to infer 
causal relationships. Nevertheless, the relationships described have been 
extensively replicated in other prospective cohort studies. Finally, with regard 
to statistical procedures employed in analysis, the possibility of model over-
fitting or type II errors cannot be discounted, and results should be 
considered preliminary and exploratory, as future studies with larger sample 
sizes and greater statistical power might find other relationships [211]. 
 
 
2.5 Conclusions 
The prevalence of type 2 diabetes within the Republic of Ireland is consistent 
with trends worldwide [175,212], and is primarily driven by the increasing 
obesity epidemic [13,175,213]. Despite policies and continued investment in 
services which promote awareness and knowledge of a disease that is 
largely preventable, the prevalence of diabetes in Ireland may be rising [178]. 
 
Socio-economic and health service inequalities are significant risk factors for 
having undiagnosed diabetes. The results from this study indicate that 
subjects with state-subsidised healthcare insurance, and those without 
private or state-assisted medical cover, are more likely to be undetected. 
These findings suggest that individuals from lower socio-economic 
backgrounds should be targeted. Observed low levels of physical activity, 
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adiposity assessment and recognition of untreated cardiometabolic 
conditions may also improve identification of diabetes cases within clinical 
practice. Finally, as a successful programme to detect patients with type 2 
diabetes may depend on regular General Practice attendance, a strategic 
approach that identifies subjects without access to primary healthcare 
services, and which furthers efforts to promote affordable and equitable 
healthcare, is needed to prevent predictable sequelae for affected 
individuals. 
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Table 2––Characteristics of the study population.  
 
Feature No  
diabetes 
N=1873 (91.5%) 
Undiagnosed  
diabetes 
N=72 (3.5%) 
Diagnosed 
diabetes 
N=102 (5.0%) 
Health conditions
    
 
Male 893 (47.8) 43 (59.7) 69 (67.6) 
 
Age 59 (54-64) 60 (56-65) 62 (57-65) 
 
Age >60 875 (46.9) 38 (52.8) 65 (63.7) 
 
On Rx for hypertension 486 (26.0) 32 (44.4) 66 (64.7) 
 
On Rx for cholesterol 609 (32.6) 35 (48.6) 67 (65.7) 
 
BMI (kg/m
2
) 28.3 ± 4.6 33.1 ± 6.3 31.2 ± 4.4 
 
BMI category:    
 
<25  439 (23.6) 4 (5.6) 2 (2.0) 
 
25-29.9 857 (46.0) 24 (33.3) 43 (42.2) 
 
>30  566 (30.4) 44 (61.1) 57 (55.9) 
 
Family diabetes history 315 (16.9) 21 (29.2) 54 (52.9) 
 
CVD 167 (8.9) 16 (22.2) 29 (28.4) 
Socio-economic
    
 
Education: 
   
 
Bachelor or higher 175 (10.0) 4 (5.9) 5 (5.3) 
 
Diploma 239 (13.7) 6 (8.8) 6 (6.3) 
 
Secondary 863 (49.5) 31 (45.6) 40 (42.1) 
 
Primary only 466 (26.7) 27 (39.7) 44 (46.3) 
 
Social class:    
 
High income 244 (18.2) 6 (11.5) 11 (13.3) 
 
Middle income 396 (29.5) 18 (34.6) 25 (30.1) 
 
Low income 704 (52.4) 28 (53.8) 47 (56.6) 
Medical cover
    
 
Health insurance: 
   
 
Private insurance 1196 (64.0) 27 (37.5) 51 (50.0) 
 
State insurance 437 (23.4) 29 (40.3) 44 (43.1) 
 
No insurance 236 (12.6) 16 (22.2) 7 (6.9) 
Health behaviours
    
 
Physical activity: 
   
 
High 795 (48.4) 10 (17.5) 31 (34.8) 
 
Moderate 536 (32.6) 19 (33.3) 35 (39.3) 
 
No physical exercise 313 (19.0) 28 (49.1) 23 (25.8) 
 
Smoker 889 (47.6) 38 (52.8) 60 (58.8) 
 
Alcohol use:    
 
Non-drinker 800 (44.7) 38 (55.1) 54 (53.5) 
 
Occasional drinker 367 (20.5) 12 (17.4) 27 (26.7) 
 
Regular drinker 623 (34.8) 19 (27.5) 20 (19.8) 
Metabolic
    
 
Triglycerides (mmol/l) 1.19 (0.9-1.6) 1.80 (1.3-2.4) 1.36 (1.0-2.0) 
 
Triglycerides >1.7 417 (23.0) 37 (52.9) 36 (37.5) 
 
HDL-C (mmol/l) 1.48 ± 0.4 1.22 ± 0.3 1.18 ± 0.3 
 
Low HDL-C
1
 267 (14.7) 32 (45.7) 45 (45.0) 
 
Dyslipidaemia
2
 122 (6.7) 24 (34.3) 21 (21.0) 
 
SBP (mmHg) 129.25 ± 16.7 134.18 ± 19.3 132.94 ± 16.4 
 
DBP (mmHg) 80.20 ± 9.7 80.12 ± 10.9 78.79 ± 9.5 
 
Hypertension
3
 552 (29.7) 28 (39.4) 28 (27.5) 
 
FPG (mmol/l) 4.90 (4.6-5.3) 6.60 (5.6-7.5) 7.50 (5.7-9.4) 
 
FPG >5.6 
 
238 (13.1) 58 (80.6) 80 (80.8) 
 
Mean and + SD are shown for continuous and % are shown for categorical variables.  
Age, triglycerides and FPG are shown as a median (interquartile range). Numbers and % (in brackets)  
for categorical variables will vary in different analyses as some variables have missing values.  
1
HDL-C <1.03 (males) or <1.29 (females).  
2
Dyslipidaemia: triglycerides >1.7 and HDL-C <1.03 (males) or <1.29 (females).  
3
Hypertension: SBP >140 and/or DBP >90. 
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Table 3––Odds ratios (95% CI) of having undiagnosed or diagnosed type  
2 diabetes compared to no diabetes – multivariable logistic regression 
adjusting for age, gender and all significant covariates. 
 
Feature Odds ratio 95% CI 
Undiagnosed diabetes compared to no diabetes
1
   
 Male 1.4 (0.8-2.5) 
 Age >60 1.0 (0.6-1.9) 
 On Rx for cholesterol 2.2 (1.2-3.9) 
 BMI category:   
 <25 1  
 25-29.9 4.5 (1.0-19.5) 
 >30 6.8 (1.6-29.4) 
 Family diabetes history 1.9 (1.0-3.6) 
 Health insurance:   
 Private insurance 1  
 State insurance 2.2 (1.2-4.2) 
 No insurance 2.3 (1.0-5.2) 
 Physical activity:   
 High 1  
 Moderate 1.9 (0.8-4.2) 
 No physical exercise 5.8 (2.7-12.5) 
 Dyslipidaemia
3
 4.3 (2.3-8.3) 
Diagnosed diabetes compared to no diabetes
2
   
 Male 2.5 (1.5-4.1) 
 Age >60 1.4 (0.9-2.3) 
 On Rx for hypertension 2.7 (1.7-4.4) 
 On Rx for cholesterol 2.0 (1.2-3.3) 
 BMI category:   
 <25 1  
 25-29.9 8.2 (1.9-34.6) 
 >30 9.4 (2.2-40.3) 
 Family diabetes history 5.9 (3.7-9.4) 
 CVD 2.0 (1.1-3.5) 
 Alcohol use:   
 Non-drinker 1  
 Occasional drinker 1.3 (0.7-2.2) 
 Regular drinker 0.4 (0.2-0.7) 
 Dyslipidaemia
3
 1.9 (1.0-3.5) 
 
1
Model excludes subjects with diagnosed diabetes. Final model covariates entered 
in order: dyslipidaemia, BMI category, physical activity, health insurance, on Rx for 
cholesterol, family diabetes history, age and gender.  
2
Model excludes subjects with undiagnosed diabetes. Final model covariates 
entered in order: family diabetes history, on Rx for hypertension, BMI category, on 
Rx for cholesterol, CVD, dyslipidaemia, alcohol use, age and gender. 
3
Dyslipidaemia: triglycerides >1.7 and HDL-C <1.03 (males) or <1.29 (females).  
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Table 4––Univariate odds ratios (95% CI) of having undiagnosed compared to diagnosed type 2 
diabetes.
 
 
 
Feature Undiagnosed  
diabetes 
N=72 (41.4%) 
Diagnosed 
diabetes 
N=102 (58.6%) 
Odds ratio 
 
95% CI 
Health conditions     
 Female 29 (40.3) 33 (32.4) 1  
 Male 43 (59.7) 69 (67.6) 0.7  (0.4-1.3) 
 Age <60 years  34 (47.2) 37 (36.3) 1  
 Age >60 years  38 (52.8) 65 (63.7) 0.6  (0.3-1.2) 
 Not on Rx for 
hypertension  
40 (55.6) 36 (35.3) 1  
 On Rx for hypertension 32 (44.4) 66 (64.7) 0.4  (0.2-0.8) 
 Not on Rx for cholesterol 37 (51.4) 35 (34.3) 1  
 On Rx for cholesterol 35 (48.6) 67 (65.7) 0.5  (0.3-0.9) 
 BMI (kg/m
2
) 33.1 ± 6.3 31.2 ± 4.4 1.1  (1.0-1.1) 
 BMI category:     
 <25  4 (5.6) 2 (2.0) 1  
 25-29.9 24 (33.3) 43 (42.2) 0.3  (0.1-1.7) 
 >30  44 (61.1) 57 (55.9) 0.4  (0.1-2.2) 
 No family diabetes history 51 (70.8) 48 (47.1) 1  
 Family diabetes history 21 (29.2) 54 (52.9) 0.4  (0.2-0.7) 
 No CVD 56 (77.8 73 (71.6) 1  
 CVD 16 (22.2) 29 (28.4) 0.7  (0.4-1.5) 
Socio-economic     
 Education:     
 Bachelor or higher 4 (5.9) 5 (5.3) 1  
 Diploma 6 (8.8) 6 (6.3) 1.3  (0.2-7.1) 
 Secondary 31 (45.6) 40 (42.1) 1.0  (0.2-3.9) 
 Primary only 27 (39.7) 44 (46.3) 0.8  (0.2-3.1) 
 Social class:     
 High income 6 (11.5) 11 (13.3) 1  
 Middle income 18 (34.6) 25 (30.1) 1.3  (0.4-4.2) 
 Low income 28 (53.8) 47 (56.6) 1.1  (0.4-3.3) 
Medical cover     
 Health insurance:     
 Private insurance 27 (37.5) 51 (50.0) 1  
 State insurance 29 (40.3) 44 (43.1) 1.2  (0.6-2.4) 
 No insurance 16 (22.2) 7 (6.9) 4.3  (1.6-11.8) 
Health behaviours     
 Physical activity:     
 High 10 (17.5) 31 (34.8) 1  
 Moderate 19 (33.3) 35 (39.3) 1.7  (0.7-4.2) 
 No physical exercise 28 (49.1) 23 (25.8) 3.8  (1.5-9.3) 
 Non-smoker 34 (47.2) 42 (41.2) 1  
 Smoker 38 (52.8) 60 (58.8) 0.8  (0.4-1.4) 
 Alcohol use:     
 Non-drinker 38 (55.1) 54 (53.5) 1  
 Occasional drinker 12 (17.4) 27 (26.7) 0.6  (0.3-1.4) 
 Regular drinker 19 (27.5) 20 (19.8) 1.4  (0.6-2.9) 
Metabolic     
 Triglycerides (mmol/l) 1.80 (1.3-2.4) 1.36 (1.0-2.0) 1.5  (1.1-2.0) 
 Triglycerides <1.7 33 (47.1) 60 (62.5) 1  
 Triglycerides >1.7 37 (52.9) 36 (37.5) 1.9  (1.0-3.5) 
 HDL-C (mmol/l) 1.22 ± 0.3 1.18 ± 0.3 1.7  (0.6-4.7) 
 Optimal HDL-C 38 (54.3) 55 (55.0) 1  
 Low HDL-C
1
 32 (45.7) 45 (45.0) 1.0  (0.6-1.9) 
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Table 4 continued 
 
 
 
 
 
 
 
 
 
Feature Undiagnosed  
diabetes 
N=72 (41.4%) 
Diagnosed 
diabetes 
N=102 (58.6%) 
Odds ratio 
 
95% CI 
Metabolic     
 No dyslipidaemia 46 (65.7) 79 (79.0) 1  
 Dyslipidaemia
2
 24 (34.3) 21 (21.0) 2.0  (1.0-3.9) 
 SBP (mmHg) 134.18 ± 19.3 132.94 ± 16.4 1.0  (0.99-1.0) 
 DBP (mmHg) 80.12 ± 10.9 78.79 ± 9.5 1.0  (0.98-1.0) 
 No hypertension
 
43 (60.6) 74 (72.5) 1  
 Hypertension
3
 28 (39.4) 28 (27.5) 1.7  (0.9-3.3) 
 Mean and + SD are shown for continuous variables. Triglycerides are shown as a median (interquartile range). 
Numbers and % (in brackets) for categorical variables will vary in different analyses as some variables have 
missing values.  
1
HDL-C <1.03 (males) or <1.29 (females).  
2
Dyslipidaemia: triglycerides >1.7 and HDL-C <1.03 (males) or <1.29 (females).  
3
Hypertension: SBP >140 and/or DBP >90. 
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Table 5––Odds ratios (95% CI) of having undiagnosed compared to diagnosed type 
2 diabetes – multivariable logistic regression adjusting for all significant covariates.
 
 
Feature Model 1 Model 2
1
 
 Odds ratio 95% CI Odds ratio 95% CI 
BMI (kg/m
2
) 1.1 (1.0-1.2) 1.1 (1.0-1.2) 
On Rx for hypertension 0.3 (0.2-0.7) 0.3 (0.1-0.7) 
Family diabetes history 0.4 (0.2-0.8) 0.4 (0.2-0.8) 
Physical activity:     
High 1  1  
Moderate 1.6 (0.6-4.3) 1.6 (0.6-4.3) 
No physical exercise 3.5 (1.3-9.3) 3.4 (1.3-9.1) 
Final model covariates entered in order: family diabetes history, physical activity, on Rx for 
hypertension and BMI. 
1
Adjusted for age and gender. 
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Figure 2––Receiver operating characteristic curves for models to discriminate 
subjects with undiagnosed type 2 diabetes. The c statistics were c=0.74 (95% CI: 
0.67-0.80) for a model including health insurance and physical activity and c=0.81 
(95% CI: 0.76-0.87) for a model including health insurance, physical activity and BMI. 
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Figure 3––Receiver operating characteristic curves for models to discriminate 
subjects with diagnosed type 2 diabetes. The c statistics were c=0.61 (95% CI: 
0.54-0.67) for a model including health insurance and physical activity and c=0.70 
(95% CI: 0.65-0.75) for a model including health insurance, physical activity and BMI. 
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3.0 Abstract 
Background and Objectives 
Glycated haemoglobin A1c (HbA1c) measurement is recommended as an 
alternative to fasting plasma glucose (FPG) for the diagnosis of pre-diabetes 
and type 2 diabetes. However, evidence suggests discordance between 
HbA1c and FPG. In this study we examine a range of cardiometabolic 
features, pro-inflammatory cytokines, acute-phase response proteins, 
coagulation factors and white blood cell counts to determine which assay 
more accurately identifies individuals at increased cardiometabolic risk. 
 
 
Materials and Methods 
This was a cross-sectional study involving a random sample of 2,047 men 
and women aged 46-73 years. Binary and multinomial logistic regression 
were employed to examine risk feature associations with pre-diabetes [either 
HbA1c levels 5.7%-6.4% (39-46 mmol/mol) or impaired FPG levels 5.6-6.9 
mmol/l] and type 2 diabetes [either HbA1c levels >6.5% (>48 mmol/mol) or 
FPG levels >7.0 mmol/l]. Receiver operating characteristic curve analysis 
was used to evaluate the ability of HbA1c to discriminate pre-diabetes and 
diabetes defined by FPG. 
 
 
Results 
Stronger associations with diabetes-related phenotypes were observed in 
pre-diabetic subjects diagnosed by FPG compared to those detected by 
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HbA1c. Individuals with type 2 diabetes exhibited cardiometabolic profiles that 
were broadly similar according to diagnosis by either assay. Pre-diabetic 
participants classified by both assays displayed a more pro-inflammatory, 
pro-atherogenic, hypertensive and insulin resistant profile. Odds ratios of 
having three or more cardiometabolic disease features were also noticeably 
increased (OR: 4.0, 95% CI: 2.8-5.8) when compared to subjects diagnosed 
by either HbA1c (OR: 1.4, 95% CI: 1.2-1.8) or FPG (OR: 3.0, 95% CI: 1.7-5.1) 
separately. 
 
 
Conclusions 
In middle-aged Caucasian-Europeans, HbA1c alone is a poor indicator of 
cardiometabolic risk but is suitable for diagnosing diabetes. Combined use of 
HbA1c and FPG may be of additional benefit for detecting individuals at 
highest odds of type 2 diabetes development. 
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3.1 Introduction 
The prevalence of type 2 diabetes, a chronic disease which causes 
significant mortality, has increased considerably in world populations, 
representing a major public health issue [175]. Diabetes is associated with a 
clustering of cardiometabolic features including obesity, dyslipidaemia, 
hypertension, insulin resistance, chronic low-grade inflammation [23,214], 
and may lead to severe cardiovascular complications [215]. 
 
Pre-diabetes, a condition defined by glycaemic profiles that are higher than 
normal but which do not meet thresholds for diabetes, is a strong risk factor 
for type 2 diabetes and related complications [216]. The American Diabetes 
Association (ADA) classifies type 2 diabetes as a fasting plasma glucose 
(FPG) level >7.0 mmol/l and pre-diabetes as impaired FPG levels between 
5.6-6.9 mmol/l [23]. In 2009 the International Expert Committee 
recommended glycated haemoglobin A1c (HbA1c) as an alternative marker 
[217], and in 2010 the ADA introduced HbA1c cut-points of >6.5% (>48 
mmol/mol) for diabetes diagnosis and between 5.7%-6.4% (39-46 mmol/mol) 
as a criterion to identify individuals at a high-risk state of developing diabetes 
[23]. Perceived benefits of the use of HbA1c measurement, over FPG, include 
greater pre-analytical stability, lower biological variability and that the assay 
may be performed in non-fasting blood samples [24,218]. However, use of 
HbA1c as a screening tool has been controversial, with research showing 
discordance between HbA1c and FPG [192,196,219,220], and several studies 
suggesting that factors such as age or ethnicity may influence diagnostic 
performance [191,221,222].  
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The aim of this study was to compare the metabolic profiles in subjects with 
pre-diabetes and type 2 diabetes, using ADA-recommended HbA1c and FPG 
diagnostic thresholds, in a random sample of 2,047 middle-aged men and 
women. In particular, we examined a range of diabetes risk factors, 
metabolic syndrome (MetS) features, pro-inflammatory cytokines, acute-
phase response proteins, coagulation factors and white blood cell (WBC) 
counts to determine which assay more accurately identifies individuals at 
increased cardiometabolic risk. 
 
 
3.2 Materials and Methods 
3.2.1 Study design 
The study design is described in detail in Chapter 1. In summary, the Cork 
and Kerry Diabetes and Heart Disease Study (Phase II) was a single centre, 
cross-sectional study conducted between 2010 and 2011. A random sample 
was recruited from a large primary care centre in Mitchelstown, County Cork, 
Ireland. The Livinghealth Clinic serves a population of approximately 20,000, 
with a mix of urban and rural residents. Stratified sampling was employed to 
recruit equal numbers of men and women from all registered attending 
patients in the 46-73 year age group. In total, 3,807 potential participants 
were selected from the practice list. Following the exclusion of duplicates, 
deaths, and subjects incapable of consenting or attending appointment, 
3,051 were invited to participate in the study and of these, 2,047 (49.2% 
male) completed the questionnaire and physical examination components of 
the baseline assessment (response rate: 67.1%). Details regarding the study 
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design, sampling procedures and methods of data collection have been 
reported previously [183].  
 
Ethics committee approval conforming to the Declaration of Helsinki was 
obtained from the Clinical Research Ethics Committee of University College 
Cork. A letter signed by the contact GP in the clinic was sent out to all 
selected participants with a reply slip indicating acceptance or refusal. All 
subjects gave signed informed consent, including permission to use their 
data for research purposes. 
 
 
3.2.2 Clinical and laboratory procedures 
Study participants attended the clinic in the morning after an overnight fast 
and blood samples were taken on arrival. Data on age, gender, family 
diabetes history, physician-diagnosed type 2 diabetes and prescription (Rx) 
medication use were gathered through a self-completed General Health 
Questionnaire [170]. Triglyceride and high-density lipoprotein cholesterol 
(HDL-C) levels were measured by Cork University Hospital Biochemistry 
Laboratory on Olympus 5400 biochemistry analysers with Olympus reagents 
using standardised procedures and fresh samples (Olympus Diagnostica 
GmbH, Hamburg, Germany). Fasting glucose concentrations were 
determined using a glucose hexokinase assay (Olympus Life and Material 
Science Europa Ltd., Lismeehan, Co. Clare, Ireland) and HbA1c levels were 
measured in the haematology laboratory on an automated high-pressure 
liquid chromatography instrument Tosoh G7 [Tosoh HLC-723 (G7), Tosoh 
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Europe N.V, Tessenderlo, Belgium]. Serum insulin, c-reactive protein (CRP), 
tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), adiponectin, leptin, 
resistin and plasminogen activator inhibitor-1 (PAI-1) were assessed using a 
biochip array system (Evidence Investigator; Randox Laboratories, UK). 
Complement component 3 (C3) was measured by immunoturbidimetric 
assay (RX Daytona; Randox Laboratories). White blood cell counts were 
determined by flow cytometry technology as part of a full blood count.  
 
Three independent measurements of systolic and diastolic blood pressure 
(BP) were obtained with the subject in a seated position using an Omron M7 
digital sphygmomanometer (Omron Healthcare Co. Ltd., Japan). The mean 
of the second and third readings was considered to be a subject’s BP. The 
weight and height of each participant were measured to the nearest 0.1 kg 
and 0.1 cm respectively. Portable electronic Tanita WB-100MA weighing 
scales (Tanita Corporation, IL, USA) were placed on a firm, flat surface and 
were calibrated weekly to ensure accuracy. Height was measured using a 
portable Seca Leicester height/length stadiometer (Seca, Birmingham, UK) 
and body mass index (BMI) was calculated as weight divided by the square 
of height. A BMI >30 kg/m2 was classified as obese [94]. Waist 
circumference (WC) was measured midway between the lowest rib and iliac 
crest on bare skin. Subjects were instructed to breathe in, and then out, and 
to hold their breath while measurement was made to the nearest 0.1 cm 
using a Seca 200 measuring tape. Two independent measurements of WC 
were taken and the mean of the two was used in analysis. Central obesity 
was defined as a WC level >102 cm for males and >88 cm for females [12].  
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3.2.3 Classification of biochemical and blood pressure measurements 
Lipid, lipoprotein and BP measurements were classified according to 
National Cholesterol Education Program: Adult Treatment Panel III (NCEP: 
ATP III) guidelines [184]. Abnormal metabolic risks were defined as high 
triglycerides >1.7 mmol/l and low HDL-C (<1.03 mmol/l in males or <1.29 
mmol/l in females). Dyslipidaemia was determined according to both high 
triglyceride and low HDL-C levels. Elevated BP was classified as systolic BP 
>130 mmHg and/or diastolic BP >85 mmHg or Rx anti-hypertensive 
medication use. High serum insulin was defined as a level equal to or above 
the 75th percentile in the study sample.  
 
Metabolic syndrome was determined according to a modified version of the 
NCEP: ATP III criterion, substituting serum insulin 75th percentile for impaired 
FPG. Three or more MetS features (>3 MetS) was characterised as any 
combination of the following: obesity defined by WC, high triglyceride levels, 
low HDL-C, elevated BP and high insulin concentrations. According to ADA 
guidelines, pre-diabetes was classified as elevated HbA1c levels between 
5.7%-6.4% (39-46 mmol/mol) or impaired FPG levels between 5.6-6.9 
mmol/l. Type 2 diabetes was defined as HbA1c >6.5% (>48 mmol/mol) or 
FPG >7.0 mmol/l [23].  
 
As internationally agreed risk cut-points for the examined biomarkers have 
not been established, low-grade inflammation was determined as a level 
above the study population median for each biomarker (C3, CRP, IL-6, TNF-
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α, leptin, resistin, PAI-1 and WBC) with the exception of adiponectin (below 
median level).  
 
 
3.2.4 Statistical analysis  
Descriptive characteristics were examined according to diagnosis of pre-
diabetes and type 2 diabetes. Categorical features are presented as 
percentages and continuous variables are displayed as a mean (plus or 
minus one standard deviation) or a median and interquartile range for 
skewed data. Binary logistic regression was used to explore diabetes-related 
risk factor and inflammatory biomarker relationships with pre-diabetes 
(compared to normoglycaemic subjects) and type 2 diabetes (compared to 
individuals without diabetes) defined using HbA1c and FPG diagnostic cut-
points. Models examining metabolic feature associations with pre-diabetes 
excluded patients with type 2 diabetes indicated by either HbA1c or FPG, a 
physician diagnosis or Rx diabetes medication use. Risk feature 
relationships with pre-diabetes (either HbA1c alone, FPG alone or dual 
categorisation by both HbA1c and FPG) were further evaluated using 
multinomial logistic regression. Subjects classified as normoglycaemic by 
both assays were used as the reference category.  
 
The ability of HbA1c to discriminate pre-diabetes (defined by impaired FPG) 
and type 2 diabetes (defined by FPG levels >7.0 mmol/l) was assessed using 
receiver operating characteristic curve (ROC) analysis. The area under the 
curve (AUC) provides a scale from 0.5 to 1.0 (with 0.5 representing random 
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chance and 1.0 indicating perfect discrimination) by which to compare the 
ability of a marker to detect a positive result [150]. The diagnostic properties 
of different HbA1c thresholds were contrasted by determining sensitivity and 
false positive rates (FPR). Levels of agreement between diagnostic methods 
were ascertained using Cohen’s kappa coefficient.  
 
Primary data analysis was conducted using IBM SPSS Statistics Version 20 
(IBM Corp., Armonk, NY, USA) for Windows. Confidence intervals for 
prevalence proportions were calculated using the VasserStats statistical 
website [187]. For all analyses, a P value (two-tailed) of less than 0.05 was 
considered to indicate statistical significance. Assay results for HbA1c and 
FPG were available for 1,995 (97.5%) and 1,994 (97.4%) subjects. 
Participants missing either HbA1c or FPG data were excluded from 
multinomial and ROC analyses. Low-level missing values were found within 
most independent variables. Analysis indicated a similar percentage of 
missing data according to either HbA1c or FPG pre-diabetes and diabetes 
classifications. Missing independent variable data were thus assumed to be 
ignorable and missing at random.  
 
 
3.3 Results 
3.3.1 Descriptive characteristics  
Characteristics of the study population according to pre-diabetes and type 2 
diabetes classifications are presented in Table 6. The prevalence of pre-
diabetes was 47.9% (95% CI: 45.7%-50.0%) by elevated HbA1c and 11.2% 
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(95% CI: 9.9%-12.7%) by impaired FPG. Subjects categorised as pre-
diabetic using HbA1c had lower BMI and WC levels, lower triglyceride and 
insulin concentrations, higher HDL-C levels, were less hypertensive, and a 
greater proportion were female when compared to individuals with pre-
diabetes defined by FPG.  
 
 
3.3.2 Logistic regression  
In binary logistic regression analyses (Table 7), associations between 
commonly assessed diabetes risk features and pre-diabetes were stronger in 
subjects diagnosed by FPG. Odds ratios for pre-diabetes indicated by HbA1c 
were non-significant for having a family diabetes history and elevated 
triglyceride levels, while there was a three-fold increased likelihood (OR: 3.0, 
95% CI: 2.2-3.9) of having >3 MetS features in participants identified by FPG 
compared to an odds ratio of 1.6 (95% CI: 1.3-2.0) in pre-diabetes by HbA1c. 
In contrast, metabolic risk factor relationships with type 2 diabetes were 
generally comparable according to diagnosis by either assay, with odds 
ratios of having >3 MetS features being 6.1 (95% CI: 4.2-8.8) and 6.8 (95% 
CI: 4.1-11.2) for subjects diagnosed by HbA1c and FPG respectively. 
Regardless of definition, patients with pre-diabetes and type 2 diabetes 
displayed a chronic pro-inflammatory profile as characterised by elevated 
C3, IL-6, WBC levels and reduced adiponectin concentrations.  
 
The results from multinomial regression models exploring risk factor 
relationships with pre-diabetes classified by HbA1c alone, FPG alone, or by 
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both HbA1c and FPG together are displayed in Table 8. Odds ratios of having 
high levels of adiposity, elevated BP, increased insulin concentrations and 
MetS were higher for participants classified by both assays, with four-fold 
increased odds (OR: 4.0, 95% CI: 2.8-5.8) of having >3 MetS features, 
compared to either HbA1c alone (OR: 1.4, 95% CI: 1.2-1.8) or FPG alone 
(OR: 3.0, 95% CI: 1.7-5.1). Stronger associations with markers of low-grade 
inflammation were also observed in subjects identified by both criteria. 
 
 
3.3.3 ROC analysis 
Receiver operating characteristic curves for HbA1c to detect pre-diabetes and 
type 2 diabetes are shown in Figures 4 and 5. The ability of HbA1c to 
discriminate pre-diabetes characterised by impaired FPG was low 
(AUC=0.67, 95% CI: 0.63-0.71). The HbA1c >5.7% (>39 mmol/mol) pre-
diabetes threshold demonstrated marginal sensitivity (72%) and a high FPR 
(52%). The level of agreement between both diagnostic methods was also 
poor (Kappa: 0.084). Discriminatory capacity for type 2 diabetes defined by 
FPG >7.0 mmol/l was high (AUC=0.94, 95% CI: 0.90-0.98). Sensitivity, FPR 
and Kappa for the ADA-recommended HbA1c >6.5% (>48 mmol/mol) cut-off 
were 84%, 4% and 0.60 respectively.   
 
 
3.4 Discussion 
In this study of 2,047 middle-aged Caucasian-European men and women we 
show that subjects with HbA1c levels 5.7%-6.4% (39-46 mmol/mol) or FPG 
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levels 5.6-6.9 mmol/l may exhibit different cardiometabolic profiles. Stronger 
relationships with diabetes-related risk features were found using impaired 
FPG compared to elevated HbA1c to diagnose pre-diabetes. Conversely, the 
metabolic profiles of patients with type 2 diabetes, defined by either HbA1c 
>6.5% (>48 mmol/mol) or FPG >7.0 mmol/l concentrations, were broadly 
similar. In addition, it was noted that pre-diabetic individuals diagnosed by 
both tests displayed the least optimal profile when compared to subjects 
classified by either assay separately. These results suggest that a 
combination of both criteria may be useful for detecting patients at increased 
cardiometabolic risk. 
 
Noticeably, within this population, a higher percentage of patients were 
identified as having pre-diabetes by HbA1c (47.9% versus 11.2% for FPG). A 
higher prevalence of pre-diabetes by HbA1c in a United Kingdom cohort 
(N=8,696) was also noted by Mostafa et al. [223], who reported a prevalence 
of 44.9% in participants diagnosed by HbA1c compared to 16.2% in subjects 
detected by an oral glucose tolerance test (OGTT). Similar findings were 
determined using FPG as the glucose-based criterion. Our results are also 
consistent with those reported in a recent Chinese study (N=2,318) and from 
research examining a Palestinian Arab population (N=1,370). Du et al. [194] 
and Kharroubi et al. [224] found reasonable or moderate concordance 
between HbA1c and FPG for type 2 diabetes, but a higher prevalence by 
HbA1c and limited overlap for pre-diabetes using ADA-designated thresholds. 
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However, our results contrast with findings reported in the United States by 
the Insulin Resistance Atherosclerosis Study (N=855), which found a higher 
prevalence of pre-diabetes by FPG (31.1% versus 10.6% for HbA1c) [225]. 
Similarly, research utilising data from the National Health and Nutrition 
Examination Survey (1999-2006) found the prevalence of pre-diabetes in a 
sample of 7,029 adults to be 28.2% and 12.6% using FPG and HbA1c 
respectively [195]. Possible reasons for observed prevalence disparities 
between HbA1c and FPG may include age, gender or ethnic differences in 
examined populations [192,221,222]. In addition, as glucose continues to be 
metabolized in blood cells even after sampling, discrepancies may be due to 
biochemical analysis intervals within different studies [24,224].  
 
Longitudinal research has suggested that combined use of HbA1c and FPG 
may be beneficial for identifying high-risk subjects. In two Asian studies, 
Inoue et al. [226] and Heianza et al. [227] demonstrated hazard ratios for 
type 2 diabetes to be greater for subjects classified by both assays when 
compared to those diagnosed by either HbA1c or FPG separately. Findings 
from the Kansai Healthcare Study showed that joint use of both methods 
improved predictive ability [228]. In ROC analysis, AUCs for models including 
both HbA1c and FPG were larger than those for HbA1c (0.853 versus 0.771, 
P<0.001) or FPG (0.853 versus 0.818, P<0.001) alone. Recent research by 
Lipska et al. also revealed that addition of HbA1c to a model with impaired 
FPG improved discrimination and calibration [229]. The results from the 
present study imply that the mechanism for this association is that individuals 
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with diabetes-related phenotypes are more accurately identified using 
combined criteria.  
 
Established risk factors for type 2 diabetes include adiposity, raised 
triglyceride and low HDL-C levels, hypertension and insulin resistance [19]. 
In particular, subjects with a combination of these features have been shown 
to have a five-fold increased risk of developing diabetes [230]. 
Cardiometabolic disease and type 2 diabetes are also characterised by a 
low-grade but chronic inflammatory state [231,232]. This may be reflected in 
an increased production of pro-inflammatory cytokines and proteins (IL-6, 
TNF-α, leptin, resistin) and also in higher levels of acute-phase response 
proteins (C3, CRP), coagulation factors (PAI-1), macrophages and immune 
cells and lower levels of adiponectin, the anti-inflammatory adipokine 
[232,233].  
 
In our study it was noted that pre-diabetic individuals categorised by both 
assays demonstrated a stronger association with cardiometabolic feature 
clustering and displayed a more pro-inflammatory, pro-atherogenic, 
hypertensive and insulin resistant profile. Though few prospective studies 
have comprehensively identified features related to pre-diabetes 
development, it has been suggested that risk factors for pre-diabetes mirror 
those for type 2 diabetes [234]. Subsequently, on the basis of the similar risk 
profiles noted in this study between pre-diabetes (defined using both HbA1c 
and FPG) and type 2 diabetes (classified by either method), these findings 
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also indicate that combined use of both assays may be clinically useful for 
detecting individuals at highest odds of developing diabetes. 
 
Although HbA1c has long been used as a marker for glycaemic control, its 
diagnostic performance for type 2 diabetes is still questioned [235-237]. 
Though a more expensive assay, when compared with FPG, HbA1c has 
advantages including convenience, greater pre-analytical stability, lower 
biological variability and increasing international standardisation [24,237]. 
Moreover, HbA1c has been shown to correlate with cardiovascular disease 
and all-cause mortality [238]. However, as diabetes is clinically defined by 
elevated blood glucose, and not by glycation of proteins, there is concern 
that using HbA1c to classify type 2 diabetes may lead to major changes in the 
pathophysiological paradigm that defines the condition [24]. Although a 
report from the United States inferred that diagnosis by HbA1c, rather than 
FPG, would not significantly alter type 2 diabetes prevalence, and that 
categorisation would remain unchanged in as many as 97.7% of subjects 
[193], this is still uncertain [165].  
 
Within our sample, a higher prevalence of diabetes was determined using 
HbA1c (7.1%, 95% CI: 6.1%-8.3%) compared to FPG (4.2%, 95% CI: 3.4%-
5.1%). However, a similar type 2 diabetes prevalence rate in middle-aged 
Irish adults, defined by HbA1c, was recently reported using data from the 
nationally representative SLÁN 2007: Survey of Lifestyle, Attitudes and 
Nutrition (7.1%, 95% CI: 5.2%-9.0%) [35,165]. It was also noted that diabetic 
subjects identified by HbA1c or FPG within the present study displayed 
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markedly similar cardiometabolic profiles. In addition, HbA1c demonstrated 
excellent discrimination of type 2 diabetes diagnosed by FPG >7.0 mmol/l 
levels. Conversely, HbA1c showed poor discriminatory capacity for pre-
diabetes defined by impaired FPG.  
 
As HbA1c reflects long-term glycaemic exposure, including postprandial 
glucose spikes, rather than the acute dysglycaemia indicated by FPG, it is 
rational to assume that each assay may identify different individuals. Our 
results suggest that HbA1c may provide greater sensitivity for diagnosing type 
2 diabetes within this sample. However, the limited overlap and substantially 
varied cardiometabolic profiles in subjects diagnosed with pre-diabetes, by 
either HbA1c or FPG, imply that HbA1c alone may lack specificity to 
accurately detect individuals at risk of diabetes development. It was also 
noted that metabolic risk profiles in pre-diabetic subjects, classified by 
impaired FPG levels only, were also increased. This indicates that a 
percentage of at-risk individuals would be missed if HbA1c was employed as 
a sole diagnostic criterion.  
 
 
3.4.1 Strengths and limitations of the research 
This study has several strengths, including a high participation rate (67%). 
As far as we are aware, ours is the first to compare pre-diabetes and type 2 
diabetes prevalence, defined using both HbA1c and FPG criteria, in a middle-
aged Irish population. Additionally, few studies have compared a broad 
range of metabolic risk features and biomarkers with pre-diabetes and type 2 
 
 
92 | P a g e  
 
diabetes diagnosed by both assays. Our results are of potential clinical 
significance in terms of screening and the use of HbA1c as a method for 
diagnosing diabetes, assessing cardiometabolic risk and for defining 
outcomes within epidemiological research. Accurate estimates of 
progression rates to type 2 diabetes are needed for efficient allocation of 
resources in order to optimise public health prevention strategies [239]. 
Importantly, these findings indicate that caution should be taken with regard 
to how risk is defined as inexact methods may overestimate future diabetes 
burden [240,241]. 
 
Notwithstanding these strengths, several limitations can be identified. These 
include single measurements of HbA1c and FPG and that we did not have 
OGTT results as a comparison test. Although use of a third assay would 
have allowed a more thorough evaluation of HbA1c and FPG, as discussed 
by Bonora et al. [24], comparisons between diagnostic methods for pre-
diabetes and type 2 diabetes are ambiguous as a true gold standard test is 
unavailable. Also, cross-sectional data precludes examination of temporal 
relationships. Consequently, though results from our research suggest 
associations between variables, they do not demonstrate an ability to predict 
type 2 diabetes or future cardiovascular events.  
 
Equally of concern is that our data were derived from a single primary care 
based sample. Although results from the Cork and Kerry Diabetes and Heart 
Disease Study demonstrate prevalence rates for overweight/obesity and type 
2 diabetes that are comparable to those observed in other nationally 
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representative Irish studies [13,35,165], the possibility that this sample is not 
representative of the source population must be acknowledged. However, 
previous research suggests that approximately 98% of Irish adults are 
registered with a GP and that, even in the absence of a universal patient 
registration system, it is possible to perform population-based 
epidemiological studies that are representative using our methods [210]. In 
addition, Ireland presents a generally ethnically homogeneous population 
[242]. Thus, the associations we observed between cardiometabolic features 
and HbA1c and FPG may be similar in other middle-aged Irish adults. As 
random sampling of subjects and the use of validated methods for data 
collection ensured internal sample validity, it is equally possible that the 
relationships described may be generalisable to a similar middle-aged 
Caucasian-European population. Nevertheless, future studies utilising 
longitudinal data in different samples will be needed to confirm these 
findings. In particular, it will be necessary to determine whether risk 
stratification, using both assays, is clinically useful as a method for predicting 
type 2 diabetes. 
 
 
3.5 Conclusions 
In summary, our results suggest that in middle-aged Caucasian-Europeans, 
when using ADA-recommended cut-points, HbA1c alone is a poor indicator of 
diabetes risk, but is appropriate for type 2 diabetes diagnosis. Furthermore, 
combined use of HbA1c and FPG identifies subjects at substantially increased 
cardiometabolic risk. Although the efficacy and cost-effectiveness of routine 
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screening for diabetes in primary care has not been established [179-181], in 
light of the increasing prevalence of type 2 diabetes worldwide, there is a 
need to identify high-risk patients. Dual screening, utilising both HbA1c and 
FPG, may provide a more accurate method for predicting type 2 diabetes. 
Earlier detection of high-risk subjects could enable earlier targeted 
interventions or therapies, thus attenuating development of diabetes and 
related cardiovascular complications.  
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Table 6––Characteristics of the study population according to pre-diabetes and type 2 diabetes status. 
 
Feature Full cohort  Pre-diabetes
1
  Type 2 diabetes
2
 
  HbA1c  FPG  HbA1c  FPG  
 (N=2047) (N=980) (N=230) (N=146) (N=85) 
Male 1008 (49.2) 441 (45.0) 150 (65.2) 95 (65.1) 59 (69.4) 
Age 59 (55-64) 60 (55-64) 61 (56-65) 60 (57-65) 61 (57-65) 
Age >60 981 (47.9) 510 (52.0) 125 (54.3) 83 (56.8) 51 (60.0) 
Diagnosed diabetes 101 (4.9) - - 73 (50.0) 51 (60.0) 
On Rx for diabetes 78 (3.8) - - 60 (41.1) 41 (48.2) 
On Rx for hypertension 584 (28.5) 307 (31.3) 98 (42.6) 81 (55.5) 48 (56.5) 
On Rx for cholesterol 711 (34.7) 385 (39.3) 93 (40.4) 88 (60.3) 49 (57.6) 
BMI (kg/m
2
) 28.6 ± 4.7 28.8 ± 4.7 30.5 ± 5.2 32.2 ± 5.5 31.8 ± 5.5 
BMI >30 668 (32.7) 345 (35.2) 109 (47.4) 85 (58.2) 49 (57.6) 
WC (cm)  97.0 ± 13.2 97.1 ± 12.9 102.4 ± 12.8 107.9 ± 13.7 108.5 ± 13.9 
WC (HIGH) 1119 (54.8) 562 (57.4) 150 (65.2) 119 (81.5) 66 (77.6) 
Family diabetes history 390 (19.1) 176 (18.0) 46 (20.0) 62 (42.5) 41 (48.2) 
Triglycerides (mmol/l) 1.22 (0.9-1.7) 1.23 (0.9-1.7) 1.41 (1.0-2.0) 1.58 (1.2-2.3) 1.68 (1.2-2.3) 
Triglycerides >1.7 490 (24.6) 230 (23.8) 85 (37.9) 65 (45.5) 40 (48.8) 
HDL-C (mmol/l) 1.45 ± 0.4 1.45 ± 0.4 1.32 ± 0.3 1.17 ± 0.3 1.17 ± 0.4 
HDL-C (LOW) 353 (17.6) 165 (17.0) 59 (26.1) 66 (45.2) 35 (41.2) 
Dyslipidaemia 168 (8.4) 78 (8.0) 32 (14.0) 37 (25.3) 22 (25.9) 
Systolic BP (mmHg) 129.60 ± 16.8 130.10 ± 16.1 134.78 ± 15.5 134.19 ± 17.3 136.24 ± 17.4 
Diastolic BP (mmHg) 80.12 ± 9.7 80.24 ± 9.6 82.25 ± 9.1 79.50 ± 10.3 80.72 ± 10.5 
BP >130/85 1045 (51.3) 521 (53.4) 155 (67.7) 89 (61.4) 56 (66.7) 
Insulin (µU/ml) 8.65 (5.3-14.1) 8.98 (4.6-11.8) 12.67 (7.4-19.5) 18.27 (10.6-31.9) 19.21 (12.1-30.9) 
Insulin 75
th
 percentile 497 (25.0) 238 (24.6) 98 (43.2) 94 (65.7) 59 (70.2) 
>3 MetS features
3
 606 (29.6) 298 (30.4) 112 (48.7) 103 (70.5) 63 (74.1) 
HbA1c (%) 5.7 (5.5-6.0) 5.9 (5.7-6.0) 5.8 (5.6-6.1) 7.0 (6.7-8.1) 7.6 (6.8-9.0) 
HbA1c (mmol/mol) 39 (37-42) 41 (39-42) 40 (38-43) 53 (50-65) 60 (51-75) 
FPG (mmol/l) 4.90 (4.7-5.4) 5.00 (4.7-5.3) 5.80 (5.7-6.1) 6.90 (6.0-9.0) 8.50 (7.6-10.8) 
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Table 6 continued 
 
Feature Full cohort  Pre-diabetes
1
  Type 2 diabetes
2
 
  HbA1c  FPG  HbA1c  FPG  
 (N=2047) (N=980) (N=230) (N=146) (N=85) 
C3 (mg/dl) 135.92 ± 24.7 138.85 ± 24.5 141.41 ± 25.8 148.13 ± 28.6 149.20 ± 24.9 
CRP (ng/ml) 1.35 (1.0-2.3) 1.43 (1.0-2.4) 1.38 (1.0-2.3) 1.79 (1.1-3.2) 1.91 (1.2-3.0) 
IL-6 (pg/ml) 1.81 (1.2-2.9) 1.91 (1.3-3.0) 2.02 (1.5-3.0) 2.92 (1.7-4.8) 2.83 (1.8-4.6) 
TNF-α (pg/ml) 5.97 (4.9-7.3) 6.02 (5.0-7.3) 5.94 (4.9-7.5) 6.99 (5.5-8.3) 7.09 (5.6-8.1) 
Adiponectin (ng/ml) 4.75 (2.9-7.5) 4.92 (3.1-7.5) 3.63 (2.4-5.6) 2.82 (1.7-4.6) 2.73 (1.9-4.7) 
Leptin (ng/ml) 1.95 (1.1-3.1) 2.09 (1.3-3.5) 2.06 (1.3-3.8) 2.28 (1.3-3.9) 2.09 (1.1-3.4) 
Resistin (ng/ml) 5.07 (3.9-6.7) 4.93 (3.8-6.6) 4.89 (3.7-6.7) 6.15 (4.6-7.3) 5.53 (4.5-7.3) 
PAI-1 (ng/ml) 27.38 ± 12.6 27.87 ± 12.0 29.56 ± 13.2 31.35 ± 15.9 30.03 ± 11.0 
WBC (10
9
/l) 6.00 ± 1.9 6.12 ± 2.1 6.33 ± 1.72 7.39 ± 2.4 7.21 ± 1.9 
Mean and ± standard deviation are shown for continuous variables. Age, triglycerides, insulin, HbA1c, FPG, CRP, IL-6, TNF-
α, adiponectin, leptin and resistin are shown as a median (interquartile range). Numbers and % (in brackets) for categorical 
variables will vary in different analyses as some variables have missing values.  
1
Pre-diabetes: HbA1c levels 5.7%-6.4% (39-46 mmol/mol) or FPG levels 5.6-6.9 mmol/l.  
2
Type 2 diabetes: HbA1c >6.5% (>48 mmol/mol) or FPG >7.0 mmol/l.  
3
MetS features: WC (HIGH), triglycerides >1.7, HDL-C (LOW), BP >130/85 or Rx and insulin 75
th
 percentile.  
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Table 7––Odds ratios (95% CI) of having risk features according to diagnosis of pre-diabetes and type 2 diabetes  
by HbA1c or FPG. 
 
Feature Odds ratios (95% CI)
1
 
Pre-diabetes compared to normoglycaemia
2
 Type 2 diabetes compared to no diabetes
3
 
HbA1c  P value FPG  P value HbA1c  P value FPG  P value 
Male 0.8 (0.6-0.9) <0.001 2.3 (1.7-3.0) <0.001 2.0 (1.4-2.9) <0.001 2.5 (1.5-3.9) <0.001 
Age >60  1.6 (1.3-1.9) <0.001 1.4 (1.1-1.9) 0.011 1.5 (1.1-2.2) 0.018 1.7 (1.1-2.7) 0.017 
Family diabetes history 1.2 (0.9-1.5) 0.182 1.4 (1.0-2.1) 0.043 4.1 (2.9-5.9) <0.001 5.2 (3.3-8.1) <0.001 
BMI >30 1.8 (1.4-2.2) <0.001 2.2 (1.7-3.0) <0.001 3.1 (2.2-4.3) <0.001 2.8 (1.8-4.4) <0.001 
WC (HIGH) 1.5 (1.2-1.9) 0.001 2.0 (1.4-3.1) 0.001 5.4 (2.5-11.8) <0.001 7.4 (2.3-23.5) 0.001 
Triglycerides >1.7 1.2 (0.9-1.5) 0.134 2.1 (1.5-2.8) <0.001 2.5 (1.8-3.6) <0.001 2.8 (1.8-4.4) <0.001 
HDL-C (LOW) 1.4 (1.1-1.8) 0.018 2.3 (1.7-3.3) <0.001 4.6 (3.2-6.6) <0.001 3.6 (2.3-5.7) <0.001 
Dyslipidaemia 1.6 (1.1-2.4) 0.019 2.6 (1.7-4.1) <0.001 4.3 (2.8-6.5) <0.001 4.1 (2.4-6.9) <0.001 
BP >130/85 or Rx 1.4 (1.2-1.7) <0.001 2.5 (1.8-3.5) <0.001 3.0 (1.9-4.8) <0.001 4.4 (2.2-8.6) <0.001 
Insulin 75
th
 percentile 1.6 (1.3-2.0) <0.001 3.1 (2.3-4.2) <0.001 6.5 (4.5-9.4) <0.001 7.2 (4.4-11.7) <0.001 
>3 MetS features
4
 1.6 (1.3-2.0) <0.001 3.0 (2.2-3.9) <0.001 6.1 (4.2-8.8) <0.001 6.8 (4.1-11.2) <0.001 
C3
5
 1.8 (1.5-2.2) <0.001 1.4 (1.0-1.8) 0.032 3.3 (2.2-4.9) <0.001 3.1 (1.9-5.0) <0.001 
CRP
5
 1.4 (1.1-1.7)  0.001 1.2 (0.9-1.5) 0.293 1.5 (1.1-2.2) 0.02 1.6 (1.0-2.6) 0.032 
IL-6
5
 1.6 (1.3-1.9) <0.001 1.5 (1.1-2.0) 0.005 2.8 (1.9-4.1) <0.001 2.8 (1.7-4.6) <0.001 
TNF-α
5
 1.2 (1.0-1.4) 0.078 1.0 (0.7-1.3) 0.738 2.3 (1.6-3.3) <0.001 2.7 (1.6-4.4) <0.001 
Adiponectin
5
 1.4 (1.1-1.7) 0.004 2.0 (1.4-2.7) <0.001 4.0 (2.5-6.2) <0.001 3.2 (1.8-5.6) <0.001 
Leptin
5
 1.5 (1.2-1.8) <0.001 1.4 (1.1-1.9) 0.014 1.5 (1.0-2.1) 0.026 1.2 (0.8-1.8) 0.48 
Resistin
5
 0.9 (0.8-1.1) 0.305 0.9 (0.7-1.2) 0.391 2.4 (1.7-3.5) <0.001 1.8 (1.1-2.8) 0.012 
PAI-1
5
 1.3 (1.1-1.6) 0.005 1.3 (1.0-1.7) 0.108 1.5 (1.0-2.1) 0.028 1.5 (1.0-2.4) 0.078 
WBC
5
 1.7 (1.4-2.1) <0.001 1.6 (1.2-2.1) 0.001 3.4 (2.3-5.0) <0.001 3.3 (2.0-5.5) <0.001 
1
Binary logistic regression. Gender adjusted for age (continuous), age >60 adjusted for gender, all other variables adjusted 
for age (continuous) and gender.  
2
Pre-diabetes: HbA1c >5.7% (>39 mmol/mol) or FPG >5.6 mmol/l, models exclude subjects with type 2 diabetes: HbA1c >6.5% 
(>48 mmol/mol) or FPG >7.0 mmol/l or physician diagnosis or Rx diabetes medication use.  
3
Models exclude 24 subjects that indicated a physician diagnosis or Rx diabetes medication use but who did not have 
positive HbA1c or FPG test results.  
4
MetS features: WC (HIGH), triglycerides >1.7, HDL-C (LOW), BP >130/85 or Rx and insulin 75
th
 percentile.  
5
Threshold: above median level in the study population except adiponectin (below median level).  
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Table 8––Odds ratios (95% CI) of having risk features according to diagnosis of pre-
diabetes
1
 by HbA1c alone, FPG alone, or by both HbA1c and FPG together. 
 
Feature Odds ratios (95% CI)
2
 
 HbA1c alone P value FPG alone P value HbA1c & FPG P value 
 (N=814)  (N=62)  (N=162)  
Male 0.8 (0.6-0.9) 0.006 3.3 (1.8-5.9) <0.001 1.6 (1.2-2.3) 0.005 
Age >60 1.6 (1.3-1.9) <0.001 1.4 (0.8-2.3) 0.251 2.0 (1.4-2.8) <0.001 
Family diabetes history 1.1 (0.8-1.4) 0.474 1.2 (0.6-2.4) 0.651 1.7 (1.1-2.6) 0.013 
BMI >30 1.6 (1.3-2.0) <0.001 1.7 (1.0-3.0) 0.051 3.4 (2.4-4.9) <0.001 
WC (HIGH) 1.4 (1.2-1.8) <0.001 2.0 (1.2-3.4) 0.011 2.6 (1.8-3.7) <0.001 
Triglycerides >1.7 1.2 (0.9-1.5) 0.267 2.5 (1.4-4.3) 0.001 2.3 (1.4-4.3) <0.001 
HDL-C (LOW) 1.3 (1.0-1.7) 0.095 2.5 (1.3-4.7) 0.004 2.8 (1.8-4.3) <0.001 
Dyslipidaemia 1.6 (1.0-2.5) 0.041 3.5 (1.6-7.8) 0.002 3.5 (2.0-6.2) <0.001 
BP >130/85 or Rx 1.3 (1.0-1.6) 0.012 2.2 (1.2-3.9) 0.009 3.3 (2.2-5.1) <0.001 
Insulin 75
th
 percentile 1.5 (1.2-2.0) 0.002 3.4 (2.0-5.9) <0.001 4.1 (2.8-5.9) <0.001 
>3 MetS features
3
 1.4 (1.2-1.8) 0.003 3.0 (1.7-5.1) <0.001 4.0 (2.8-5.8) <0.001 
C3
4
 1.8 (1.5-2.3) <0.001 1.4 (0.9-2.4) 0.17 2.2 (1.5-3.1) <0.001 
CRP
4
 1.4 (1.1-1.7) 0.002 1.1 (0.7-2.0) 0.640 1.5 (1.1-2.2) 0.017 
IL-6
4
 1.5 (1.2-1.9) <0.001 1.4 (0.8-2.4) 0.212 2.1 (1.5-3.0) <0.001 
TNF-α
4
 1.2 (1.0-1.5) 0.096 0.8 (0.5-1.4) 0.524 1.1 (0.8-1.6) 0.446 
Adiponectin
4
 1.3 (1.0-1.6) 0.043 1.3 (0.7-2.3) 0.373 2.6 (1.8-3.9) <0.001 
Leptin
4
 1.4 (1.2-1.8) <0.001 1.3 (0.8-2.2) 0.345 2.0 (1.4-2.9) <0.001 
Resistin
4
 1.0 (0.8-1.2) 0.626 1.3 (0.7-2.1) 0.389 0.8 (0.5-1.1) 0.139 
PAI-1
4
 1.3 (1.1-1.6) 0.008 1.4 (0.8-2.4) 0.2 1.6 (1.1-2.2) 0.014 
WBC
4
 1.6 (1.3-2.0) <0.001 1.3 (0.7-2.2) 0.371 2.6 (1.8-3.7) <0.001 
1
Pre-diabetes: HbA1c >5.7% (>39 mmol/mol) or FPG >5.6 mmol/l, models exclude subjects with type 2 
diabetes: HbA1c >6.5% (>48 mmol/mol) or FPG >7.0 mmol/l or physician diagnosis or Rx diabetes 
medication use.  
2
Multinomial logistic regression, reference category: normoglycaemia by both HbA1c and FPG. Gender 
adjusted for age (continuous), age >60 adjusted for gender, all other variables adjusted for age 
(continuous) and gender.  
3
MetS features: WC (HIGH), triglycerides >1.7, HDL-C (LOW), BP >130/85 or Rx and insulin 75
th
 
percentile.  
4
Threshold: above median level in the study population except adiponectin (below median level). 
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Figure 4––Receiver operating characteristic curve for HbA1c to discriminate 
subjects with pre-diabetes. The figure shows an ROC curve for HbA1c (continuous) 
to discriminate subjects with pre-diabetes (impaired FPG >5.6 mmol/l). The area under 
the curve value was AUC=0.67, 95% CI: 0.63-0.71.  
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Figure 5––Receiver operating characteristic curve for HbA1c to discriminate 
subjects with type 2 diabetes. The figure shows an ROC curve for HbA1c 
(continuous) to discriminate subjects with type 2 diabetes (FPG >7.0 mmol/l). The 
area under the curve value was AUC=0.94, 95% CI: 0.90-0.98.  
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4.0 Abstract 
Background and Objectives 
Despite recommendations that central obesity assessment should be 
employed as a marker of cardiometabolic health, no consensus exists 
regarding measurement protocol. This study examined a range of 
anthropometric variables and their relationships with cardiometabolic 
features and type 2 diabetes in order to ascertain whether measurement site 
influences discriminatory accuracy. In particular, we compared waist 
circumference (WC) measured at two sites: (1) immediately below the lowest 
rib (WC rib) and (2) between the lowest rib and iliac crest (WC midway), 
which has been recommended by the World Health Organisation and 
International Diabetes Federation. 
 
 
Materials and Methods 
This was a cross-sectional study involving a random sample of 2,002 men 
and women aged 46-73 years. Metabolic profiles and WC, hip 
circumference, pelvic width and body mass index (BMI) were determined. 
Correlation, logistic regression and area under the receiver operating 
characteristic curve analyses were used to evaluate adiposity variable 
relationships with metabolic risk phenotypes and type 2 diabetes.  
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Results 
WC rib measures displayed the strongest associations with non-optimal lipid 
and lipoprotein levels, high blood pressure, insulin resistance, impaired 
fasting glucose, a clustering of metabolic risk features and type 2 diabetes, in 
both genders. Rib-derived indices improved discrimination of type 2 diabetes 
by 3%-7% compared to BMI and 2%-6% compared to WC midway (in men) 
and 5%-7% compared to BMI and 4%-6% compared to WC midway (in 
women). Index models including BMI and central obesity variables displayed 
a significantly higher area under the curve for WC rib (AUC=0.78, P=0.003), 
Rib/height ratio (AUC=0.80, P<0.001), Rib/pelvis ratio (AUC=0.79, P<0.001), 
but not for WC midway (AUC=0.75, P=0.127), when compared to one with 
BMI alone (AUC=0.74). 
 
 
Conclusions 
WC rib is easier to assess and our data suggest that it is a better method for 
determining obesity-related cardiometabolic risk than WC midway. The 
clinical utility of rib-derived indices, or alternative WC measurements, 
deserves further investigation.  
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4.1 Introduction 
Obesity is associated with dyslipidaemia, hypertension, insulin resistance 
and the development of metabolic syndrome and type 2 diabetes [6], leading 
to a greater likelihood of premature death. However, not all obese subjects 
are at increased cardiometabolic risk as a proportion are considered to be 
metabolically healthy [232]. The prevalence of obesity has escalated in many 
world populations [2,5]. Thus, there is an increasing need for inexpensive 
and non-invasive risk assessment tools for use in clinical practice to help 
identify overweight and obese individuals at highest odds of developing 
metabolic abnormalities and type 2 diabetes.  
 
Body mass index (BMI) has traditionally been the chosen surrogate method 
used to determine excess body fat, but because it is a weight-for-height 
measure, BMI is unable to distinguish between fat and lean mass. Recent 
research has indicated that general obesity categorisation based on BMI 
might be inadequate [61,99], and studies have shown that BMI may 
misclassify adiposity [243-245].  
 
Increasing evidence suggests that central obesity is a more important 
cardiometabolic risk factor [79,83] and waist circumference (WC) 
measurement has been recommended as a method for central obesity 
assessment. However, partly due to a lack of agreement on a universal 
measurement protocol, its clinical usefulness and superiority over BMI for 
detecting patients at increased cardiometabolic risk has been questioned 
[12,246]. Various transformations of WC have also been used, such as the 
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waist-height ratio (WHtR) [143] and waist-hip ratio (WHR) [114]. Although 
extensive research has attempted to quantify relationships between different 
adiposity measures and morbidity [246], considerable controversy still exists 
as to which measurement site or index most accurately defines non-optimal 
body fat distribution [151]. 
 
In this study we examined a range of anthropometric variables and their 
relationships with metabolic risk phenotypes, including lipid and lipoprotein 
levels, high blood pressure (BP), insulin resistance, impaired fasting plasma 
glucose (FPG), a clustering of metabolic risk features and type 2 diabetes, in 
a random sample of 2,002 middle-aged men and women. In particular, we 
compared the discriminatory performance of WC measured at two locations 
(immediately below the lowest rib, and between the lowest rib and iliac 
crest), and variations of these measures, to explore the hypothesis that the 
measurement site for central obesity affects its accuracy as a discriminator of 
cardiometabolic risk.  
 
 
4.2 Materials and Methods 
4.2.1 Study design 
The study design is described in detail in Chapter 1. In summary, the Cork 
and Kerry Diabetes and Heart Disease Study (Phase II) was a single centre, 
cross-sectional study conducted between 2010 and 2011. A random sample 
was recruited from a large primary care centre in Mitchelstown, County Cork, 
Ireland. The Livinghealth Clinic serves a population of approximately 20,000, 
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with a mix of urban and rural residents. Stratified sampling was employed to 
recruit equal numbers of men and women from all registered attending 
patients in the 46-73 year age group. In total, 3,807 potential participants 
were selected from the practice list. Following the exclusion of duplicates, 
deaths, and subjects incapable of consenting or attending appointment, 
3,051 were invited to participate in the study and of these, 2,047 (49.2% 
male) completed the questionnaire and physical examination components of 
the baseline assessment (response rate: 67.1%). Details regarding the study 
design, sampling procedures and methods of data collection have been 
reported previously [183].  
 
Ethics committee approval conforming to the Declaration of Helsinki was 
obtained from the Clinical Research Ethics Committee of University College 
Cork. A letter signed by the contact GP in the clinic was sent out to all 
selected participants with a reply slip indicating acceptance or refusal. All 
subjects gave signed informed consent, including permission to use their 
data for research purposes.  
 
 
4.2.2 Clinical and laboratory procedures  
Study participants attended the clinic in the morning after an overnight fast 
and blood samples were taken on arrival. Data on age, gender, physician-
diagnosed type 2 diabetes and prescription (Rx) medication use were 
gathered through a self-completed General Health Questionnaire [170]. 
Triglyceride and high-density lipoprotein cholesterol (HDL-C) levels were 
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measured by Cork University Hospital Biochemistry Laboratory on Olympus 
5400 biochemistry analysers with Olympus reagents using standardised 
procedures and fresh samples (Olympus Diagnostica GmbH, Hamburg, 
Germany). Fasting plasma glucose concentrations were determined using a 
glucose hexokinase assay (Olympus Life and Material Science Europa Ltd., 
Lismeehan, Co. Clare, Ireland) and fasting serum insulin was calculated 
using a biochip array system (Evidence Investigator; Randox Laboratories, 
UK). Glycated haemoglobin A1c (HbA1c) levels were measured in the 
haematology laboratory on an automated high-pressure liquid 
chromatography instrument Tosoh G7 [Tosoh HLC-723 (G7), Tosoh Europe 
N.V, Tessenderlo, Belgium]. Three independent measurements of systolic 
and diastolic BP were obtained with the subject in a seated position using an 
Omron M7 digital sphygmomanometer (Omron Healthcare Co. Ltd., Japan). 
The mean of the second and third readings was considered to be a subject’s 
BP.  
 
 
4.2.3 Anthropometric variables 
Anthropometric measurements were taken by researchers who were 
thoroughly trained according to the study research protocols [183]. The 
weight and height of each subject were measured to the nearest 0.1 kg and 
0.1 cm respectively. Portable electronic Tanita WB-100MA weighing scales 
(Tanita Corporation, IL, USA) were placed on a firm, flat surface and were 
calibrated weekly to ensure accuracy. Height was assessed using a portable 
Seca Leicester height/length stadiometer (Seca, Birmingham, UK) and BMI 
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was calculated as weight divided by the square of height. Midway WC (WC 
midway) was measured between the lowest rib and iliac crest on bare skin. 
Participants were instructed to breathe in, and then out, and to hold their 
breath while measurement was made to the nearest 0.1 cm using a Seca 
200 measuring tape. Rib WC (WC rib) was measured immediately below the 
lowest rib at the mid-axillary line and hip circumference was determined at 
the maximum perimeter of the hips. Pelvic width was calculated as the 
diameter between the right and left iliac crests using callipers. For each 
central obesity variable, the mean of two independent readings was used in 
analysis. Height, hip circumference and pelvic width were divided into WC 
midway and WC rib measurements deriving six variables: (1) Midway/height 
ratio, (2) Midway/hip ratio, (3) Midway/pelvis ratio and (4) Rib/height ratio, (5) 
Rib/hip ratio, (6) Rib/pelvis ratio. 
 
 
4.2.4 Classification of biochemical and blood pressure measurements 
According to American Diabetes Association guidelines, type 2 diabetes was 
defined as HbA1c >6.5% (>48 mmol/mol) or FPG >7.0 mmol/l [23]. Individuals 
on insulin therapy and subjects indicating a diagnosis of diabetes (either self-
reported physician diagnosis or Rx diabetes medication use), but who did not 
have positive HbA1c or FPG test results, were excluded from analysis 
(N=45). 
 
Lipid, lipoprotein, FPG and BP measurements were classified according to 
National Cholesterol Education Program: Adult Treatment Panel III criteria 
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[184]. Abnormal metabolic risks were defined as high triglyceride levels >1.7 
mmol/l, low HDL-C (<1.03 mmol/l in males or <1.29 mmol/l in females) and 
impaired FPG levels 5.6-6.9 mmol/l. High BP was classified as systolic BP 
>130 mmHg and/or diastolic BP >85 mmHg or Rx anti-hypertensive 
medication use. The Homeostasis Model Assessment Index of Insulin 
Resistance (HOMA-IR) [247] was derived from FPG and insulin 
concentrations as [(FPG x fasting serum insulin)/22.5], and insulin resistance 
was defined as a level equal to or above the 75th percentile in the study 
population. Having three or more cardiometabolic risk features was 
characterised as any combination of these variables.  
 
 
4.2.5 Statistical analysis  
The distribution of each metabolic characteristic was assessed using 
Shapiro-Wilk and Kolmogorov-Smirnov statistics. Categorical features are 
presented as percentages and continuous data are shown as a mean, plus 
or minus one standard deviation, or a median and interquartile range. 
Gender differences were evaluated using chi-square tests, independent t-
tests or a Mann-Whitney U for skewed data. Relationships between 
anthropometric measurements and continuous cardiometabolic variables 
were investigated using partial correlations. Variables presenting a non-
normal distribution were log transformed. All obesity measures were gender-
standardised and separate and stratified binary logistic regression models 
were used to compare index associations with cardiometabolic risk features 
and type 2 diabetes, adjusting for age.  
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The ability of selected indices to discriminate three or more cardiometabolic 
risk features and type 2 diabetes was measured using receiver operating 
characteristic curve (ROC) analysis. The area under the curve (AUC) 
provides a scale from 0.5 to 1.0 (with 0.5 representing random chance and 
1.0 indicating perfect discrimination) by which to appraise the capability of an 
adiposity measure to detect a positive result [150]. A higher AUC generally 
indicates greater diagnostic accuracy. Covariate-adjusted analysis [248] was 
performed to account for the potential confounding influence of both age and 
gender (full cohort) or age alone in stratified models. The AUC values were 
compared for statistical differences and were further evaluated by 
determining false positive rates at specific points on the curve corresponding 
to 90%, 80%, 70% and 60% sensitivities. 
 
To further judge the ability of central adiposity to discriminate type 2 
diabetes, we compared a logistic regression model containing BMI to models 
which included both BMI and selected central obesity measures. The 
accuracy of each model was assessed using the ROC curve. We additionally 
evaluated discrimination using integrated discrimination improvement (IDI) 
analysis, which indicates the magnitude of improvement in the performance 
of a model by adding another variable [249]. To assess goodness-of-fit, the 
likelihood ratio (LR) chi-square statistics were examined by comparing 
models with or without an additional anthropometric measure. Calibration 
was measured using the Hosmer-Lemeshow (HL) test.  
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Data analysis was conducted using IBM SPSS Statistics Version 20 (IBM 
Corp., Armonk, NY, USA) and Stata SE Version 13 (Stata Corporation, 
College Station, TX, USA) for Windows. Seven subjects had missing 
anthropometric values. For all analyses, a P value (two-tailed) of less than 
0.05 was considered to indicate statistical significance.  
 
 
4.3 Results 
4.3.1 Descriptive characteristics  
Characteristics of the study population are presented in Table 9. According 
to BMI classification recommended by the World Health Organisation (WHO) 
[23], 1,550 (77.7%) participants were either overweight or obese, with 835 
(85.6%) male subjects having a BMI >25 kg/m2 compared to 715 (70.2%) 
females (P for difference <0.001). Mean WC and pelvic width measurements 
were also significantly increased in men while hip circumference levels were 
greater in women. Distinctions between WC midway and WC rib were 
observed in both genders, with average midway values being higher. With 
consideration to metabolic risk factors, male subjects were significantly more 
likely to have abnormal triglyceride levels, high BP, insulin resistance, 
impaired FPG, a clustering of cardiometabolic risk features and type 2 
diabetes. 
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4.3.2 Partial correlations between anthropometric measurements and 
cardiometabolic variables 
After adjustment for age, positive correlations for triglycerides, systolic BP, 
diastolic BP, HOMA-IR, HbA1c, FPG, and negative correlations for HDL-C, 
were observed with weight, BMI and measurements of central adiposity 
(Table 10). Significant inverse relationships were also noted for height with 
triglyceride and FPG concentrations in men, while HDL-C was positively 
correlated with height in women. Relationships were stronger between WC 
rib and a majority of metabolic variables, with triglycerides, HDL-C and 
HOMA-IR showing the highest correlative strengths. Nevertheless, metabolic 
variable correlations with BMI and WC midway, although reduced, were of a 
similar magnitude in men. 
 
 
4.3.3 Associations between adiposity measures and adverse 
cardiometabolic features and type 2 diabetes 
The results from regression models examining adiposity variable 
associations with individual metabolic risk factors (Appendix 2, Supporting 
Figure 1), three or more cardiometabolic risk features (Figure 6) and type 2 
diabetes (Figure 7) are shown. Results are adjusted for age and odds ratios 
represent the odds associated with a one standard deviation increase in 
each obesity measure. Although the strength of relationship varied according 
index type, WC rib or rib-derived indices displayed, without exception, 
stronger associations with individual cardiometabolic risk factors, metabolic 
feature clustering and type 2 diabetes, in both genders. In general, stronger 
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relationships with cardiometabolic variables were noted in women, with 
differences between BMI and central obesity being less pronounced in male 
subjects.  
 
 
4.3.4 ROC analysis 
In ROC analysis, both WC rib and Rib/height ratio demonstrated a 
significantly higher AUC to detect three or more cardiometabolic risk features 
compared to WC midway in male subjects (Figure 8). In females, significant 
differences in the AUC were observed when compared to both WC midway 
and BMI. For type 2 diabetes (Figure 9), WC rib measures showed a higher 
discriminatory capacity in both genders, with the exception of the Rib/hip 
ratio in men. Rib-derived indices improved discrimination by 3%-7% 
compared to BMI and 2%-6% compared to WC midway (in men) and 5%-7% 
compared to BMI and 4%-6% compared to WC midway (in women). Rib 
measures also displayed greater specificity across a range of sensitivities 
(Figure 10). At higher sensitivities classification accuracy was improved by 
10% or more. However, false positive rates for the Rib/hip ratio were 
noticeably increased when compared to other adiposity variables in men.  
 
 
4.3.5 Evaluation of index discrimination models 
As presented in Table 11, we compared models which included BMI and an 
additional central obesity measure to discriminate type 2 diabetes. The HL 
test showed P values that were non-significant, suggesting that model fits 
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were acceptable. Additionally, the LR chi-squares were reduced in models 
including central adiposity variables, indicating improved goodness-of-fit. 
Using the IDI statistic, a significant but marginal increase in discrimination 
was observed for WC midway, with a small and non-significant increase in 
the AUC (AUC=0.75, P=0.127) (Figure 11). In contrast, models including BMI 
and WC rib measures displayed significantly higher AUC values (Figures 12-
14) for WC rib (AUC=0.78, P=0.003), Rib/height ratio (AUC=0.80, P<0.001) 
and Rib/pelvis ratio (AUC=0.79, P<0.001) when compared to a model with 
BMI alone (AUC=0.74).  
 
 
4.4 Discussion 
Both the WHO and International Diabetes Federation (IDF) have suggested 
midway WC measurement as the preferred method for central obesity 
assessment [12,19]. In contrast, the United States National Institutes of 
Health (NIH) recommend measuring WC at the superior border of the iliac 
crest [103]. However, there is a lack of scientific rationale to support either of 
these measurement protocols [102]. Although previous studies have 
compared these two criteria, to the best of our knowledge, this is the first to 
comprehensively evaluate both rib and midway WC measurements and BMI. 
Our findings suggest that WC rib, rather than WC midway, is a better 
indicator of central obesity as it improves discrimination of type 2 diabetes 
within our population. One possible explanation for this relationship may be 
that rib-level measurement is less influenced by inter-individual variables 
 
 
115 | P a g e  
 
such as body posture or elasticity of the abdominal wall, which are partly 
unrelated to actual body adiposity.  
 
The results from previous research investigating different WC measurement 
criteria are conflicting. A systematic review of 120 studies [107] concluded 
that measurement procedure had no substantial influence on WC 
relationships with morbidity and mortality, leading the authors to recommend 
the NIH protocol as it may be more readily adapted by healthcare 
practitioners and is more suitable for self-measurement by the general 
public. However, effect sizes and discriminatory differences between WC 
sites were not compared. In contrast, Ma et al. [250] found WC midway to be 
slightly better than NIH-recommended iliac measurement to predict 
hypertension, metabolic syndrome and diabetes. Nevertheless, WC rib was 
not assessed in this study. Bosy-Westphal et al. [102] also observed reduced 
associations between the iliac site and metabolic characteristics and visceral 
adipose tissue (VAT) in females. Relationships between cardiometabolic 
variables and WC midway and rib were similar in men, while WC rib was 
more strongly correlated with VAT in women.  
 
Regardless of controversies surrounding WC measurement protocol, both 
advantages and disadvantages exist regarding the general application of 
central obesity assessment within clinical practice. Although some studies 
have suggested WC to be the simplest and best overall method for 
cardiometabolic health appraisal [127], as metabolic risk cut-points for WC 
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are different between genders, and vary between ethnic groups [12,251], the 
practical usability of WC measurement is still uncertain [246].  
 
In keeping with other findings [115,143], our results imply that 
transformations of WC may improve discrimination. The use of a ratio to 
define central adiposity is also potentially beneficial as it might allow uniform 
diagnostic thresholds to be used (between ethnicities, genders or both), 
making it attractive from a public health perspective [125,126]. Notably, 
however, the WHR was a markedly poor indicator of risk in male subjects 
within this sample. Reduced associations for WHR were also observed by 
Schneider et al. [121], who theorised that as both WC and hip circumference 
exhibit strong relationships with cardiometabolic features, a ratio of the two 
may show less. Additionally, both measures may increase or decrease 
proportionally in an individual [117]. It could be that sex differences observed 
for WHR are due to gender variations in body composition, and that changes 
in hip circumference, relative to WC, are more pronounced in middle-aged 
men than in women. 
 
Although WC rib measures demonstrated stronger relationships with 
metabolic variables, consistent with previous research [246], our study also 
revealed that index associations with a majority of the examined 
cardiometabolic features and type 2 diabetes were reduced in men. One 
possible explanation for this finding is the greater prevalence of overweight 
and obesity amongst males within this population, thus reducing associations 
between variables and discriminatory abilities. It was also noted that 
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discriminatory differences between central adiposity and BMI were greater 
when detecting type 2 diabetes compared to a clustering of metabolic 
features, in both genders. A reason for this may be that central obesity 
independently predicts type 2 diabetes, beyond commonly assessed 
cardiometabolic disease markers [100].  
 
Compared with BMI, central adiposity is thought to be more strongly 
correlated with VAT [83]. Research has suggested that fatty acids released 
from VAT drain into the liver and skeletal muscle causing metabolic 
dysfunction within these organs [78]. Proteins secreted from VAT may also 
contribute to cardiometabolic disease through inflammation of adipose and 
vascular tissue [79]. Increased VAT levels have been shown to be 
associated with increased risk of dyslipidaemia, hypertension and type 2 
diabetes [75,76]. Subsequently, differences in discrimination of 
cardiometabolic disease features and type 2 diabetes (observed within this 
sample) might suggest that central obesity should be independently 
evaluated as a diabetes risk factor, and that its inclusion as a mandatory 
component of the metabolic syndrome may be appropriate [19]. The idea 
that central obesity assessment provides additional information related to 
diabetes – beyond commonly measured cardiometabolic disease features, 
including BMI – is explored further in Chapter 5. 
 
Nevertheless, the findings from previous studies which have compared 
central adiposity variables with BMI have been inconclusive [151,246]. 
Possible reasons for variations between studies may include different WC 
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measurement protocols or dissimilar methods for classifying chronic 
conditions. Although AUC values for central obesity measures are frequently 
reported to be larger when compared to BMI for discriminating type 2 
diabetes [143], as the AUC lacks clinical relevance, there is argument 
against using it as a summary statistic of the ROC curve as similar AUC 
values may have different diagnostic properties [248]. Though other studies 
have reported metabolic risk thresholds for obesity indices based on 
maximum sensitivity, optimal sensitivity and specificity, the furthest distance 
from the chance line or the shortest distance to the y axis [12], cut-points are 
necessarily arbitrary, and may vary between different populations.  
 
Central obesity measures have been proposed as stand-alone, pre-
screening tools [126] for use in high-risk populations to enable clinicians to 
detect those who might benefit from further diagnostic or therapeutic 
procedures [252,253]. In this scenario it is desirable to optimise sensitivity 
(the percentage of people with or at risk of a condition, who would be 
correctly identified), in order to rule out healthy subjects. Importantly, by 
comparing false positive rates (the proportion of healthy individuals who 
would be misclassified) across a range of sensitivities for multiple indices, 
our results demonstrate WC rib measures to be more accurate classifiers, at 
higher sensitivities, compared to WC midway and BMI.  
 
However, debate exists regarding the clinical efficacy of central adiposity 
assessment. To some extent this is due to a lack of evidence regarding how 
much of an increase in discriminatory accuracy central obesity measures 
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might add over traditionally assessed indicators of cardiometabolic disease 
[246]. Though findings from this study suggest that central adiposity indices 
provide additional information when compared to general adiposity measured 
by BMI, these results also demonstrate that the degree of improvement is 
significantly influenced by the procedure used for estimating WC.  
 
While only requiring a flexible measuring tape, midway WC is difficult to 
obtain as it requires the identification of two bony landmarks, a computed 
distance between the two, and a circumference evaluation – essentially four 
separate measurements. Given that central obesity assessment competes 
for the limited time available during patient appraisal, and necessitates 
specific training to ensure reliable data are obtained [83], a simpler 
measurement protocol is desirable. WC rib is more easily determined and 
offers a more practical method for use within healthcare practice and 
epidemiological research, and would be equally suitable for self-assessment. 
Furthermore, Bosy-Westphal et al. [102] and Wang et al. [254] also 
concluded that WC rib had a higher reproducibility. As measurement error 
may limit the minimal detectable difference in a parameter [102], it is possible 
that the higher discriminatory accuracy we observed may be due to greater 
measurement precision.  
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4.4.1 Limitations of the research 
Though our findings are of potential public health and clinical significance, 
several limitations should be considered. Given the modest number of 
outcomes within our sample we did not adjust for multiple factors in 
analyses. Our primary aim was to compare general and central obesity 
relationships, rather than to determine overall strengths of association. 
Nevertheless, the possibility that confounding features may influence 
adiposity variables in different ways cannot be discounted and future studies 
with larger samples might find different relationships. Also, cross-sectional 
data precludes examination of the temporal relationship between adiposity 
and diabetes. Thus, although our results may suggest a rationale for central 
adiposity assessment as a method for indentifying patients with type 2 
diabetes, and for assessing cardiometabolic risk, they do not demonstrate 
that central obesity measures would be useful to predict type 2 diabetes or 
related cardiovascular outcomes.  
 
Equally of concern is that we did not have other WC measurement sites to 
contrast and that our data were derived from a single primary care based 
sample. However, Ireland presents a generally ethnically homogeneous 
population [242]. In addition, random sampling of subjects and the use of 
validated methods for data collection ensured internal sample validity and the 
relationships described may be generalisable to a similar middle-aged 
Caucasian-European population. Nonetheless, future studies utilising 
longitudinal data in different samples will be needed to evaluate the validity 
and reliability of alternative WC measurements. In particular, it will be 
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necessary to determine whether employing central obesity measures for risk 
stratification is clinically useful and superior to currently recommended BMI 
classification [94]. 
 
 
4.5 Conclusions 
In summary, our results indicate that measurement protocol for WC may be 
important for determining central obesity and assessing cardiometabolic 
health. Rib-level measures were more strongly associated with 
cardiometabolic risk features and improved discrimination of patients with 
type 2 diabetes. In light of the increasing prevalence of obesity, 
cardiometabolic disease and diabetes worldwide, effective methods to detect 
individuals with type 2 diabetes, and those at increased cardiometabolic risk, 
are needed [51]. The clinical utility of WC measured at the lowest rib, rib-
derived indices or alternative WC measurements as potentially more 
accurate discriminators of metabolic risk and type 2 diabetes, compared to 
WHO and IDF-recommended midway WC measurement or BMI, deserves 
further investigation. 
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Table 9––Characteristics of the study population. 
 
Feature Males  
(N=981) 
Females 
(N=1021) 
P value 
Age 59 (55-64) 59 (54-64) 0.791 
Weight (kg) 87.4 ± 13.8 71.6 ± 13.6 <0.001 
Height (m) 1.7 ± 0.1 1.6 ± 0.1 <0.001 
BMI (kg/m
2
)
 
29.1 ± 4.2 28.0 ± 5.2 <0.001 
WC midway (cm) 102.6 ± 11.1 91.4 ± 12.7 <0.001 
WC rib (cm) 99.9 ± 10.1 85.1 ± 12.2 <0.001 
Hip circumference (cm) 99.0 ± 8.7 101.8 ± 10.7 <0.001 
Pelvic width (cm) 33.0 ± 2.4  32.0 ± 2.7 <0.001 
Triglycerides (mmol/l) 1.32 (0.9-1.9) 1.10 (0.8-1.5) <0.001 
High triglycerides
1 
313 (32.9) 164 (16.5) <0.001 
HDL-C (mmol/l) 1.28 ± 0.3 1.62 ± 0.4 <0.001 
Low HDL-C
2 
166 (17.3) 169 (16.8) 0.676 
Average systolic BP (mmHg) 130.83 ± 15.6 128.44 ±17.9 0.001 
Average diastolic BP (mmHg) 79.94 ± 9.6 80.42 ± 9.9 0.339 
High BP
3 
628 (64.3) 593 (58.3) 0.006 
HOMA-IR 3.27 (1.3-3.8) 2.32 (1.0-2.7) <0.001 
Insulin resistance
4 
301 (32.0) 179 (18.2) <0.001 
FPG (mmol/l)
5 
5.00 (4.7-5.4) 4.80 (4.5-5.2) <0.001 
Impaired FPG
5,6 
150 (17.3) 80 (8.5) <0.001 
Three or more cardiometabolic risk features
5 
178 (20.0) 106 (10.9) <0.001 
Type 2 diabetes 92 (9.5) 50 (5.0) <0.001 
Mean and ± standard deviation are shown for continuous variables, P value calculated with a 
Student’s t-test. Age, triglycerides, HOMA-IR and FPG are shown as a median (interquartile 
range) with a P value according to a Mann-Whitney U. % are shown for categorical values 
with x
2 
for difference in proportions. Numbers and (%) may vary as some variables have 
missing values.  
1
Triglycerides >1.7.  
2
HDL-C <1.03 (males) or HDL-C <1.29 (females).  
3
BP >130/85 or on Rx for hypertension.  
4
HOMA-IR 75
th
 percentile.  
5
Excluding subjects with type 2 diabetes.  
6
FPG >5.6.  
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Table 10––Partial correlations
1
 between anthropometric measurements and 
cardiometabolic variables, stratified by gender. 
 
Cardiometabolic 
Feature 
Weight Height BMI WC 
midway 
WC 
rib 
Hip 
circumference 
Pelvic 
width 
MALES        
 Triglycerides
2 
0.249 -0.062 0.306 0.296 0.319 0.257 0.162 
 HDL-C -0.347 0.063
3 
-0.350 -0.345 -0.354 -0.327 -0.295 
 Systolic BP 0.189 -0.002
3
 0.205 0.175 0.218 0.168 0.138 
 Diastolic BP 0.220 0.012
3
 0.230 0.198 0.228 0.187 0.168 
 HOMA-IR
2 
0.497 -0.005
3
 0.557 0.570 0.572 0.517 0.362 
 HbA1c
2 
0.178 -0.044
3
 0.218 0.249 0.261 0.214 0.123 
 FPG
2
 0.187 -0.093 0.254 0.260 0.267 0.219 0.122 
FEMALES        
 Triglycerides
2 
0.306 -0.033
3
 0.326 0.342 0.404 0.281 0.205 
 HDL-C -0.283 0.074 -0.314 -0.301 -0.364 -0.265 -0.172 
 Systolic BP 0.148 -0.030
3
 0.163 0.135 0.161 0.126 0.078 
 Diastolic BP 0.172 -0.019
3
 0.186 0.136 0.170 0.149 0.081 
 HOMA-IR
2
 0.516 -0.052
3
 0.550 0.493 0.574 0.462 0.288 
 HbA1c
2 
0.202 -0.029
3
 0.220 0.208 0.256 0.177 0.103 
 FPG
2
 0.281 -0.017
3
 0.298 0.303 0.347 0.268 0.183 
 
1
Adjusted for age.  
2
Log transformed. All correlation coefficients are significant (P<0.05) except:  
3
P>0.05. The index associated with the highest correlative strength to the variable in the same 
row is highlighted.  
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Table 11––Tests of calibration, goodness-of-fit and discrimination for index models to detect subjects 
with type 2 diabetes. 
 
Model
1 
HL x
2 
(P value) LR x
2 
(P value) AUC (95% CI) IDI (95% CI) 
BMI alone 4.39 (0.82) 919.38 (<0.001) 0.74 (0.70-0.78) - 
BMI and WC midway 2.32 (0.97) 900.78 (<0.001) 0.75 (0.71-0.79)
2 
0.0177 (0.002-0.0334) 
BMI and WC rib 5.01 (0.76) 877.54 (<0.001) 0.78 (0.74-0.82)
3 
0.0283 (0.0111-0.0455) 
BMI and Rib/height ratio 5.34 (0.72) 858.75 (<0.001) 0.80 (0.76-0.84)
4 
0.0364 (0.0162-0.0566) 
BMI and Rib/pelvis ratio 6.58 (0.58) 860.73 (<0.001) 0.79 (0.75-0.82)
5
 0.0290 (0.0135-0.0445) 
1
All models include age and gender. 
2
P value=0.127 compared to model with BMI alone. 
3
P value=0.003 compared to model with BMI alone. 
4
P value<0.001 compared to model with BMI alone. 
5
P value<0.001 compared to model with BMI alone. 
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Figure 6––Odds ratios (95% CI) of having three or more cardiometabolic risk 
features for a one standard deviation increase in each adiposity measure. 
Results are stratified by gender and adjusted for age. All models exclude subjects with 
type 2 diabetes.  
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Figure 7––Odds ratios (95% CI) of having type 2 diabetes for a one standard 
deviation increase in each adiposity measure. Results are stratified by gender and 
adjusted for age.  
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Figure 8––Adjusted area under the receiver operating characteristic curve 
values for selected adiposity measures to discriminate subjects with three or 
more cardiometabolic risk features. Bars represent AUC values. All models exclude 
subjects with type 2 diabetes. Statistical differences in the AUC values are shown in 
superscript Arabic numbers as: 
1
P<0.05 compared to WC midway; 
2
P<0.05 compared 
to BMI.  
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Figure 9––Adjusted area under the receiver operating characteristic curve 
values for selected adiposity measures to discriminate subjects with type 2 
diabetes. Bars represent AUC values. Statistical differences in the AUC values are 
shown in superscript Arabic numbers as: 
1
P<0.05 compared to WC midway; 
2
P<0.05 
compared to BMI.  
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Figure 10––False positive rates corresponding to 90%, 80%, 70% and 60% 
sensitivities for selected adiposity measures to classify subjects with type 2 
diabetes. Results are stratified by gender and adjusted for age. Bars represent false 
positive rates (percentages).  
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Figure 11––Receiver operating characteristic curves for index models to 
discriminate subjects with type 2 diabetes. The figure shows ROC curves for a 
model including BMI and a model including BMI and WC midway. All models include 
age and gender. 
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Figure 12––Receiver operating characteristic curves for index models to 
discriminate subjects with type 2 diabetes. The figure shows ROC curves for a 
model including BMI and a model including BMI and WC rib. All models include age 
and gender. 
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Figure 13––Receiver operating characteristic curves for index models to 
discriminate subjects with type 2 diabetes. The figure shows ROC curves for a 
model including BMI and a model including BMI and Rib/height ratio. All models 
include age and gender. 
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Figure 14––Receiver operating characteristic curves for index models to 
discriminate subjects with type 2 diabetes. The figure shows ROC curves for a 
model including BMI and a model including BMI and Rib/pelvis ratio. All models 
include age and gender. 
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6.0 Abstract 
Background and Objectives 
A novel obesity classification method has been proposed using body mass 
index (BMI) and waist-height ratio (WHtR) together. However, the utility of 
this approach is unclear. In this study we compare the metabolic profiles in 
subjects defined as overweight or obese by both measures. We examine a 
range of metabolic syndrome features, pro-inflammatory cytokines, acute-
phase response proteins, coagulation factors and white blood cell counts to 
determine whether a combination of both indices more accurately identifies 
individuals at increased obesity-related cardiometabolic risk. 
 
 
Materials and Methods 
This was a cross-sectional study involving a random sample of 1,856 men 
and women aged 46-73 years. Metabolic and anthropometric profiles were 
assessed. Linear and logistic regression analyses were used to compare 
lipid, lipoprotein, blood pressure, glycaemic and inflammatory biomarker 
levels between BMI and WHtR tertiles. Multinomial logistic regression was 
performed to determine cardiometabolic risk feature associations with BMI 
and WHtR groupings. Receiver operating characteristic curve analysis was 
used to evaluate index discriminatory ability. 
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Results 
The combination of BMI and WHtR tertiles identified consistent and 
significant metabolic variable differences relative to those characterised as 
overweight or obese discordantly by BMI and WHtR. Similarly, odds ratios of 
having cardiometabolic risk features were noticeably increased in subjects 
classified as overweight or obese by both measures. Significant 
discriminatory improvement, using joint measurement, was also observed for 
detecting individual cardiometabolic disease features and adverse biomarker 
levels. In a fully adjusted model, only individuals within the highest tertile for 
both indices displayed a significant and positive association with pre-
diabetes (OR: 3.4, 95% CI: 1.9,6.0, P<0.001). 
 
 
Conclusions 
These data provide evidence that the use of BMI and WHtR together may 
improve body fat classification. Risk stratification using a composite index 
may provide a more accurate method for identifying high and low-risk 
subjects. 
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6.1 Introduction 
Excess body fat has been shown to be associated with dyslipidaemia, 
hypertension, insulin resistance, chronic low-grade inflammation and the 
development of metabolic syndrome (MetS), type 2 diabetes and 
cardiovascular complications [6,165,215,232]. Numerous studies have also 
demonstrated a high mortality rate in subjects with a body mass index (BMI) 
>30 kg/m2 [93]. But because it is a weight-for-height measure, BMI is unable 
to distinguish between fat and lean mass and elevated BMI may not always 
indicate higher levels of adiposity or increased cardiometabolic risk 
[64,98,243].  
 
Evidence suggests that central obesity is a more important metabolic risk 
factor and waist circumference (WC) measurement has been recommended 
as a method for central obesity assessment [79,83]. However, as WC 
diagnostic thresholds are different for men and women, and may vary 
between ethnic groups [12], the practical utility of WC measurement has 
been questioned [246]. 
 
The waist-height ratio (WHtR) (WC divided by height) has been advocated 
as an alternative surrogate measure of central adiposity [126]. As a ratio, this 
index may circumvent problematic issues relating to gender or population-
specific risk cut-points [125,273]. But results from studies which have 
compared BMI and WHtR have been inconclusive, with some showing WHtR 
to be only marginally superior to BMI as an indicator of obesity-related risk 
[127,148,156]. 
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The prevalence of obesity has escalated in many world populations [2,5]. 
Thus, there is an increasing need to identify overweight and obese 
individuals at highest odds of developing chronic disorders. Recently, a new 
obesity classification method was proposed, utilising BMI in conjunction with 
WHtR [273]. Risk stratification using a composite index may provide a more 
effective method for identifying high and low-risk patients. This could allow 
earlier diagnosis, thus attenuating metabolic complications and chronic 
morbidity development.  
 
The aim of this study was to compare the metabolic profiles in subjects 
defined as overweight or obese, using BMI and WHtR, in a random sample 
of 1,856 middle-aged men and women. In particular, we examined a range of 
MetS features, pro-inflammatory cytokines, acute-phase response proteins, 
coagulation factors and white blood cell (WBC) counts to determine whether 
a combination of both indices more accurately identifies individuals at 
increased obesity-related cardiometabolic risk.  
 
 
6.2 Materials and Methods 
6.2.1 Study design 
The study design is described in detail in Chapter 1. In summary, the Cork 
and Kerry Diabetes and Heart Disease Study (Phase II) was a single centre, 
cross-sectional study conducted between 2010 and 2011. A random sample 
was recruited from a large primary care centre in Mitchelstown, County Cork, 
Ireland. The Livinghealth Clinic serves a population of approximately 20,000, 
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with a mix of urban and rural residents. Stratified sampling was employed to 
recruit equal numbers of men and women from all registered attending 
patients in the 46-73 year age group. In total, 3,807 potential participants 
were selected from the practice list. Following the exclusion of duplicates, 
deaths, and subjects incapable of consenting or attending appointment, 
3,051 were invited to participate in the study and of these, 2,047 (49.2% 
male) completed the questionnaire and physical examination components of 
the baseline assessment (response rate: 67.1%). Details regarding the study 
design, sampling procedures and methods of data collection have been 
reported previously [183].  
 
Ethics committee approval conforming to the Declaration of Helsinki was 
obtained from the Clinical Research Ethics Committee of University College 
Cork. A letter signed by the contact GP in the clinic was sent out to all 
selected participants with a reply slip indicating acceptance or refusal. All 
subjects gave signed informed consent, including permission to use their 
data for research purposes.  
 
 
6.2.2 Clinical and laboratory procedures 
Study participants attended the clinic in the morning after an overnight fast 
and blood samples were taken on arrival. Data on age, gender, physician-
diagnosed diabetes, prescription (Rx) medication use and smoking/alcohol 
behaviours were gathered through a self-completed General Health 
Questionnaire (GHQ) [170]. Physical activity levels were assessed using the 
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International Physical Activity Questionnaire (IPAQ) [171]. Three 
independent measurements of systolic and diastolic blood pressure (BP) 
were obtained with the subject in a seated position using an Omron M7 
digital sphygmomanometer (Omron Healthcare Co. Ltd., Japan). The mean 
of the second and third readings was considered to be a subject’s BP.  
 
Triglyceride and high-density lipoprotein cholesterol (HDL-C) levels were 
measured by Cork University Hospital Biochemistry Laboratory on Olympus 
5400 biochemistry analysers with Olympus reagents using standardised 
procedures and fresh samples (Olympus Diagnostica GmbH, Hamburg, 
Germany). Fasting plasma glucose (FPG) concentrations were determined 
using a glucose hexokinase assay (Olympus Life and Material Science 
Europa Ltd., Lismeehan, Co. Clare, Ireland) and glycated haemoglobin A1c 
(HbA1c) levels were measured in the haematology laboratory on an 
automated high-pressure liquid chromatography instrument Tosoh G7 
[Tosoh HLC-723 (G7), Tosoh Europe N.V, Tessenderlo, Belgium]. Serum 
insulin, c-reactive protein (CRP), tumour necrosis factor alpha (TNF-α), 
interleukin 6 (IL-6), adiponectin, leptin, resistin and plasminogen activator 
inhibitor-1 (PAI-1) were assessed using a biochip array system (Evidence 
Investigator; Randox Laboratories, UK). Complement component 3 (C3) was 
measured by immunoturbidimetric assay (RX Daytona; Randox 
Laboratories). White blood cell counts were determined by flow cytometry 
technology as part of a full blood count.  
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6.2.3 Classification of biochemical and blood pressure measurements 
Patients with type 2 diabetes indicated by either HbA1c levels >6.5% (>48 
mmol/mol) or FPG levels >7.0 mmol/l [23], a self-reported physician 
diagnosis, Rx diabetes medication use, or those who were on insulin 
therapy, were excluded (N=184).  
 
Lipid, lipoprotein and BP measurements were classified according to 
National Cholesterol Education Program: Adult Treatment Panel III 
guidelines [184]. Abnormal metabolic risks were defined as high triglycerides 
>1.7 mmol/l and low HDL-C (<1.03 mmol/l in males or <1.29 mmol/l in 
females). Dyslipidaemia was determined according to both high triglyceride 
and low HDL-C levels. High BP was classified as systolic BP >130 mmHg 
and/or diastolic BP >85 mmHg or Rx anti-hypertensive medication use.  
 
The Homeostasis Model Assessment Index of Insulin Resistance (HOMA-IR) 
[247] was derived from FPG and insulin concentrations as [(FPG x fasting 
serum insulin)/22.5] and insulin resistance was defined as a level equal to or 
above the 75th percentile in the study sample. Having three or more MetS 
risk features (>3 metabolic features) was characterised as any combination 
of the following: high triglycerides, low HDL-C levels, high BP and insulin 
resistance. Subjects were classified as having pre-diabetes if they had both 
elevated HbA1c levels >5.7% (>39 mmol/mol) and impaired FPG levels >5.6 
mmol/l [23]. As internationally agreed risk cut-points for the examined 
biomarkers have not been established, low-grade inflammation was 
determined as a level equal to or above the 75th percentile for each 
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biomarker (C3, CRP, IL-6, TNF-α, leptin, resistin, PAI-1 and WBC) with the 
exception of adiponectin (equal to or below the 25th percentile).  
 
 
6.2.4 Anthropometric variables 
The weight and height of each participant were measured to the nearest 0.1 
kg and 0.1 cm respectively. Portable electronic Tanita WB-100MA weighing 
scales (Tanita Corporation, IL, USA) were placed on a firm, flat surface and 
were calibrated weekly to ensure accuracy. Height was measured using a 
portable Seca Leicester height/length stadiometer (Seca, Birmingham, UK) 
and BMI was calculated as weight divided by the square of height. Waist 
circumference was measured immediately below the lowest rib at the mid-
axillary line on bare skin. Subjects were instructed to breathe in, and then 
out, and to hold their breath while measurement was made to the nearest 0.1 
cm using a Seca 200 measuring tape. Two independent readings were taken 
for WC and the mean of the two was used in analysis. The WHtR was 
calculated as WC divided by height.  
 
Both BMI and WHtR were divided into equal tertiles. Subjects were 
categorised on the basis of their BMI or WHtR percentiles as normal weight 
(<33%), overweight (33-66%) and obese (>66%). In our sample these cut-
points corresponded to <26.2, 26.2-29.7, >29.7 for BMI and <0.52, 0.52-
0.58, >0.58 for WHtR. The BMI and WHtR groups were combined to form a 
5-category variable: (1) normal weight by both, (2) overweight by either, (3) 
overweight by both, (4) obese by either and (5) obese by both. Overweight 
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subjects classified as obese by either index were assigned to the higher 
category. Seven subjects had missing anthropometric values and were 
excluded from statistical analysis.  
 
 
6.2.5 Lifestyle data 
Lifestyle variables utilised from the IPAQ and GHQ included physical activity 
levels, smoking status and alcohol use. Self-reported physical activity within 
the previous six months was collapsed into two categories: high or moderate 
(N=1324) and no physical exercise (N=312). Subjects were considered to be 
current smokers if they smoked cigarettes during the recruitment phase of 
the study (N=257). Alcohol use was assessed by asking study participants 
how often they consumed alcohol on a monthly or weekly basis, and was 
dichotomised as follows: “never or less than once a month” and “2-4 times 
monthly” = occasional drinker (N=1165) and “twice or more weekly” = regular 
drinker (N=614).  
 
 
6.2.6 Statistical analysis  
Data analysis was conducted using IBM SPSS Statistics Version 20 (IBM 
Corp., Armonk, NY, USA) and Stata SE Version 13 (Stata Corporation, 
College Station, TX, USA) for Windows. Descriptive characteristics were 
examined according to normal weight, overweight and obese defined by BMI 
and WHtR tertiles. Dichotomous features are presented as percentages and 
continuous variables are shown as a mean (plus or minus one standard 
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deviation) or a median and interquartile range for skewed data. Linear and 
logistic regression (adjusting for gender) were used to examine continuous 
and dichotomous metabolic variable differences between overweight and 
obese categories. Skewed continuous data were log transformed. 
Multinomial logistic regression was performed to determine cardiometabolic 
risk feature associations with each BMI and WHtR tertile combination. 
Subjects classified as normal weight by both indices were used as the 
reference category. All multinomial regression models were adjusted using 
age, gender, physical activity, smoking status and alcohol use as 
independent covariates.  
 
The discriminatory ability of BMI, WHtR, and both BMI and WHtR used 
together, was assessed using receiver operating characteristic curve (ROC) 
analysis. The area under the curve (AUC) provides a scale from 0.5 to 1.0 
(with 0.5 representing random chance and 1.0 indicating perfect 
discrimination) by which to appraise the capacity of an obesity index to 
detect a positive result [150]. Three separate analyses were performed. The 
first analysis assessed each anthropometric measure as a continuous 
variable. The second analysis explored cardiometabolic risk feature 
discrimination using index tertiles. A final analysis examined the 5-category 
BMI/WHtR combination variable used in previous regression models. 
Significant differences between AUC values were determined. For all 
analyses, a P value (two-tailed) of less than 0.05 was considered to indicate 
statistical significance. 
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6.3 Results 
6.3.1 Descriptive characteristics 
The characteristics of the study population were summarised according to 
BMI and WHtR tertiles (Table 16). A higher tertile level was related to an 
increased cardiometabolic risk profile as defined by lipid/lipoprotein, BP, 
glycaemic indicator and biomarker levels, with obese groups showing the 
highest proportion of cardiometabolic risk factors. In general, cardiometabolic 
profiles were broadly similar across BMI and WHtR overweight and obese 
categories, with the percentage of subjects with dyslipidaemia, high BP, 
insulin resistance, >3 metabolic features and pre-diabetes showing little 
variation according to classification by either index. 
 
 
6.3.2 Cardiometabolic profiles according to classification of normal 
weight, overweight and obese  
The levels of agreement between normal weight, overweight and obese 
tertiles are shown in Figure 16. Kappa statistics were similar for normal and 
obese classifications (Kappa: 0.66 for normal weight versus Kappa: 0.68 for 
obese) with marginal overlap between subjects defined as overweight 
(Kappa: 0.38). In both overweight and obese groups (Table 17), the 
combination of BMI and WHtR tertiles identified consistent and significant 
metabolic variable differences relative to those characterised discordantly. 
Subjects that were classified as overweight or obese by both indices 
displayed higher mean BMI, WC and median triglyceride levels, reduced 
HDL-C and adiponectin concentrations, and a higher percentage had 
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adverse biomarker levels, insulin resistance, metabolic feature clustering and 
pre-diabetes. 
 
 
6.3.3 Associations between cardiometabolic risk features and 
BMI/WHtR combinations 
Table 18 presents results from multinomial logistic regression models 
examining each BMI and WHtR tertile combination. A clear dose-response 
relationship was noted, with odds ratios of having cardiometabolic risk 
features being noticeably increased in subjects classified concordantly by 
both indices. In univariate analysis (not shown), odds ratios of having pre-
diabetes were 0.6 (95% CI: 0.3,1.5), 1.9 (95% CI: 1.1,3.4), 1.8 (95% CI: 
1.0,3.3) and 4.1 (95% CI: 2.5,6.7) for subjects categorised as overweight by 
either, overweight by both, obese by either and obese by both measures 
respectively. In a fully adjusted model, only patients within the highest BMI 
and WHtR tertile displayed a significant and positive association with pre-
diabetes defined by both elevated HbA1c and impaired FPG levels (OR: 3.4, 
95% CI: 1.9,6.0, P<0.001). 
 
 
6.3.4 ROC analysis 
In ROC analysis (Table 19), when used as a continuous variable, 
significantly higher AUC values for WHtR were found to discriminate high 
triglycerides, >3 metabolic features, elevated C3 and WBC levels when 
compared to BMI. BMI displayed a significantly higher AUC for detecting 
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increased leptin levels compared to WHtR. A combination of both measures 
displayed significantly greater discriminatory accuracy for high triglycerides, 
metabolic feature clustering, C3 and CRP compared to BMI, and for leptin 
compared to WHtR. Significant improvement for detecting insulin resistance 
and high WBC levels were noted compared to when either BMI or WHtR 
were used independently. 
 
When indices were examined as tertiles, significant differences between BMI 
and WHtR remained for discriminating high triglyceride, leptin and WBC 
concentrations. The BMI/WHtR 5-category variable was a significantly better 
discriminator of high triglycerides, low HDL-C, pre-diabetes, high C3, CRP, 
IL-6, TNF-α and WBC levels compared to BMI, and of leptin compared to 
WHtR. Significantly higher AUC values for detecting insulin resistance and 
>3 metabolic features were also found compared to when either measure 
were used alone.  
 
 
6.4 Discussion 
The aim of this study was to determine whether risk stratification using BMI 
and WHtR together more accurately identifies individuals at increased 
obesity-related cardiometabolic risk. Our findings indicate that both 
measures classify different subjects, particularly within the overweight range. 
These results also demonstrate that individuals defined as overweight or 
obese, by both BMI and WHtR, may exhibit different cardiometabolic profiles 
compared to subjects categorised discordantly. Participants classified 
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concordantly by both measures demonstrated stronger associations with 
individual cardiometabolic risk factors, metabolic feature clustering and 
displayed a profile that was more pro-inflammatory, pro-atherogenic and 
insulin resistant. Use of both indices also significantly improved 
discrimination of individual cardiometabolic disease features. These results 
suggest that joint use of BMI and WHtR may be clinically useful as a method 
to detect individuals at risk of cardiometabolic abnormalities. 
 
Although it is straightforward to assess, and easy to calculate, limitations 
regarding the use of BMI as a sole method for adiposity appraisal have been 
widely acknowledged [98,99,243,246]. Though frequently employed within 
epidemiological research and healthcare practice, BMI does not discriminate 
between fat and lean body mass, therefore persons of short stature or 
muscular build may be misidentified [256]. Research has indicated that 
general obesity classification based on BMI might be inadequate [61]. A 
recent large study (N=40,420) which stratified participants by BMI categories 
demonstrated that nearly half of overweight, 29% of obese and even 16% of 
obese class II and III subjects were metabolically healthy [64]. Importantly, 
the finding that 30% of normal weight individuals were cardiometabolically 
unhealthy, signals that caution should be exercised with regard to how 
adiposity is defined [256].  
 
Compared with BMI, WC is thought to be more strongly correlated with 
visceral adipose tissue (VAT) which has been shown to be associated with 
increased risk of dyslipidaemia, hypertension and type 2 diabetes [75,76]. 
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Though the exact mechanism of association between VAT and metabolic risk 
is still poorly understood, research has implied that fatty acids released from 
VAT drain into the liver and skeletal muscle, causing metabolic dysfunction 
within these organs [78]. Proteins secreted from VAT may also contribute to 
cardiometabolic disease through inflammation of adipose and vascular tissue 
[79,83]. Although WC measurement has been recommended as a method 
for VAT and cardiometabolic risk assessment, controversy exists regarding 
its clinical efficacy. In particular, the need for gender and ethnic-specific risk 
cut-points, and the fact that WC does not take whole body fat distribution into 
account, indicate constraints regarding its practical application and 
usefulness within a clinical setting [246].  
 
The WHtR is potentially advantageous as it may not require conversion to 
gender or population-specific cut-offs [125]. It has been previously suggested 
that a WHtR >0.5 may serve as a useful boundary for increased 
cardiometabolic risk, with a WHtR >0.6 threshold indicating substantially 
increased risk [273]. Additionally, it has been shown that height has an 
inverse association with cardiovascular disease mortality and total mortality 
[274,275], indicating that its use within an adiposity variable may be clinically 
important. In a recent meta-analysis of 31 prospective or cross-sectional 
studies, Ashwell et al. demonstrated WHtR to be a better discriminator of 
hypertension, MetS, type 2 diabetes and cardiovascular disease when 
compared to BMI [143]. Pooled results showed that WHtR improved 
discrimination of all outcomes by 4%-5%. However, other studies have 
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suggested that differences in predictive abilities are minimal, and have 
questioned the measurement of height in addition to WC [127].  
 
The results from our research suggest that both BMI and WHtR provide 
important and independent information, and that joint measurement may help 
refine body fat classification. Within our sample it was noted that participants 
who were categorised as overweight discordantly also displayed an 
increased cardiometabolic risk profile. As a proportion of these individuals 
might be considered normal weight if either measure were used alone, these 
results indicate that use of both indices may provide a more sensitive method 
for detecting patients at increased cardiometabolic risk. We also observed 
noticeably strong associations with cardiometabolic features in subjects who 
were classified as overweight or obese by both BMI and WHtR together. This 
suggests that joint measurement may equally provide a more specific 
procedure for identifying high-risk subjects within overweight and obese 
categories. In particular, patients within the highest tertile for both indices 
were at a significantly higher risk compared subjects classified as obese 
discordantly. In addition, a significant association with pre-diabetes was only 
observed within this tertile after adjustment for other risk factors. This might 
imply that the relationship between obesity and diabetes is better indicated at 
this mode and level of adiposity. 
 
Cardiometabolic disease is thought to be multifactorial, and it has been 
suggested that subjects with a combination of adverse features are at 
highest risk of developing type 2 diabetes and obesity-related chronic 
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disorders [19,230]. Although discriminatory improvements for detecting 
individual risk features were modest when using joint measurement, overall 
discrimination of cardiometabolic risk was significantly greater than when 
either index were used separately. As a degree of measurement error is to 
be expected during any anthropometric assessment, and as measurement 
error may limit the minimal detectable difference in a cardiometabolic risk 
parameter [102], it could be that these findings are due to the greater 
measurement accuracy that joint BMI and WHtR assessment may provide. 
 
While it is hoped that public health programmes may eventually reduce the 
prevalence of obesity-related metabolic disorders, current strategies to 
combat obesity are failing as overweight and obesity rates continue to 
increase worldwide [2,5]. As a percentage of subjects with increased 
adiposity are considered to be metabolically healthy [256], there is a need for 
cheap and non-invasive methods to detect overweight and obese individuals 
at highest odds of developing type 2 diabetes and atherosclerotic vascular 
disease.  
 
In previous research we have shown that assessing both bioelectrical 
impedance-derived body fat percentage and BMI may help to discriminate 
individuals at greater cardiometabolic risk than BMI alone [245]. Those 
identified using both tools had a more metabolically unhealthy profile and 
were non-responsive to dietary changes. These findings suggest that 
stratification of obese individuals, based on their metabolic health phenotype, 
could be important in the early identification of those who should be 
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prioritised for pharmacological and lifestyle interventions [256]. Joint use of 
BMI and WHtR may provide a convenient and inexpensive means for risk 
stratification. Such a method might be useful in resource-poor settings where 
blood sampling is cost-prohibitive, or in populations without regular access to 
primary health services.  
 
 
6.4.1 Strengths and limitations of the research 
As far as we are aware, our study is the first to comprehensively examine the 
joint use of BMI and WHtR in a middle-aged European population. Strengths 
include a high participation rate, the use of questionnaires to assess lifestyle 
behaviours and inclusion of a wide range of metabolic variables to define 
cardiometabolic health. Our findings are of potential public health and clinical 
significance in terms of screening and the use of stratification based on 
obesity assessment as a method for determining cardiometabolic risk. 
 
Notwithstanding these strengths, methodological limitations should be 
considered when examining results from this study. Given the modest 
number of outcomes within our sample, we did not stratify by gender in 
analysis. Although some studies have implied heterogeneous relationships 
between measures of adiposity and cardiometabolic disease relating to 
gender [246], previous work by our group has suggested that these may be 
partly explained by sex differences in obesity prevalence [167]. In addition, 
recommended risk cut-points for BMI and WHtR are the same for men and 
women, and the gender variable was accounted for in analysis.  
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Also, given the size of our sample, the majority of analyses in this study use 
an approach comparing concordant results for both BMI and WHtR with 
subjects classified as overweight or obese discordantly. When combining the 
results of patients who were discordant by either measure, it is impossible to 
distinguish whether the poorer performance results exclusively from one or 
the other index, or from both indices equally. We acknowledge this as a 
limitation of our approach. Nevertheless, the ROC analysis did compare BMI 
and WHtR individually, and the results would support our finding that joint 
measurement may improve cardiometabolic risk classification. 
 
Equally of concern is that we did not use established adiposity index cut-offs 
and that our data were cross-sectional, as this precludes examination of 
temporal relationships. Although World Health Organisation cut-points for 
BMI are commonly used [93], and thresholds for WHtR have been 
recommended [123,273], for the purposes of this research it was necessary 
to place both variables on the same scale. Future studies, utilising 
longitudinal data, will be needed to evaluate the applicability, validity and 
reliability of joint measurement [273] using established and recommended 
diagnostic cut-points. In particular, it will be necessary to determine whether 
employing both BMI and WHtR for risk stratification is clinically useful and 
superior to currently recommended BMI classification [94].  
 
Finally, our data were derived from a single primary care based sample 
which may not be representative of the source population. However, Ireland 
presents a generally ethnically homogeneous population [242]. Thus, the 
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relationships we observed are likely to be similar in other middle-aged Irish 
adults. In addition, random sampling of subjects and the use of validated 
methods for data collection ensured internal sample validity and the results 
from this research may be generalisable to a similar middle-aged Caucasian-
European population.  
 
 
6.5 Conclusions 
In summary, our findings reveal that individuals defined as overweight or 
obese, by both BMI and WHtR, are at increased cardiometabolic risk when 
compared to subjects categorised discordantly by BMI and WHtR. Use of 
both measures also improved discrimination of individual risk features and 
identified a subset of at-risk patients who might otherwise be missed. 
Although assessment of WC, in addition to BMI, competes for the limited 
time available during patient appraisal within clinical practice [83], obtaining 
two measurements (one for general adiposity, and one for central adiposity) 
does not entail any extra cost [273]. In light of the increasing prevalence of 
cardiometabolic disease worldwide [175], effective methods that help to 
identify subjects at greatest risk are needed. Risk stratification utilising a 
composite index may provide a simple, cost-effective and more accurate 
technique for predicting obesity-related chronic disorders. Earlier 
identification of individuals at risk could enable earlier targeted interventions 
or therapies, thus attenuating development of cardiovascular complications. 
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Table 16––Characteristics of the study population. 
 
Feature Normal weight Overweight Obese 
BMI 
(N=619) 
WHtR  
(N=619) 
BMI 
(N=618) 
WHtR  
(N=618) 
BMI  
(N=619) 
WHtR  
(N=619) 
Male 212 (34.2) 145 (23.4) 346 (56.0) 349 (56.5) 327 (52.8) 391 (63.2) 
Age 58 (54,63) 57 (54,62) 59 (54,63) 59 (54,64) 60 (55,64) 60 (55,64) 
Weight (kg) 64.6 ± 8.5 65.6 ± 9.4 78.3 ± 9.1 78.6 ± 10.2 92.5 ± 12.6 91.2 ± 13.5 
BMI (kg/m
2
)
 
23.7 ± 1.8 24.3 ± 2.5 27.9 ± 1.0 27.9 ± 2.2 33.3 ± 3.5 32.7 ± 4.0 
WC (cm) 79.7 ± 8.9 77.7 ± 7.2 91.8 ± 8.0 92.2 ± 5.8 102.7 ± 10.0 104.3 ± 8.4 
WHtR 0.48 ± 0.04 0.47 ± 0.03 0.55 ± 0.04 0.55 ± 0.02 0.62 ± 0.05 0.62 ± 0.04 
Triglycerides (mmol/l) 1.0 (0.8,1.3) 1.0 (0.8,1.3) 1.2 (0.9,1.7) 1.2 (0.9,1.7) 1.4 (1.0,2.0) 1.5 (1.1,2.0) 
High triglycerides
1 
67 (11.0) 49 (8.0) 147 (24.5) 152 (25.5) 195 (33.3) 208 (35.1) 
HDL-C (mmol/l) 1.7 ± 0.4 1.7 ± 0.4 1.4 ± 0.3 1.4 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 
Low HDL-C
2 
46 (7.6) 39 (6.4) 74 (12.2) 80 (13.2) 142 (23.8) 143 (24.0) 
Dyslipidaemia 12 (2.0) 10 (1.6) 37 (6.1) 37 (6.1) 69 (11.5) 71 (11.9) 
Systolic BP (mmHg) 124.9 ± 17.4 124.8 ± 17.2 129.5 ± 15.5 129.2 ± 15.5 133.0 ± 15.9 133.4 ± 16.0 
Diastolic BP (mmHg) 77.2 ± 9.6 77.8 ± 9.6 80.7 ± 8.8 80.3 ± 9.4 82.5 ± 9.9 82.3 ± 9.5 
High BP
3 
271 (43.8) 263 (42.5) 359 (58.2) 366 (59.3) 471 (76.3) 472 (76.5) 
Insulin (µU/ml) 5.3 (3.8,7.9) 5.3 (3.8,7.9) 8.4 (5.7,12.0) 8.3 (5.6,12.2) 12.9 (8.2,18.4) 12.9 (8.4,18.4) 
HOMA-IR 1.1 (0.8,1.7) 1.1 (0.8,1.7) 1.8 (1.2,2.7) 1.8 (1.2,2.7) 2.9 (1.8,4.3) 2.9 (1.9,4.3) 
Insulin resistance
4 
31 (5.2) 29 (4.9) 121 (20.2) 122 (20.4) 293 (49.4) 294 (49.6) 
>3 metabolic features 16 (2.6) 13 (2.1) 63 (10.2) 59 (9.5) 163 (26.3) 170 (27.5) 
HbA1c (%) 5.6 (5.4,4.8) 5.6 (5.4,5.8) 5.7 (5.5,5.8) 5.7 (5.5,5.9) 5.7 (5.5,6.0) 5.7 (5.5,6.0) 
FPG (mmol/l) 4.8 (4.5,5.0) 4.7 (4.5,5.0) 4.9 (4.6,5.2) 4.9 (4.7,5.2) 5.1 (4.7,5.4) 5.1 (4.8,5.5) 
Pre-diabetes
5 
27 (4.4) 26 (4.3) 49 (8.1) 41 (6.7) 86 (14.2) 95 (15.7) 
C3 (mg/dl) 125.7 ± 22.9 125.2 ± 22.4 134.2 ± 22.7 135.2 ± 22.8 144.5 ± 22.9 144.0 ± 22.8 
High C3
6 
79 (13.2) 77 (12.8) 133 (22.0) 137 (22.6) 239 (39.8) 237 (39.6) 
CRP (ng/ml) 1.1 (0.8,1.6) 1.1 (0.8,1.6) 1.3 (1.0,1.9) 1.3 (1.0,2.0) 1.7 (1.2,3.1) 1.8 (1.2,3.0) 
High CRP
6 
91 (15.1) 85 (14.1) 124 (20.5) 136 (22.4) 236 (39.4) 230 (38.5) 
IL-6 (pg/ml) 1.4 (1.0,2.3) 1.4 (1.0,2.1) 1.6 (1.2,2.5) 1.7 (1.2,2.5) 2.1 (1.5,3.3) 2.2 (1.5,3.4) 
High IL-6
6 
118 (19.5) 102 (16.9) 126 (20.9) 129 (21.3) 207 (34.5) 220 (36.8) 
TNF-α (pg/ml) 5.6 (4.6,6.9) 5.5 (4.5,6.6) 5.9 (4.9,7.2) 5.8 (4.9,7.1) 6.3 (5.2,7.5) 6.4 (5.3,7.7) 
High TNF-α
6 
117 (19.4) 110 (18.2) 153 (25.4) 140 (23.1) 181 (30.2) 201 (33.6) 
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Table 16 continued 
 
Feature Normal weight Overweight Obese 
 BMI  
(N=619) 
WHtR  
(N=619) 
BMI  
(N=618) 
WHtR  
(N=618) 
BMI  
(N=619) 
WHtR  
(N=619) 
Adiponectin (ng/ml) 6.6 (4.2,9.8) 6.9 (4.7,10.2) 4.6 (2.9,6.9) 4.6 (2.9,6.9) 4.1 (2.6,6.3) 3.8 (2.5,5.5) 
Low adiponectin
6 
78 (12.9) 65 (10.8) 176 (29.1) 167 (27.6) 199 (33.2) 221 (36.9) 
Leptin (ng/ml)
 
1.3 (0.6,2.0) 1.4 (0.8,2.1) 1.8 (1.0,2.7) 1.8 (1.0,2.8) 3.1 (1.9,5.1) 2.7 (1.6,4.7) 
High leptin
6
 39 (6.5) 67 (11.1) 109 (18.0) 122 (20.1) 303 (50.5) 262 (43.7) 
Resistin (ng/ml) 4.8 (3.9,6.4) 4.9 (3.8,6.4) 4.9 (3.7,6.5) 4.9 (3.8,6.6) 5.3 (4.0,7.0) 5.2 (4.0,6.7) 
High resistin
6
 133 (22.0) 136 (22.5) 141 (23.3) 152 (25.1) 178 (29.7) 164 (27.4) 
PAI-1 (ng/ml) 24.3 ± 10.3 24.0 ± 10.4 28.1 ± 13.6 27.5 ± 11.7 28.7 ± 12.0 29.7 ± 13.7 
High PAI-1
6
 100 (16.6) 94 (15.6) 164 (27.2) 161 (26.6) 187 (31.2) 196 (32.8) 
WBC (10
9
/l) 5.7 ± 2.4 5.5 ± 1.6 5.8 ± 1.6 5.9 ± 2.3 6.1 ± 1.5 6.3 ± 1.5 
High WBC
6
 125 (20.7) 103 (17.0) 149 (24.5) 153 (25.3) 177 (29.7) 195 (32.7) 
Mean and ± standard deviation are shown for continuous variables. Age, triglycerides, insulin, HOMA-IR, HbA1c, FPG, CRP, 
IL-6, TNF-α, adiponectin, leptin and resistin are shown as a median (interquartile range). % (in brackets) for dichotomous 
variables will vary as some variables have missing values.  
1
Triglycerides >1.7.  
2
HDL-C <1.03 (males) or HDL-C <1.29 (females).  
3
Systolic BP >130 and/or diastolic BP >85 or use of Rx anti-hypertensives.  
4
HOMA-IR >2.96.  
5
Both HbA1c levels >5.7% and FPG levels >5.6.  
6
Threshold: C3 >148; CRP >2.25; IL-6 >2.72; TNF-α >7.2; adiponectin <3.1; leptin >3.07; resistin >6.6; PAI-1 >33.66; WBC 
>6.6.  
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Table 17––Cardiometabolic profiles according to classification of normal weight, overweight and obese defined by BMI,  
WHtR, or both. 
 
Feature Normal weight 
by both  
(N=479) 
Overweight by 
either  
(N=263) 
Overweight by 
both  
(N=363) 
P value
1 
 
Obese by  
either  
(N=264) 
Obese by  
both 
(N=487) 
P value
2 
Male
3 
122 (25.5) 105 (39.9) 231 (63.6) <0.001 136 (51.5) 291 (59.8) 0.03 
Age
4 
58 (54,62) 58 (54,65) 59 (54,63) 0.885 59 (54,64) 60 (55,64) 0.15 
Weight (kg)
5
 63.1 ± 8.1 71.9 ± 8.0 79.6 ± 9.2 <0.001 81.8 ± 9.5 94.6 ± 12.6 <0.001 
BMI (kg/m
2
)
5 
23.3 ± 1.8
 
26.2 ± 1.5 27.9 ± 1.0 <0.001 29.7 ± 1.9 33.8 ± 3.6 <0.001 
WC (cm)
5
 76.6 ± 7.2 85.7 ± 6.7 93.0 ± 5.7 <0.001 95.1 ± 7.2 105.7 ± 8.5 <0.001 
WHtR
5
 0.46 ± 0.03 0.52 ± 0.03 0.55 ± 0.02 <0.001 0.57 ± 0.03 0.63 ± 0.05 <0.001 
Triglycerides (mmol/l)
5
 0.9 (0.7,1.2) 1.1 (0.8,1.5) 1.3 (0.9,1.7) 0.005 1.3 (1.0,1.8) 1.5 (1.1,2.0) 0.034 
High triglycerides
5 
36 (7.6) 43 (16.7) 93 (26.6) 0.031 71 (27.7) 166 (35.8) 0.06 
HDL-C (mmol/l)
5
 1.7 ± 0.4 1.6 ± 0.4 1.4 ± 0.3 <0.001 1.4 ± 0.3 1.3 ± 0.3 <0.001 
Low HDL-C
5
 31 (6.7) 23 (8.8) 46 (12.9) 0.038 39 (15.1) 123 (26.3) 0.001 
Dyslipidaemia
5
 7 (1.5) 8 (3.1) 21 (5.9) 0.059 24 (9.3) 58 (12.3) 0.253 
Systolic BP (mmHg)
5
 124.2 ± 17.5 126.4 ± 16.2 129.4 ± 14.7 0.027 132.5 ± 16.4 133.4 ± 15.8 0.52 
Diastolic BP (mmHg)
5
 77.1 ± 9.6 78.8 ± 9.4 80.5 ± 8.8 0.003 82.2 ± 9.3 82.5 ± 9.8 0.61 
High BP
5
 195 (40.7) 134 (51.0) 213 (58.8) 0.069 175 (66.3) 384 (79.2) <0.001 
Insulin (µU/ml)
5
 5.1 (3.7,7.5) 6.2 (4.3,9.2) 8.8 (6.0,12.1) <0.001 10.2 (6.8,14.3) 14.0 (9.0,20.2) <0.001 
HOMA-IR
5
 1.1 (0.8,1.6) 1.4 (0.9,2.0) 2.0 (1.3,2.7) <0.001 2.2 (1.5,3.2) 3.2 (2.0,4.6) <0.001 
Insulin resistance
5
 20 (4.4) 20 (7.8) 72 (20.5) <0.001 79 (31.1) 254 (54.5) <0.001 
>3 metabolic features
5
 8 (1.7) 13 (4.9) 35 (9.6) 0.024 39 (14.8) 147 (30.2) <0.001 
HbA1c (%)
5
 5.6 (5.4,5.8) 5.7 (5.5,5.9) 5.7 (5.4,5.8) 0.54 5.7 (5.5,5.8) 5.8 (5.6,6.0) 0.002 
FPG (mmol/l)
5 
 4.7 (4.5,5.0) 4.8 (4.6,5.1) 4.9 (4.7,5.3) 0.038 4.9 (4.7,5.2) 5.1 (4.8,5.5) <0.001 
Pre-diabetes
5
 22 (4.7) 8 (3.1) 31 (8.7) 0.018 21 (8.1) 80 (16.8) 0.002 
C3 (mg/dl)
5
 124.0 ± 23.1 130.2 ± 20.4 134.7 ± 23.0 <0.001 139.2 ± 23.2 145.7 ± 22.9 <0.001 
High C3
5
 56 (12.1)  42 (16.2) 77 (21.8) 0.013 76 (29.1) 200 (42.6) <0.001 
CRP (ng/ml)
5
 1.0 (0.8,1.5) 1.3 (1.0,2.0) 1.3 (1.0,1.8) 0.976 1.5 (1.1,2.5) 1.8 (1.2,3.2) <0.001 
High CRP
5
 60 (12.9) 52 (20.1) 67 (18.9) 0.891 78 (30.1) 194 (41.4) <0.001 
IL-6 (pg/ml)
5
 1.3 (1.0,2.1) 1.4 (1.1,2.4) 1.7 (1.2,2.4) 0.317 1.9 (1.3,2.9) 2.3 (1.6,3.5) 0.001 
High IL-6
5
 82 (17.6) 49 (18.9) 70 (19.7) 0.99 73 (28.3) 177 (37.7) 0.01 
TNF-α (pg/ml)
5
 5.5 (4.6,6.7) 5.8 (4.6,6.9) 5.9 (4.9,7.2) 0.521 5.8 (5.0,7.3) 6.4 (5.3,7.0) 0.067 
High TNF-α
5
 87 (18.7) 50 (19.4) 89 (25.1) 0.276 68 (26.4) 157 (33.4) 0.047 
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Table 17 continued 
 
Feature Normal weight 
by both 
(N=479) 
Overweight by 
either  
(N=263) 
Overweight by 
both  
(N=363) 
P value
1 
 
Obese by  
either  
(N=264) 
Obese by  
both  
(N=487) 
P value
2
 
Adiponectin (ng/ml)
5
 7.0 (4.7,10.3) 5.9 (3.8,9.0) 4.2 (2.7,6.3) <0.001 4.8 (2.9,6.7) 3.8 (2.5,5.5) 0.023 
Low adiponectin
5
 48 (10.3) 43 (16.6) 117 (33.0) 0.007 70 (27.0) 175 (37.2) 0.032 
Leptin (ng/ml)
5
 1.3 (0.7,2.0) 1.6 (1.0,2.4) 1.7 (0.9,2.7) 0.001 2.3 (1.3,4.0) 3.2 (1.9,5.2) <0.001 
High leptin
5
 30 (6.5) 39 (15.1) 56 (15.8) 0.009 87 (33.6) 239 (50.9) <0.001 
Resistin (ng/ml)
5
 4.9 (3.8,6.4) 4.8 (3.8,6.7) 4.9 (3.7,6.4) 0.946 4.9 (4.0,6.8) 5.3 (4.0,7.0) 0.274 
High resistin
5
 100 (21.5) 66 (25.5) 79 (22.3) 0.452 72 (27.9) 135 (28.7) 0.611 
PAI-1 (ng/ml)
5
 23.8 ± 10.2 25.5 ± 10.9 28.1 ± 12.0 0.033 29.3 ± 15.6 29.2 ± 12.1 0.761 
High PA1-1
5
 69 (14.8) 52 (20.2) 103 (29.0) 0.046 71 (27.5) 156 (33.2) 0.161 
WBC (10
9
/l)
5 
5.5 ± 1.7
 
5.8 ± 3.0 5.9 ± 1.6 0.92 6.1 ± 1.6 6.2 ± 1.4 0.345 
High WBC
5
 84 (17.9)
 
56 (22.0) 88 (24.6) 0.832 74 (28.7) 149 (31.9) 0.418 
Mean and ± standard deviation are shown for continuous variables. Age, triglycerides, insulin, HOMA-IR, HbA1c, FPG, CRP, IL-6, TNF-α, 
adiponectin, leptin and resistin are shown as a median (interquartile range). % (in brackets) for dichotomous variables will vary as some 
variables have missing values.  
1
P value for difference: overweight by either compared to overweight by both.  
2
P value for difference: obese by either compared to obese by both.  
3
x
2 
for difference.  
4
Mann Whitney U for difference.  
5
P value for difference adjusted for gender.  
Overweight subjects classified as obese by either index were assigned to the higher category.  
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Table 18––Odds ratios (95% CI) of having cardiometabolic risk features according to classification of overweight 
and obese. 
 
Feature Odds ratios (95% CI)
1
 
Overweight compared to normal weight
 
Obese compared to normal weight
 
 Either BMI 
or WHtR 
P value Both BMI 
and WHtR 
P value Either BMI  
or WHtR 
P value Both BMI 
and WHtR 
P value 
High triglycerides 2.1 (1.3,3.5) 0.003 3.5 (2.3,5.4) <0.001 3.4 (2.1,5.5) <0.001 5.6 (3.7,8.6) <0.001 
Low HDL-C
 
1.4 (0.8,2.5) 0.3 2.1 (1.3,3.7) 0.005 2.2 (1.2,3.8) 0.008 5.8 (3.6,9.2) <0.001 
Dyslipidaemia
 
1.8 (0.6,5.3) 0.263 3.8 (1.5,9.3) 0.004 4.6 (1.9,11.6) 0.001 8.6 (3.7,19.6) <0.001 
High BP 1.5 (1.1,2.1) 0.02 2.1 (1.5,2.8) <0.001 3.0 (2.1,4.2) <0.001 5.7 (4.1,7.9) <0.001 
Insulin resistance
 
1.8 (0.9,3.7) 0.083 5.4 (3.1,9.6) <0.001 9.5 (5.3,16.8) <0.001 26.6 (15.5,45.7) <0.001 
>3 metabolic features 2.6 (1.0,6.6) 0.043 5.4 (2.4,12.0)
 
<0.001 7.8 (3.5,17.5) <0.001 22.2 (10.5,47.0)
 
<0.001 
Pre-diabetes
 
0.6 (0.2,1.4) 0.227 1.6 (0.9,3.1) 0.142 1.6 (0.8,3.2) 0.218 3.4 (1.9,6.0) <0.001 
High C3
 
1.3 (0.8,2.1) 0.260 2.8 (1.9,4.3) <0.001 3.3 (2.1,5.0) <0.001 7.9 (5.4,11.6) <0.001 
High CRP 1.6 (1.0,2.6) 0.032 1.8 (1.2,2.7) 0.007 3.6 (2.4,5.5) <0.001 6.1 (4.2,8.9) <0.001 
High IL-6 1.0 (0.7,1.6) 0.897 1.1 (0.8,1.7) 0.541 1.7 (1.2,2.6) 0.008 2.7 (1.9,3.8) <0.001 
High TNF-α 1.1 (0.7,1.6) 0.738 1.4 (1.0,2.0) 0.089) 1.2 (0.8,1.9) 0.323 2.2 (1.5,3.1) <0.001 
Low adiponectin 1.4 (0.8,2.3) 0.204 2.7 (1.8,4.2) <0.001 2.6 (1.6,4.2) <0.001 3.9 (2.6,6.0) <0.001 
High leptin 3.6 (2.1,6.3) <0.001 5.9 (3.5,9.9) <0.001 15.7 (9.3,26.6) <0.001 46.6 (27.9,77.6) <0.001 
High resistin 1.3 (0.9,1.9) 0.205 1.3 (0.9,1.9) 0.194 1.5 (1.0,2.2) 0.046 1.8 (1.2,2.5) 0.001 
High PAI-1 1.2 (0.8,1.8) 0.460 2.0 (1.3,2.9) <0.001 1.9 (1.3,2.9) 0.002 2.7 (1.9,3.9) <0.001 
High WBC
 
1.5 (1.0,2.4) 0.073 1.9 (1.2,2.9) 0.003 2.7 (1.7,4.2) <0.001 3.2 (2.2,4.8) <0.001 
1
Multinomial logistic regression, reference category: normal weight by both BMI and WHtR.  
 Overweight subjects classified as obese by either index were assigned to the higher category.  
 All models adjusted for age, gender, physical activity, smoking and alcohol use. 
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Table 19––Area under the receiver operating characteristic curve values (95% CI) for index models to discriminate cardiometabolic risk features.  
 
Feature As a continuous variable As a categorical variable (tertiles) Overweight and obese 
by either or both
1 
 BMI alone WHtR alone Both BMI and WHtR BMI alone WHtR alone Both BMI and WHtR 
AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI 
High triglycerides 0.68 0.65,0.71 0.71
2 
0.68,0.73 0.71
2 
0.68,0.74 0.68 0.65,0.71 0.70
4 
0.67,0.73 0.70
4 
0.68,0.73 0.70
4 
0.67,0.73 
Low HDL-C
 
0.67 0.63,0.70 0.68 0.65,0.72 0.68 0.65,0.71 0.66 0.62,0.69 0.67 0.64,0.71 0.68
4 
0.65,0.71 0.68
4 
0.64,0.71 
Dyslipidaemia
 
0.68 0.64,0.73 0.70 0.65,0.74 0.70 0.65,0.74 0.69 0.64,0.73 0.69 0.65,0.73 0.70 0.66,0.74 0.70 0.66,0.74 
High BP 0.70 0.67,0.72 0.70 0.67,0.72 0.70 0.68,0.72 0.69 0.67,0.72 0.69 0.67,0.71 0.70 0.67,0.72 0.70
 
0.67,0.72 
Insulin resistance
 
0.80 0.78,0.82 0.80 0.78,0.83 0.81
2,3 
0.79,0.83 0.78 0.76,0.80 0.77 0.75,0.80 0.80
4,5 
0.77,0.82 0.79
4,5 
0.77,0.82 
>3 metabolic features 0.76 0.73,0.79 0.78
2 
0.75,0.81 0.78
2 
0.75,0.81 0.75 0.72,0.78 0.75 0.72,0.78 0.77
4,5 
0.74,0.80 0.77
4,5 
0.74,0.80 
Pre-diabetes
 
0.70 0.66,0.74 0.70 0.66,0.74 0.70 0.66,0.74 0.67 0.63,0.71 0.68 0.64,0.72 0.69 0.65,0.73 0.69
4 
0.65,0.73 
High C3
 
0.70 0.67,0.73 0.72
2 
0.69,0.75
 
0.72
2 
0.69,0.75 0.69 0.66,0.71 0.70 0.67,0.73 0.71
4 
0.68,0.74 0.71
4 
0.68,0.73 
High CRP 0.69 0.66,0.72 0.69 0.67,0.72 0.70
2 
0.67,0.72 0.67 0.64,0.70 0.68 0.65,0.71 0.69
4 
0.66,0.72 0.69
4 
0.66,0.72 
High IL-6 0.66 0.63,0.69 0.67 0.64,0.69 0.67 0.64,0.69 0.65 0.62,0.68 0.66 0.63,0.69 0.66 0.63,0.69 0.66
4 
0.63,0.69 
High TNF-α 0.63 0.60,0.66 0.63 0.60,0.66 0.63 0.60,0.66 0.62 0.59,0.65 0.63 0.61,0.66 0.63 0.61,0.66 0.63
4 
0.60,0.66 
Low adiponectin 0.79 0.77,0.81 0.79 0.77,0.81 0.79 0.77,0.81 0.79 0.77,0.81 0.79 0.76,0.81 0.79 0.77,0.81 0.79 0.77,0.81 
High leptin 0.86
3 
0.84,0.87 0.84 0.82,0.86 0.86
3 
0.84,0.88 0.84
5 
0.82,0.86 0.81
 
0.79,0.83 0.85
5 
0.83,0.87 0.84
5 
0.82,0.86 
High resistin 0.57 0.54,0.60 0.56 0.53,0.59 0.57 0.54,0.60 0.57 0.54,0.60 0.56 0.53,0.59 0.57 0.54,0.60 0.56 0.53,0.60 
High PAI-1 0.61 0.58,0.64 0.62 0.59,0.65 0.62 0.59,0.65 0.62 0.59,0.64 0.62 0.59,0.65 0.62 0.59,0.65 0.62 0.59,0.65 
High WBC
 
0.59 0.56,0.62 0.61
2 
0.58,0.64 0.63
2,3 
0.60,0.66 0.58 0.55,0.61 0.60
4 
0.57,0.63 0.61
4 
0.58,0.64 0.59
4 
0.56,0.62 
All models include age and gender.  
1
5-category variable: (1) normal weight by both, (2) overweight by either, (3) overweight by both, (4) obese by either and (5) obese by both.  
Overweight subjects classified as obese by either index were assigned to the higher category. 
2
P<0.05 compared to BMI (continuous). 
3
P<0.05 compared to WHtR (continuous). 
4
P<0.05 compared to BMI (categorical). 
5
P<0.05 compared to WHtR (categorical).  
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Figure 16––Overlap of normal weight, overweight and obese defined by BMI and 
WHtR. The figure shows Venn diagrams illustrating overlap of BMI and WHtR tertiles 
for (A) normal weight, (B) overweight and (C) obese.  
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_____________________________CHAPTER 7  
DISCUSSION AND 
RECOMMENDATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
188 | P a g e  
 
7.0 Introduction 
This thesis aimed to contribute to the current evidence base regarding the 
use of anthropometric measures of adiposity to detect patients with type 2 
diabetes, and those at increased obesity-related cardiometabolic risk. This 
chapter outlines the major findings from this thesis and discusses them in the 
context of the current literature. The clinical implications of the research are 
considered, and the main strengths and limitations of the work are high-
lighted. Areas for future study are also proposed. 
 
7.1 Main Findings 
7.1.1 Literature review 
As discussed in Chapter 1, despite a large number of studies which have 
compared adiposity indices with features of cardiometabolic disease, type 2 
diabetes and cardiovascular and mortality outcomes [127,138-149], 
controversy still exists as to which surrogate measure of adiposity better 
indicates obesity-related risk. In particular, uncertainty exists as to whether 
central adiposity indices provide additional information, beyond that which is 
assessed by BMI, and whether more accurate adiposity measurement within 
healthcare practice might be clinically useful. 
 
Limitations regarding previous research were identified. These included 
statistical procedures used to evaluate adiposity measures, methods used 
for disease classification and the lack of a universal protocol for WC 
measurement. These limitations were investigated in the thesis chapters. 
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7.1.2 Diabetes prevalence and rationale for adiposity measurement 
Chapter 2 examined the prevalence of undiagnosed and diagnosed type 2 
diabetes within our sample. The total prevalence of diabetes was found to be 
8.5%, which is comparable to the estimate determined from previous 
nationally representative research using data from the SLÁN 2007: Survey of 
Lifestyle, Attitudes and Nutrition (8.9%) [35,178]. It is also similar to the 9.5% 
prevalence rate reported from a recent study utilising data from The Irish 
Longitudinal Study on Ageing (TILDA) [276]. Notably, within our sample, a 
high percentage of diabetes cases were undiagnosed (41%). This is greater 
than the 30% indicated by the SLÁN survey, and considerably higher than 
the prevalence of undiagnosed diabetes suggested by the TILDA data 
(0.9%). As geographic location was significantly associated with having 
undiagnosed diabetes in the TILDA study, these results suggest that in 
certain areas within Ireland, between one-third and almost 50% of middle-
aged adult diabetes cases are undiagnosed. 
 
It was observed that undiagnosed subjects displayed a less-optimal 
cardiometabolic profile compared to diagnosed patients. Access to primary 
healthcare may partly account for these differences, as undiagnosed study 
participants were less likely to have private medical insurance, a finding 
which has since been replicated using the TILDA data [276]. However, within 
our sample, a majority of undiagnosed patients did have health insurance 
(either private or state-assisted), indicating that other factors, such as better 
methods to detect high-risk subjects, are needed. 
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We evaluated clinically relevant variables to identify undiagnosed cases. 
Models which included health insurance status, physical activity levels and 
BMI displayed a higher discriminatory capacity to detect subjects with 
undiagnosed diabetes compared to diagnosed individuals. Subsequently, 
these findings suggest a rationale for accurate adiposity measurement; as a 
procedure to help identify undiagnosed, high-risk patients within clinical 
practice. 
 
 
7.1.3 Defining cardiometabolic risk 
Chapter 3 explored metabolic feature relationships with type 2 diabetes and 
pre-diabetes in order to determine how diabetes and cardiometabolic risk 
should be diagnosed within clinical practice and epidemiological research. 
Specifically, it compared diabetes and pre-diabetes classifications using 
HbA1c and FPG. In keeping with previous findings, the results of this 
research suggest discordance between these two methods for diagnosing 
type 2 diabetes and assessing cardiometabolic risk [24,192,196,220]. 
Markedly, the prevalence of both diabetes and pre-diabetes was higher using 
HbA1c. The prevalence of type 2 diabetes diagnosed by HbA1c was almost 
double that compared to the estimate determined using FPG. This finding is 
important regarding implied increases in diabetes prevalence within Ireland. 
Studies which compare current prevalence estimates with those obtained 
before 2010 [169] need to acknowledge that part of the reason for observed 
higher prevalence rates may be due to the use of a different diagnostic test 
[34,35,276].  
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Nevertheless, we found that the cardiometabolic profiles in subjects 
diagnosed with type 2 diabetes, by either assay, were broadly similar. This 
suggests that both methods are valid for diagnosing diabetes within clinical 
practice. These data also indicated that either test was acceptable for 
classifying diabetes within our sample. Both methods were used to define 
this outcome in subsequent chapters. 
 
However, when pre-diabetes cases were examined, it was noted that 
subjects diagnosed by HbA1c alone did not display a moderate or strong 
association with any of the examined cardiometabolic features. These 
individuals were also clearly less obese compared to those diagnosed by 
either FPG, or both HbA1c and FPG together. These results were surprising 
given that numerous studies have shown HbA1c to strongly predict incident 
diabetes [24,226,227,277]. Nevertheless, these findings have implications 
regarding how type 2 diabetes and cardiometabolic risk should be defined 
within epidemiology, in particular within our study, as correct classification of 
high-risk subjects is needed in order to properly assess relationships 
between exposure variables and outcomes.  
 
These results are also important regarding future diabetes estimates within 
Ireland, as accurate assessment of progression rates to type 2 diabetes is 
needed for efficient allocation of resources in order to optimise public health 
prevention strategies. Notably, although prevalence rates for type 2 diabetes 
in middle-aged Irish adults are comparable between our sample, the SLÁN 
survey [35] and the TILDA study [276], prevalence estimates for pre-diabetes 
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using HbA1c vary widely (47.9% for our study, versus 19.8% for SLÁN [36], 
versus 5.5% for TILDA [276]). These findings suggest both validity and 
reliability concerns with HbA1c measurement, and that standardisation issues 
with regard to different procedures used for assessing HbA1c levels need to 
be addressed. 
 
Consistent with previous research, we found high BP, atherogenic 
dyslipidaemia, insulin resistance and adverse cardiometabolic feature 
clustering to be significantly associated with both type 2 diabetes and pre-
diabetes [19]. Subjects with these outcomes also displayed a chronic low-
grade pro-inflammatory profile as indicated by the examined biomarkers. 
Relationships between adiposity measures and these metabolic markers 
were explored in following chapters.  
 
 
7.1.4 General adiposity compared to central adiposity  
In Chapter 4, adiposity variable relationships with features of cardiometabolic 
disease and type 2 diabetes were examined. In particular, we compared BMI 
with central adiposity indices. In logistic regression models it was observed 
that central adiposity measures displayed stronger associations with adverse 
cardiometabolic features, metabolic feature clustering and type 2 diabetes. 
Central adiposity indices were also noticeably better discriminators of 
patients with type 2 diabetes. These findings concur with previous research 
which suggest that central adiposity, as defined by WC, WHR or WHtR, is a 
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better indicator of cardiometabolic disease and type 2 diabetes than BMI 
[58,115,143].  
 
However, it was also noted that the utility of these additional measures was 
significantly influenced by measurement procedure. When compared to BMI, 
our results imply that, within our middle-aged population, the WHO and IDF-
recommended midway WC measurement protocol provides little additional 
information. As this is the most commonly employed method used for 
assessing WC within clinical practice and epidemiological research [107], 
these results have implications for future study and how previous research 
should be assessed. Importantly, the results from studies [13] which report 
obesity prevalence rates using midway WC thresholds, and compare them to 
BMI overweight and obese classifications, must be treated with caution, as 
this is not necessarily demonstrating a higher level of risk, but rather a 
different way of dividing the risk continuum.  
 
In this chapter we have provided evidence which suggest that rib-level WC 
measurement is superior to midway WC measurement in terms of identifying 
subjects with type 2 diabetes. However, whether rib-level measurement is 
the optimal procedure for assessing WC could not be determined in our 
sample as we did not have other WC measurement sites to contrast. 
Nonetheless, our findings do suggest an urgent need for a universal WC 
measurement protocol. This would make comparisons with other 
epidemiological studies, and across multiple populations, more intuitive and 
facilitate interpretation of the clinical utility of central adiposity variables for 
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obesity-related risk stratification [106]. Also, as observed in our sample and 
previous research [278], as the magnitude of WC is also influenced by 
measurement procedure, small differences may be amplified using 
dichotomous cut-points, such as used in MetS definitions and diabetes risk 
scores, thus diagnosing different patients as being at risk and leading to 
misclassification.  
 
 
7.1.5 Adiposity and chronic low-grade inflammation 
Although it was noted in Chapter 4 that central adiposity measures displayed 
stronger associations with commonly assessed cardiometabolic disease 
features, we also observed that relationships between central adiposity 
indices and type 2 diabetes were particularly strong when compared to BMI. 
This suggested that the relationship between central adiposity and diabetes 
may also be mediated by other metabolic processes beyond those captured 
through commonly assessed cardiometabolic disease markers.  
 
Chapter 5 compared BMI and WC relationships with biomarkers of 
inflammation. We found that WC measurement was more strongly related to 
a majority of the examined biomarkers and adverse biomarker clustering. 
The association between low-grade inflammation and diabetes was also 
reduced in analyses including either BMI or WC, with models incorporating 
WC showing the greatest attenuation. It was also noted that models which 
included both adiposity variables together did not display any further 
attenuation. Collectively, these findings suggest that central adiposity is more 
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strongly associated with obesity-induced inflammation than BMI, and that 
central adiposity may also account for a greater variance of diabetes-related 
systemic low-grade inflammation.  
 
Previous research by our group which examined metabolically healthy and 
unhealthy obese and non-obese phenotypes indicated that favourable 
inflammatory status may be positively associated with metabolic health. 
Metabolically healthy subjects presented lower concentrations of 
inflammatory biomarkers compared to their metabolically unhealthy 
counterparts [232]. A recent Korean study also demonstrated that chronic 
low-grade inflammation may be an important early marker of risk of 
developing type 2 diabetes, as metabolically healthy obese subjects with 
systemic inflammation were at increased risk [279]. Although the added 
value of novel biomarkers in type 2 diabetes risk prediction algorithms has 
yet to be established [280-283], the results from our study support the theory 
that central adiposity measures may be better markers of visceral fat. 
However, as the association between chronic low-grade inflammation and 
diabetes was not completely attenuated in models which included adiposity 
variables, these results also indicated that alternative adiposity measurement 
procedures may be needed to better assess the pro-inflammatory state 
associated with type 2 diabetes and obesity-related disorders. 
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7.1.6 Assessing the utility of a composite index 
In Chapter 6, we investigated the utility of composite index for assessing 
cardiometabolic risk. This research addressed the hypothesis that the use of 
two indices to define overweight and obese classifications might provide 
additional and independent information. Body mass index is the most 
commonly used method for assessing general adiposity, and our previous 
findings suggested WHtR to be the best overall method for determining 
central obesity. Therefore, we examined a range of cardiometabolic disease 
features and inflammatory markers to explore whether joint measurement 
might improve cardiometabolic risk classification.  
 
It was found that a combination of BMI and WHtR tertiles identified 
consistent and significant metabolic variable differences relative to those 
characterised as overweight or obese discordantly by BMI and WHtR. 
Similarly, associations with cardiometabolic features and inflammatory 
biomarkers were noticeably increased in subjects classified as overweight or 
obese by both measures. This indicated that joint measurement may provide 
a more specific procedure for identifying high-risk patients within overweight 
and obese BMI/WHtR categories. It was also noted that in a logistic 
regression model which adjusted for age, gender, physical activity, smoking 
and alcohol use, only individuals who were classified as obese by both 
indices displayed a significant and positive association with pre-diabetes. 
This inferred that the relationship between obesity and diabetes is better 
indicated at this mode and level of adiposity. In addition, it was observed that 
patients classified as overweight discordantly also displayed an increased 
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cardiometabolic risk profile. As a proportion of these individuals might be 
considered normal weight if either index were used alone, this suggested 
that joint measurement could also provide an effective procedure for 
identifying normal weight subjects at increased risk who would not otherwise 
be detected.  
 
Although our study is the first to explore the utility of a composite index using 
BMI and WHtR together in a middle-aged Irish population, a number of 
studies have evaluated joint use of general and central adiposity measures 
to assess cardiometabolic risk. In a cross-sectional analysis of 2,924 elderly 
men, Wannamethee et al. [284] found BMI and WC to be of similar value for 
identifying adverse cardiometabolic feature clustering in ROC analysis. 
However, it was noted that within normal weight and overweight BMI 
categories, elevated WC was associated with increased odds of having 
MetS, leading the authors to recommend using BMI cut-offs for initial 
assessment, and WC as a complimentary indicator of health risk. In contrast, 
Ardern et al. [285] found the odds associated with having MetS to be 
increased in both overweight and obese women with a high WC, but not 
men, in a study of 7,981 subjects aged 20-74 years. Park et al. [120] showed 
that the prevalence of metabolic risk factors and MetS were significantly 
increased across quartiles of WHtR in normal weight men and women aged 
20-79 years (N=2,952). Similarly, using a WHtR ≥0.5 threshold value, 
Ashwell et al. [286] observed that male and female subjects classified as 
“healthy weight” using BMI had significantly higher cardiometabolic risk 
factors compared to a group with a healthy BMI and WHtR below 0.5, in a 
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recent analysis using data from the United Kingdom National Diet and 
Nutrition Survey (N=1,453). 
 
Contrary to other studies [138], we found that joint measurement significantly 
improved discrimination of individual cardiometabolic disease features and 
adverse inflammatory biomarker levels when indices were examined as both 
continuous and categorical variables, though discriminatory differences were 
modest. It was also noted that although WHtR was a better overall 
discriminator of cardiometabolic risk than BMI when compared as a linear 
variable, significant discriminatory differences between WHtR and BMI were 
reduced when examined as tertiles. This indicates that both adiposity 
variables are more likely to have independent effects on cardiometabolic risk 
when a threshold approach is used, such as employed in a clinical setting. 
These results suggest that use of BMI and WHtR together may help refine 
body fat classification. However, as diagnostic risk cut-offs for both indices 
are defined arbitrarily, optimal categorical thresholds for joint measurement 
should be examined. The utility of combined univariable cut-points based on 
linear combinations of both measures should also be explored.  
  
Although the focus of Chapter 6 was on assessing cardiometabolic risk, it 
was also noted in Chapter 4 that a discrimination model for type 2 diabetes, 
using age, gender, BMI and WHtR displayed an AUC value of 0.80 (95% CI: 
0.76-0.84). However, further analysis (not shown) indicated that this was only 
marginally higher than the AUC for a model including age, gender and WHtR 
alone (AUC=0.79, 95% CI: 0.75-0.83), a difference which was not statistically 
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significant (P=0.08). Nevertheless, both AUCs were significantly higher than 
models which only included age and gender (AUC=0.63, 95% CI: 0.58-0.67, 
P<0.001 for both) and are comparable to AUC values obtained in studies 
which have evaluated non-invasive diabetes risk scores to screen for 
undiagnosed type 2 diabetes [287-292]. As diabetes risk scores typically 
include a number of variables, some of which must be subjectively assessed 
or may be unknown, the findings from Chapters 4 and 6 suggest that 
accurate adiposity measurement within a clinical setting might provide useful 
non-subjective, diagnostic or prognostic information a clinician could obtain 
by performing three, relatively simple, non-invasive procedures.  
 
 
7.2 Strengths and Limitations of the Research 
This section provides a summary of the overall strengths and limitations of 
this research. The individual strengths and limitations of the five papers 
included in this thesis have also been acknowledged and discussed in the 
previous chapters. 
 
As one of the largest cross-sectional studies performed to date within the 
Republic of Ireland, the Cork and Kerry Diabetes and Heart Disease Study 
sample size is comparable to other related Irish studies. Strengths include a 
high participation rate, the use of a range questionnaires to assess lifestyle 
behaviours, the use of two procedures to classify glycaemic status and the 
inclusion of a wide range of metabolic markers and anthropometric 
measurements to define cardiometabolic health.  
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This thesis addressed a timely and relevant research area within Ireland with 
regard to adiposity measurement, cardiometabolic disease, type 2 diabetes 
and the need for effective tools to help identify high-risk patients within 
clinical practice. The findings from this work are of potential public health and 
clinical significance in terms of screening, and in particular, the use of 
stratification based on accurate adiposity measurement as a method for 
identifying patients with type 2 diabetes and for assessing cardiometabolic 
risk. The relevance of this work is perceptible in that our results have been 
presented at a number of scientific conferences, both nationally and 
internationally (Appendix 4), and have also attracted attention from online 
media [293-297]. To date, four of the included papers have been published in 
peer-reviewed scientific journals (Appendix 6) [165-168].  
 
Notwithstanding these strengths, methodological limitations must be 
considered when assessing findings from this work. The data used in this 
thesis were derived from a single primary care based sample. In addition, a 
potential limitation of any cohort study is potential bias because of initial non-
response. The current study was based in a single primary care centre which 
serves a well defined catchment area.  The response rate of 67% is typical of 
response rates currently achieved in developed country settings.  
Additionally the response rate was similar in men and women and likewise 
for age groups. Nevertheless, although prevalence rates for 
overweight/obesity and type 2 diabetes found within our sample are 
comparable to those observed in other recent nationally representative Irish 
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studies [13,35,276], the possibility that these data are not representative of 
the source population must be acknowledged.  
 
However, as mentioned in preceding chapters, it is estimated that 98% of 
Irish adults are registered with a GP, and that, even in the absence of 
universal patient registration system, it is possible to perform population-
based epidemiological studies that are representative using our methods 
[210]. Also, as previously discussed, Ireland is an ethnically homogeneous 
population [242]. Hence, there is little reason to believe that the metabolic 
relationships we observed would be any different in other middle-aged Irish 
adults. As random sampling of subjects and the use of validated methods for 
data collection ensured internal sample validity, it is equally possible that our 
findings may be generalisable to a similar middle-aged Caucasian-European 
population. 
 
Of greater concern is that our data were cross-sectional, as this precludes 
examination of temporal relationships. Thus, although this research suggests 
a potential rationale for accurate adiposity measurement as a procedure for 
identifying patients with type 2 diabetes, and also for assessing 
cardiometabolic disease risk, it does not demonstrate that surrogate 
measures of adiposity would be clinically useful to predict future diabetes 
cases. Equally, it does not show that they would be useful for predicting 
future CVD events or mortality outcomes. These limitations, in particular, will 
need to be addressed in future work utilising longitudinal data. 
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7.3 Recommendations 
Although central adiposity measurement has been recommended as a 
method for assessing cardiometabolic health, a recent straw poll of clinicians 
in the United Kingdom showed that only 10% regularly measured WC [298]. 
In addition, the need for any type of adiposity measurement within healthcare 
practice has been questioned, as it has been suggested that a simple 
“eyeball test” is sufficient in most instances [299]. The findings from this 
thesis suggest that non-subjective assessment of adiposity provides 
important information regarding disease and risk status. However, our results 
also demonstrate that a reluctance to measure WC in clinical practice is not 
misplaced, as such an assessment may provide additional information 
compared to BMI, or almost none at all, according to the procedure used for 
estimating WC. For this reason, we cannot recommend regular WC 
measurement within healthcare practice in Ireland at the present time. 
 
We have just begun a re-screen of the Mitchelstown Cohort (5 year follow-
up) which includes two further WC measurements (iliac crest and umbilical 
level), in addition to the two previously examined. This will allow us to 
determine whether rib-level measurement is the optimal procedure for 
assessing WC in our population, and also to further examine adiposity 
variable relationships with features of cardiometabolic disease. Importantly, it 
will also allow us to ascertain whether a composite index, using measures of 
general and central adiposity, might be clinically useful as a method for 
predicting type 2 diabetes.  
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This work will need to be duplicated in other nationally representative Irish 
studies. The need for a universal WC measurement protocol will also have to 
be explored in research utilising data from other ethnic populations. In 
addition, although we suggest that WC measurement would not entail any 
extra cost when compared to invasive blood testing, it would compete for the 
limited time a GP or clinician has available during patient appraisal. 
Therefore, examination of feasibility and cost-implications regarding central 
adiposity measurement is warranted and should be a focus of future health 
services research.  
 
Consistent with other research [121,128,143,156], our findings suggest that 
of the currently used surrogate measures of central adiposity, the WHtR may 
be the most accurate method for assessing obesity-related risk. Future 
epidemiological studies which examine adiposity relationships with 
cardiometabolic features, type 2 diabetes, obesity-related diseases and 
mortality outcomes should concentrate on this index and BMI. The WHtR is 
also probably the most practical method for determining central adiposity as 
it may allow the use of universal risk thresholds [125,300]. Notably, we did 
not determine cut-points for use within our population as we felt that, in the 
absence of an agreed WC measurement protocol, this would be premature. 
Optimal cut-offs using WHtR may differ according to the disease to be 
predicted. It is also possible that WHtR measurement may only be useful as 
a pre-screening diagnostic tool to help identify current type 2 diabetes cases 
within clinical practice. 
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Nevertheless, results from this thesis suggest that accurate adiposity 
measurement (through anthropometry or other means) might provide a 
greater amount of predictive information regarding a patient’s future health 
status than that provided by any other single cardiometabolic disease feature 
(with the exception of glycaemic status) or many non-invasive variables 
typically included in diabetes risk scores. However, this is speculative and 
remains to be determined. Although anthropometry continues to be the 
preferred method for assessing adiposity within healthcare practice, future 
studies should also investigate the use of other more sophisticated 
procedures for measuring body composition, such as bioelectrical 
impedance or photonic scanning [156]. The development of other low-cost, 
clinically practical methods for assessing adiposity should also be explored. 
 
Finally, our results may have implications regarding how excess adiposity 
should be defined within epidemiological research. We noted that a 
percentage of individuals who might be classified as normal weight be either 
BMI or WHtR also displayed an increased cardiometabolic risk profile. In 
addition, cardiometabolic profiles for subjects within each overweight and 
obese category varied considerably. This suggests a possible explanation for 
the “obesity paradox”, as such individuals might be misclassified and 
included in a reference category, or a low or high-risk group, in studies which 
investigate adiposity relationships with morbidity and mortality outcomes 
[61,99,149]. Therefore, research examining overweight and obese 
associations with these outcomes should consider defining adiposity using 
joint measurement. Studies which adjust for adiposity should also 
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contemplate using both general and central obesity variables in analysis to 
prevent residual confounding.  
 
 
7.4 Conclusions 
Public health prevention strategies should be prioritised as a method for 
reducing the prevalence of obesity and obesity-related diseases within 
Ireland. However, clinicians should be aware that a high percentage of 
overweight and obese patients will not have type 2 diabetes [67-70] or ever 
develop the condition and related cardiovascular complications [71,72]. As 
the prevalence of obesity continues to rise within Ireland [13,14] and other 
world populations [5], classification of excess adiposity based on BMI 
measurement alone will increasingly identify a majority of the population as 
being at risk. In addition, a percentage of subjects who are defined as normal 
weight by BMI may be at high-risk of obesity-induced chronic disorders 
[64,164,243,301].  
 
Though no level of increased adiposity should necessarily be considered to 
be “healthy” at a population level, accurate classification of high-risk subjects 
is desirable. This is particularly pertinent within healthcare practice, as losing 
weight is difficult and clinical interventions should be targeted to those most 
at risk and who would benefit most from earlier identification. Accurate 
adiposity assessment, using surrogate measures of both general and central 
adiposity, may be a useful tool for stratifying high and low-risk patients. Other 
novel adiposity measurement procedures might also prove beneficial. Earlier 
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identification of subjects at increased risk, and those with type 2 diabetes, 
could allow earlier targeted interventions to be implemented, thus improving 
the quality of life of patients affected. Collectively, the results from this thesis 
may help in improving the characterisation of obesity-related health risk in 
order to reduce premature mortality and financial costs associated with the 
obesity epidemic within Ireland.  
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Appendix 1: Supporting Table 1 
 
 
 
Univariate odds ratios (95% CI) of having undiagnosed or diagnosed type 2 diabetes compared 
to no diabetes. 
 
Feature Odds ratio (95% CI) of having 
undiagnosed diabetes compared to 
no diabetes
1
 
Odds ratio (95% CI) of having 
diagnosed diabetes compared to no 
diabetes
2
 
 Odds ratio 95% CI Odds ratio 95% CI 
Health conditions     
 Male 1.6  (1.0-2.6) 2.3  (1.5-3.6) 
 Age >60 years  1.3  (0.8-2.0) 2.0  1.3-3.1) 
 On Rx for hypertension 2.3  (1.4-3.6) 5.1  (3.4-7.8) 
 On Rx for cholesterol 1.9  (1.2-3.1) 3.9  (2.6-5.9) 
 BMI category:     
 <25  1  1  
 25-29.9 3.1  (1.1-8.9) 11.0  (2.7-45.6) 
 >30  8.7  (3.1-24.3) 22.5  (5.5-92.8) 
 Family diabetes history 2.0  (1.2-3.4) 5.4  (3.6-8.2) 
 CVD 2.9  (1.6-5.2) 4.0  (2.5-6.3) 
Socio-economic     
 Education:     
 Bachelor or higher 1  1  
 Diploma 1.1  (0.3-4.0) 0.9  (0.3-2.9) 
 Secondary 1.6  (0.6-4.5) 1.6  (0.6-4.2) 
 Primary only 2.6  (0.9-7.5) 3.3  (1.3-8.5) 
 Social class:     
 High income 1  1  
 Middle income 1.6  (0.7-4.0) 1.4  (0.7-2.9) 
 Low income 1.9  (0.7-4.8) 1.5  (0.8-2.9) 
Medical cover     
 Health insurance:     
 Private insurance 1  1  
 State insurance 3.0  (1.8-5.1) 2.4  (1.6-3.6) 
 No insurance 3.0  (1.6-5.6) 0.8  (0.3-1.7) 
Health behaviours     
 Physical activity:     
 High 1  1  
 Moderate 2.8  (1.3-6.1) 1.7  (1.0-2.7) 
 No physical exercise 7.0  (3.4-14.7) 1.9  (1.1-3.3) 
 Smoker 1.2  (0.8-2.0) 1.5  (1.0-2.3) 
 Alcohol use:     
 Non-drinker 1  1  
 Occasional drinker 0.7  (0.4-1.3) 1. (0.7-1.8) 
 Regular drinker 0.6  (0.4-1.1) 0.5  (0.3-0.8) 
Metabolic     
 Triglycerides >1.7 3.7  (2.3-6.0) 2.0  (1.3-3.1) 
 Non-optimal HDL-C
3
 4.9  (3.0-7.9) 4.8  (3.2-7.3) 
 Dyslipidaemia
4
 7.2  (4.3-12.2) 3.9  (2.3-6.5) 
 Hypertension
5
 1.6  (1.0-2.5) 0.9  (0.6-1.4) 
 
1
Models excluding subjects with diagnosed diabetes.  
2
Models excluding subjects with undiagnosed diabetes.  
3
HDL-C <1.03 (males) or <1.29 (females).  
4
Dyslipidaemia: triglycerides >1.7 and HDL-C <1.03 (males) or <1.29 (females). 
5
Hypertension: SBP >140 and/or DBP >90. 
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Appendix 2: Supporting Figure 1 
 
Odds ratios (95% CI) of having cardiometabolic risk features for a one standard 
deviation increase in each adiposity measure. 
 
 
HIGH TRIGLYCERIDES 
 
LOW HDL-C 
 
HIGH BP 
 
 
 
 
 
 
 
233 | P a g e  
 
INSULIN RESISTANCE 
 
 
IMPAIRED FPG1  
 
 
1
FPG >5.6 mmol/l. Models exclude subjects with type 2 diabetes.  
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Appendix 3: Supporting Table 2 
 
Relationships between adverse cytokine levels and type 2 diabetes adjusting for either BMI, WC, or both.  
 
Feature Model 1 Model 2 Model 3 Model 4 Model 5 
 Odds ratios (95% CI)    
Either high IL-6 or high TNF-α  2.80 (1.94-4.04)2 2.17 (1.48-3.18)2 2.02 (1.38-2.97)2 2.07 (1.41-3.05)2 1.95 (1.26-3.02)2 
BMI1  1.88 (1.60-2.21)2  0.70 (0.48-1.03) 0.74 (0.48-1.14) 
WC1   2.26 (1.89-2.69)2 3.13 (2.11-4.64)2 2.68 (1.71-4.20)2 
 Odds ratios (95% CI)    
Both high IL-6 and high TNF-α  3.16 (2.09-4.78)2 2.33 (1.50-3.61)2 2.03 (1.30-3.18)2 2.05 (1.31-3.21)2 2.27 (1.36-3.78)2 
BMI1  1.92 (1.63-2.26)2  0.73 (0.50-1.07) 0.76 (0.50-1.17) 
WC1   2.30 (1.93-2.75)2 3.07 (2.06-4.57)2 2.66 (1.70-4.17)2 
Model 1 adjusted for age and gender.  
Model 2 adjusted for age, gender and BMI. 
Model 3 adjusted for age, gender and WC. 
Model 4 adjusted for age, gender, BMI and WC. 
Model 5 adjusted for age, gender, BMI, WC, use of anti-inflammatory medications, physical activity, smoking and alcohol use.  
1
1 SD increase. 
2
P<0.05. 
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Appendix 4: Research Outputs and Dissemination 
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Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 
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Millar SR, Perry IJ, Broeck JVD, Phillips CM. (2015) Optimal Central 
Obesity Measurement Site for Assessing Cardiometabolic and Type 2 
Diabetes Risk in Middle-Aged Adults. PLOS ONE. 
 
Millar SR, Perry IJ, Phillips CM. (2015) HbA1c Alone Is a Poor Indicator of 
Cardiometabolic Risk in Middle-Aged Subjects with Pre-Diabetes but is 
Suitable for Type 2 Diabetes Diagnosis: A Cross-Sectional Study. PLOS 
ONE.  
 
Millar SR, Perry IJ, Phillips CM. (2015) Assessing Cardiometabolic Risk in 
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Other journal articles 
 
Gaye A, Marcon Y, Isaeva J, LaFlamme P, Turner A, Jones EM, Minion 
J, Boyd AW, Newby CJ, Nuotio ML, Wilson R, Butters O, Murtagh B, 
Demir I, Doiron D, Giepmans L, Wallace SE, Budin-Ljøsne I, Schmidt 
CO, Boffetta P, Boniol M, Bota M, Carter KW, deKlerk N, Dibben C, 
Francis RW, Hiekkalinna T, Hveem K, Kvaløy K, Millar SR, Perry IJ, 
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RP, Fortier I, Harris JR, Woffenbuttel BHR, Murtagh MJ, Ferretti V and 
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Appendix 5: Anthropometric Measurement Procedures 
1.0 Weight Measurements 
1.1 Introduction 
Height and weight measurements provide the necessary details to calculate 
the body mass index of participants.  
 
1.2 Responsibilities 
Research nurses trained in the method are responsible for recording weight 
measurements for all participants. 
 
1.3 Equipment 
 Portable electronic TANITA WB-100MA weighing scale  
 Calibration weights (75kgs) 
 
1.4 Methods 
1.4.1 Set up requirements: 
 Make sure the scales are placed on a firm, flat surface. Place the 
display unit on an even surface nearby. Do not place the scales on 
carpet, sloping surfaces or rough, uneven surfaces.  
1.4.2 Calibration 
 It will be necessary to calibrate the scales on a regular basis to ensure 
it accurately records weight on an ongoing basis.  
 The weighing scales will have been calibrated by the suppliers before 
the study commenced (June 2008). 
 Further calibration will be carried out weekly in the department using 
the 75kg calibration weights. Any calibration drifts should be recorded 
in the calibration record book and the research nurse co-ordinator 
informed (Vera Mc Carthy).  
1.4.3 Procedure: 
 Ask the participant to remove heavy outer garments (jackets, coats 
etc) and footwear (shoes, slippers, sandals etc) and socks. 
 Ask the participant to step onto the centre of the scale with one foot 
on each side of the scale (not having weight distributed evenly may 
affect measurement) 
 Ask the participant to:  
- stand still  
- face forward  
- place arms by their side and  
- wait until asked to step off  
 Record the weight in kilograms on the Clinical Report Form.  
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Important guidelines regarding the use of the weighing scales:  
 Use only the adapter provided with the scale. This adapter should 
have TANITA written on it.  
 Do not wrap cables around the screen part of the scale. 
 Place the scales in the bag with the screen facing down. 
 
 
2.0 Height Measurements 
 
2.1 Introduction 
Height should be measured in all selected respondents, except wheelchair 
bound individuals, persons who have difficulty standing steady or straight, 
and participants with a hairstyle or headdress (e.g. turban) that prevent 
proper use of the height measuring equipment. 
 
2.2 Responsibilities 
Research nurses trained in the method are responsible for recording weight 
measurements for all participants. 
 
2.3 Equipment 
 Portable Seca Leicester height/length measuring rule  
 
2.4 Methods 
2.4.1 Requirements for examination  
 Ask the participant to remove their:  
- footwear (shoes, slippers, sandals etc)  
- heavy outer clothes (coat, jackets etc) 
- head gear (hat, cap, hair bows, comb, ribbons, etc). Note: If it 
would be insensitive to seek removal of a scarf or veil, the 
measurement may be taken over light fabric. 
 Ask the participant to stand on the Standiometer Platform facing you 
with: 
- feet together  
- knees straight  
 Ask the participant to look straight ahead and not look up (make sure 
eyes are the same level as the ears). 
 Move the measure arm gently down onto the head of the participant 
and ask the participant to breathe in and stand tall.  
 Record the height measurement in centimetres on the Clinical Report 
Form. 
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3.0 Central Adiposity Measurements: Waist Circumference, Hip 
Circumference and Pelvic Width 
3.1 Introduction 
A variety of different measurements can be used to predict body density or 
fat content. For this study we will assess waist circumference, hip 
circumference and pelvic width. 
 
3.2 Responsibilities 
Research nurses trained in the method are responsible for recording waist 
circumference for all participants.  
 
3.3 Equipment 
 Seca 200 measuring tape 
 Marker pen 
 Plastic 15cm ruler 
 
3.4  Methods 
3.4.1 Calibration 
 Calibration should be conducted with a steel tape measure on the last 
day of each month.  
 Set the tape measure to obtain a reading of 50.0cm and then measure 
the actual distance with the steel tape measure. Repeat this 
procedure for 100.0cm, 150.0, and 200.0 cm.  
 All readings should be recorded in the Tape Measure Calibration Log 
(Appendix 4).  
 If a discrepancy is identified contact the research nurse co-ordinator 
(Ms Vera Mc Carthy) who will organise a replacement tape.  
 
3.4.2 Set up requirements 
Ideally, this measurement should be taken against the skin, but if participant 
prefers, it may be taken over thin layer of clothing e.g. a vest or t-shirt. It 
must not be taken over thick or bulky clothing.  
How to take the measurement:  
This measurement should be taken:  
 At the end of a normal expiration [breath out] 
 With the arms relaxed at the sides  
 Under the midline of the participant's armpit, at the midpoint between 
the lower part of the last rib and the top of the hip.  
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3.5 Procedure for (Midway) Waist Circumference 
 Ask the participant to:  
- stand with their feet together and pointing forward,  
- place their arms at their side with the palms of their hands facing 
inwards, and  
- breathe gently and relax the abdomen [If you feel the respondent 
is trying to 'hold in' their abdomen, engage them in conversation so 
that they relax]. 
- Feel for the subject’s lower rib margin in the mid-axillary line and 
make a mark (with the marker pen) on the skin at this point. 
- Palpate the iliac crest in the mid-axillary line and make a mark on 
the skin surface. 
- Using the plastic ruler, measure the distance between these two 
points. Now make a distinct mark half-way between these two 
points on the skin surface. 
- Ensure that you make the marks on both sides of the body as this 
improves the reproducibility of the measurement. 
- Apply the metric tape horizontally around the subject’s body, line 
the tape over the two middle marks and ensure that it is sitting 
evenly, not tilted up on one side. Tighten/loosen the tape so that it 
sits comfortably around the subject’s body. The tape should be 
tight enough so that you can just put two fingers underneath it. 
- Instruct the subject to breathe in and then breathe out and hold, at 
the time the measurement is taken. 
- Record the measurement in centimetres in the clinical report form. 
Take two measurements on each participant to test for 
reproducibility. 
 
 
NOTE: Use the side of the tape measure which begins at 
5cm-this side takes into account the 5cm for the box 
 
 
3.6 Procedure for Waist Circumference - Lowest Rib 
 Ask the participant to:  
- stand with their feet together and pointing forward,  
- place their arms at their side with the palms of their hands facing 
inwards, and  
- breathe gently and relax the abdomen [If you feel the respondent 
is trying to 'hold in' their abdomen, engage them in conversation so 
that they relax]. 
 Feel for the subject’s lower rib margin in the mid-axillary line and make 
a mark (with the marker pen) on the skin at this point. 
 Apply the metric tape horizontally around the subject’s body, line the 
tape over mark at the lower rib margin. Tighten/loosen the tape so that 
it sits comfortably around the subject’s body. The tape should be tight 
enough so that you can just put two fingers underneath it. 
 Instruct the subject to breathe in and then breathe out and hold, at the 
time the measurement is taken. 
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 Record the measurement in centimetres in the clinical report form. 
Take two measurements on each participant to test for reproducibility. 
 
 
NOTE: Use the side of the tape measure which begins at 
5cm-this side takes into account the 5cm for the box 
 
 
3.7  Procedure for Hip circumference 
 Following on from the waist circumference, ensure the subject 
remains in the same position and breathing normally. 
 With the metric tape, measure the point yielding the maximum 
circumference around the hips. As before the tape should sit 
horizontally around the body, without a tilt and should allow two 
fingers to slide under it. 
 Record the measurement in centimetres in the clinical report form. 
Take two measurements on each subject to test for reproducibility. 
 Participation in the procedure is now complete. 
 
3.8 Procedure for Pelvic Width Measurement 
 Bi-iliac breadth, is the maximum diameter between right and left iliac 
crests measured from the rear of the participant. Ask the participant 
to:  
- stand with their feet approximately 5cm apart to prevent them from 
swaying. 
- fold their arms across their chest,  
- measurement, using the calipers, is done from behind the 
participant. 
- palpate the landmarks, the outer edges of the upper iliac bones, 
- apply the caliper to these landmarks at a 45o angle ensuring that 
the maximum breadth is recorded and applying gentle pressure 
- take two separate measurements on each participant for 
reproducibility and record on the clinical report form. 
 
3.9 Additional information 
To ensure the reproducibility of anthropometric readings it is crucial to 
maintain the standards laid down in the anthropometric standard operating 
procedures document. 
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